Document:

EX-10.3

 Exhibit 10.3 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT 

THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“Agreement”) dated as of March 26, 2016 (“Execution
Date”), is entered into between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“XenoPort”) and Dr. Reddy’s Laboratories, S.A., a
Swiss corporation having its principal place of business at Elisabethenanlage 11, 4051, Basel, Switzerland (“DRL”). 

BACKGROUND 
 A. XenoPort
is developing a prodrug of monomethyl fumarate (as further defined below, “MMF”), known internally at XenoPort as XP23829, (as further defined below, the “Compound”), a formulation of which is currently targeted for
the treatment of psoriasis and multiple sclerosis. XenoPort owns or controls certain patents, know-how and other intellectual property relating to such Compound, and products containing such Compound (as further defined below,
“Products”); 
 B. DRL desires to develop, manufacture and commercialize Products in the United States, and XenoPort
desires to have Products developed and commercialized in the United States by DRL, all in accordance with this Agreement. 
 NOW, THEREFORE,
in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE I 
 DEFINITIONS

 1.1 “Affiliate” of a Party shall mean any person, corporation or other entity that, directly or indirectly through
one or more intermediaries, controls, is controlled by or is under common control with such Party, as the case may be, for as long as such control exists. As used in this Section 1.1, “control” shall mean: (a) to possess,
directly or indirectly, the power to direct the management and policies of such person, corporation or other entity, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or (b) direct
or indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital in such person, corporation
or other entity. [ * ] 

 1.2 “ANDA” shall mean an Abbreviated New Drug Application (or its equivalent) as
defined in Section 505(j) of the FDCA. 
 1.3 “Annual Net Sales” shall mean total Net Sales of either Equivalent
Products or Non-Equivalent Products, as applicable, sold in the Territory in a particular fiscal year (i.e., April 1 to March 31). For such purposes, units of Product shall be considered sold when such Product is shipped to a customer or
the revenue from such sale is recognized by the seller for financial reporting purposes, whichever occurs first. 
 1.4 “Applicable
Laws” means the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions,
orders, permits (including Marketing Approvals) of or from any court, arbitrator, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item. 

1.5 “Change of Control” shall mean either: (a) a sale of all or substantially all of the assets of a Party in one or a
series of integrated transactions not in the ordinary course of business to a Third Party; or (b) the acquisition of control (as defined in Section 1.1 above) of a Party by a Third Party by means of any transaction or series of related
transactions to which such Party is a party (including, any stock acquisition, merger or consolidation). For clarity, a Change of Control would not include any transaction or series of transactions in which the holders of voting securities of a
Party outstanding immediately prior to such transaction continue to retain (either by such voting securities remaining outstanding or by such voting securities being converted into voting securities of the surviving entity), as a result of shares in
the Party held by such holders prior to such transaction, fifty percent (50%) or more of the total voting power represented by the voting securities of the acquiring entity outstanding immediately after such transaction or series of
transactions. 
 1.6 “Compound” shall mean that certain compound (N,N-Diethylcarbamoyl)methyl methyl
(2E)but-2-ene-1,4-dioate or 1-[2-(diethylamino)-2-oxoethyl] 4-methyl (2E)-but-2-ene-1,4-dioate, referred to internally at XenoPort as XP23829, the structure of which is set forth on Exhibit 1.6, together with all isomers and/or mixtures
of isomers thereof, and/or any salts of any of the foregoing. 
 1.7 “Control” (including any variations such as
“Controlled” and “Controlling”) shall mean, in the context of intellectual property rights, Data or information, possession of the ability to grant an assignment, license or sublicense to such intellectual property,
Data and/or information, and/or to disclose and deliver such Data and/or information, as the case may be, of or within the scope set forth in this Agreement, without violating the terms of any agreement or other arrangement with any Third Party.

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 1.8 “Data” shall mean any and all research data, pharmacology data, preclinical
data, clinical data and/or all regulatory documentation, information and submissions pertaining to, or made in association with an IND, NDA, Marketing Approval or the like for, the Compound or a Product, in each case that are Controlled by a Party
as of the Effective Date or during the term of this Agreement after the Effective Date. Data also shall include any such data generated by DRL’s Affiliates or under authority of DRL or any of its Affiliates during the term of this Agreement.

 1.9 “Diligent Efforts” shall mean, with respect to a Compound or Product, the carrying out of obligations under this
Agreement in a sustained manner [ * ] the Compound or Product, as applicable, taking into account [ * ]. 
 1.10 “DRL
Know-How” shall mean all scientific, medical, technical, marketing, manufacturing, formulation, regulatory and other information relating to the Compound or a Product (including Data), that are owned or Controlled by DRL or its Affiliates
during the term of this Agreement, [ * ] in order for XenoPort to exercise its rights or perform its obligations under this Agreement [ * ]. Notwithstanding the foregoing [ * ], DRL Know-How shall also include [ * ]. 

1.11 “Effective Date” shall mean the HSR Clearance Date. 

1.12 [ * ] shall mean [ * ]. 

1.13 “Existing Inventory” shall mean [ * ] owned or controlled by XenoPort as of the Execution Date set forth on
Exhibit 1.13, in the form described in such exhibit. 
 1.14 “FDA” shall mean the United States Food and Drug
Administration, or any successor entity thereto performing similar functions. 
 1.15 “FDCA” shall mean the United States
Federal Food, Drug, and Cosmetic Act, as amended. 
 1.16 “Field” shall mean the treatment, diagnosis and/or prevention of
human and/or animal diseases and conditions. 
 1.17 “Filing” of an NDA shall [ * ]. 

1.18 [ * ] shall mean the [ * ]. 

1.19 “Generic Product” shall [ * ]. 

1.20 “IND” shall mean any Investigational New Drug Application (including any amendments thereto) filed with the FDA pursuant
to 21 C.F.R. §321 before the commencement of clinical trials of a Product, or any comparable filings with any Regulatory Authority in any other jurisdiction. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 1.21 “Marketing Approval” shall mean all approvals, licenses, registrations or
authorizations of the Regulatory Authority in a country, necessary for the manufacture, use, storage, import, marketing and sale of a Product in such country, excluding any governmental pricing and/or reimbursement approvals and/or authorizations.

 1.22 “MMF” means [ * ] set forth on Exhibit 1.22. 

1.23 “MS Indication” shall mean an indication for a Product involving multiple sclerosis. 

1.24 “NDA” shall mean a new drug application (or its equivalent) submitted to the FDA, including new drug applications as
defined by Sections 505(b)(1) and 505(b)(2) of the FDCA . 
 1.25 “Net Sales” shall mean the gross amount billed or
invoiced by DRL and/or its Affiliates, as applicable, for all sales of Product to Third Party customers [ * ] To the extent applicable, components of Net Sales shall [ * ]. For the purposes of calculating Net Sales, the Parties
understand and agree that: [ * ]; and [ * ]. If a Product is sold or transferred for consideration other than cash, the Net Sales from such sale or transfer shall be deemed the then fair market value of such Product. 

In the event that [ * ], the Net Sales of [ * ], where [ * ], and [ * ], in each case in the Territory during the
applicable reporting period or, if sales of [ * ], then the [ * ]. In the event that [ * ], then Net Sales for [ * ]. 

1.26 [ * ] shall mean: (a) [ * ] and including all [ * ]; or (b) any other [ * ]. 

1.27 “Orange Book” shall mean the Approved Drug Products with Therapeutic Equivalence Evaluation published as of the
Execution Date by the FDA’s Center for Drug Evaluation and Research, as updated and modified from time to time, or a successor register thereto that has a similar function. 

1.28 “Psoriasis Indication” shall mean an indication for a Product involving psoriasis, including psoriatic arthritis. 

1.29 “Party” shall mean XenoPort or DRL individually, and “Parties” shall mean XenoPort and DRL
collectively. 
 1.30 “Patent(s)” shall mean any patents and patent applications (whether provisional or nonprovisional),
together with all additions, divisions, continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, supplemental protection certificates and renewals of any of the foregoing.

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 1.31 “Product” shall mean any pharmaceutical product containing the Compound,
alone or in combination with one or more other active pharmaceutical ingredients, in any dosage form or formulation. 
 1.32
“Product Trademarks” shall mean (a) [ * ]; (b) all registrations and applications for registration for such trademarks [ * ]; (c) any corresponding trademarks, and registrations or applications for
registration of such trademarks, [ * ]; (d) any renewals and extensions of any of the foregoing registrations and all other corresponding rights that are or may be secured under the laws; and (e) all good will associated with any of
the foregoing. 
 1.33 “Regulatory Authority” shall mean the FDA, or a regulatory body with similar regulatory authority in
any other jurisdiction. 
 1.34 “Regulatory Exclusivity” shall mean any exclusive marketing rights or data exclusivity
rights conferred by an applicable Regulatory Authority or other governmental authority in the Territory, including any regulatory data protection exclusivity and any extensions to such exclusivity rights. 

1.35 “ROW Territory” shall mean all countries in the world other than the Territory. 

1.36 “Territory” shall mean the United States, and its territories and possessions. 

1.37 “Third Party” shall mean any person, corporation, joint venture or other entity, other than XenoPort, DRL and their
respective Affiliates. 
 1.38 “Valid Claim” means a claim (or claims) [ * ] that has (have) not been revoked or
held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue, interference proceedings, disclaimer or otherwise; [ * ]. 

1.39 “XenoPort IP” shall mean the XenoPort Know-How and XenoPort Patents. 

1.40 “XenoPort Know-How” shall mean all scientific, medical, technical, manufacturing, formulation, regulatory and other
information relating to the Compound and/or Products (including Data): (a) to the extent Controlled by XenoPort as of the Effective Date or, subject to [ * ], during the term of this Agreement after the Effective Date; and (b) that
[ * ] the Compound or a Product prior to the Effective Date, or that [ * ] DRL to exercise its rights or perform its obligations under this Agreement. 

1.41 “XenoPort Patents” shall mean all issued, unexpired patents and all reissues, renewals, re-examinations and extensions
thereof, and patent applications therefor, and any divisions 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
or continuations, in whole or in part, thereof, including those patents and applications set forth in Exhibit 1.41 and, if applicable, XenoPort’s interest in patents and
applications described in [ * ]: (a) to the extent Controlled by XenoPort as of the Effective Date or, subject to [ * ], during the term of this Agreement after the Effective Date; and (b) that [ * ]. 

1.42 Additional Definitions. Each of the following terms shall have the meaning described in the corresponding section of this
Agreement indicated below: 
  

			
	Term	  	Section Defined
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]
	Agreement	  	Introduction
	CoAs	  	8.1(a)
	Commercialization Plan	  	5.1(a)(i)
	[ * ]	  	[ * ]
	Confidential Information	  	9.1
	[ * ]	  	[ * ]
	Delivery Date	  	8.1(a)
	Development Plan	  	4.2(a)
	DOJ	  	16.2
	DRL	  	Introduction
	DRL Indemnitees	  	14.2
	DRL IP	  	10.1
	Enforcement Action	  	10.3(a)
	Execution Date	  	Introduction
	 [ * ]
	  	[ * ]
	Existing Inventory Acceptance Notice	  	8.1(a)
	FTC	  	16.2
	Hart-Scott-Rodino Act	  	16.1
	HSR Clearance Date	  	16.1
	HSR Conditions	  	16.1
	Improvements	  	10.1
	Improvement Patents	  	10.1
	Indemnitee	  	14.3
	Indemnitor	  	14.3
	Indirect Taxes	  	7.2(b)
	Infringement Actions	  	10.4
	Infringing Product	  	10.3(a)
	Joint Steering Committee / JSC	  	3.1
	Jointly-Owned IP	  	10.1
	Liabilities	  	14.1
	Orange Book	  	1.37
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	Paragraph IV Certification	  	10.3(b)
	PK	  	4.1(a)(i)

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

			
	Term	  	Section Defined
	Product Liability Claim	  	14.1
	Product Materials	  	12.2(f)
	Prosecution and Maintenance / Prosecute and Maintain	  	10.2(a)
	[ * ]	  	[ * ]
	Revenue	  	2.5(b)(iv)(d)
	Royalty Term	  	6.4(d)
	Senior Executives	  	3.1(d)
	Stability Studies	  	8.1(a)
	Term	  	11.1
	Third Party IP	  	10.5
	Third Party Claim	  	14.1
	[ * ]	  	[ * ]
	Withdrawal Notice	  	3.2
	XenoPort	  	Introduction
	XenoPort CMO	  	8.1(a)
	XenoPort Indemnitees	  	14.1

 ARTICLE II 

GRANT OF LICENSE 
 2.1
License. Subject to the terms and conditions of this Agreement, XenoPort hereby grants to DRL an exclusive license during the term of this Agreement under the XenoPort Patents and XenoPort Know-How to: (a) develop, use, make, have made,
offer for sale, sell, import, market, distribute and promote Products; and (b) to use, make and have made the Compound for the purposes of developing, making and having made Products; in each case, solely in the Territory for use in the Field.
In addition, DRL may: (i) manufacture or have manufactured the Compound and/or Product(s) outside the Territory solely for the purposes of (A) making Compound and/or Product for DRL and its Affiliates for sale and distribution of Products
in the Territory for use within the Field or (B) providing Products for use in clinical trials for Products conducted by or under the authority of DRL outside the Territory in accordance with clause (ii) below, and (ii) perform
clinical studies in countries of the ROW Territory as approved by the JSC and in accordance with the Development Plan, for the sole purpose of seeking and/or obtaining Marketing Approval in the Territory and for use within the Field. The rights and
licenses granted in the first sentence of this Section 2.1 shall be exclusive even as to XenoPort, except that XenoPort shall continue to have the right to (and to authorize others to): (1) make and have made the Compound and Products in
the Territory for use, distribution and/or sale outside the Territory or for use in clinical studies described in the following clause (2) and (2) to perform clinical studies in the Territory for the sole purpose of seeking and/or
obtaining Marketing Approval in a jurisdiction(s) in the ROW Territory. 
 2.2 Affiliates; Sublicensees. DRL shall have the right, in
accordance with this Section 2.2, to extend the licenses granted under Section 2.1 above to its Affiliates, solely for so long as such entity remains an Affiliate of DRL. DRL shall also have the right to grant sublicenses under

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
the license granted to DRL under Section 2.1 to the extent necessary to allow a Third Party contract manufacturer inside or outside the Territory to make the Compound and/or Products for the
benefit of DRL and solely for the purposes of DRL and/or its Affiliates using such Compound and using and selling Products in the Territory for use in the Field or providing Products for use in clinical trials for Products conducted by or under the
authority of DRL outside the Territory in accordance within this Agreement. [ * ] DRL shall ensure that each of its Affiliates and sublicensees is bound by a written agreement containing provisions at least as protective of the Compound,
Products and XenoPort as this Agreement [ * ] and XenoPort shall be an intended third party beneficiary of each such agreement between DRL and its applicable Affiliate or sublicensee, as the case may be; and each such agreement between DRL
and its applicable Affiliate or sublicensee, as the case may be, shall include a provision acknowledging and expressly agreeing that XenoPort is a third party beneficiary of such arrangement. In any event, DRL shall remain responsible to XenoPort
for all activities of its Affiliates and sublicensees to the same extent as if such activities had been undertaken by DRL itself, and DRL shall be responsible for the payment to XenoPort of all milestone payments and royalties payable with respect
to the activities and Net Sales of any Affiliate or sublicensee of DRL. 
 2.3 Activities Outside the Territory. 

(a) DRL agrees that it shall not, and DRL shall cause its Affiliates not to, sell or provide the Compound or Products to any Third Party if DRL
or its relevant Affiliate knows, or has reason to believe, that the Compound and/or Products, as the case may be, sold or provided to such Third Party would be sold or transferred, directly or indirectly, for use in the ROW Territory, except to the
extent any such Products are for use in clinical trials conducted by or under the authority of DRL in the ROW Territory in accordance with this Agreement or such Compounds are being transferred for the purposes of manufacturing Product for use
and/or sale in the Territory or for use in the foregoing clinical trials. 
 (b) XenoPort agrees that it will not sell or provide the
Compound or Products to any Third Party if XenoPort knows, or has reason to believe, that the Compound and/or Products, as the case may be, sold or provided to such Third Party would be sold or transferred, directly or indirectly, for use in the
Territory, except to the extent any such Products are for use in clinical trials conducted by or under the authority of XenoPort or its licensees in the Territory in accordance with this Agreement. 

2.4 No Other Rights. Except for the rights and licenses expressly granted in this Agreement, XenoPort retains all rights under its
intellectual property, and no additional rights shall be deemed granted to DRL by implication, estoppel or otherwise. For clarity, the licenses and rights granted in this Agreement shall not be construed to convey any licenses or rights under the
XenoPort Patents with respect to any active pharmaceutical ingredient other than the Compound. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 2.5 Certain Covenants. 

(a) DRL Exclusivity. During the Term, except for Products as expressly permitted in accordance with this Agreement [ * ] DRL
agrees that it shall not, and DRL shall cause its Affiliates not to, develop, promote, market, distribute, manufacture, offer for sale, sell or provide [ * ] to any Third Party in any country; and DRL agrees that it shall not, and DRL shall
cause its Affiliates not to, directly or indirectly, authorize or assist any Third Party to do any of the foregoing. 
 (i) For purposes of
this Section 2.5(a), a [ * ] that: (1) is substantially [ * ]; and (2) is subject to, or has obtained, [ * ]; or [ * ] that: (1) is substantially [ * ]; provided that [ * ]. 

(ii) For the avoidance of doubt: (A) in no event shall anything in this Section 2.5 grant, or be construed as granting, to DRL or
any of its Affiliates, by implication, estoppel or otherwise, any rights under any patents [ * ]; and (B) the only licenses and rights granted to or obtained by DRL (or, subject to Section 2.2, any of its Affiliates) under this
Agreement are the express licenses granted by XenoPort to DRL in Section 2.1 above under the XenoPort Know-How and XenoPort Patents with respect to the Compound and Products and, in no event shall, DRL or any of its Affiliates have, or be
construed to have, by implication, estoppel or otherwise, any license or other rights (including any rights to enforce) under any patents [ * ] or any other patent rights or other intellectual property owned or controlled by XenoPort, or with
respect to [ * ] or other subject matter covered or included in any of the XenoPort Know-How and/or XenoPort Patents that is not a Compound or Product (or a method of manufacture or use of the foregoing). 

(b) XenoPort Covenants. 

(i) During the Term, and subject to this Section 2.5(b) below [ * ], XenoPort agrees that neither it, nor any of its Affiliates,
will promote, market, offer for sale or sell, [ * ] in the Territory and [ * ] or, if DRL [ * ]; in each case, if the [ * ]. 

(ii) Nothing in this Section 2.5(b) or otherwise shall prevent or otherwise restrict or limit XenoPort, or any of its Affiliates, from
granting a license or other rights to, or otherwise authorizing, any third party under any of the XenoPort Patents, [ * ] and/or any other patent rights or other intellectual property owned or controlled by XenoPort ([ * ]) to develop,
promote, market, manufacture, distribute, offer for sale, sell or provide [ * ] within or outside the Territory and for any indication or use. 

(iii) If, during the Term, XenoPort [ * ] or XenoPort [ * ] or, if DRL [ * ], an [ * ], then the [ * ] in
the Territory. 
 (iv) Certain Definitions: 

a) [ * ] shall mean those Patents (A) listed on Exhibit 2.5(b), together with any patents issuing thereon and all
reissues, renewals, re-examinations and extensions, divisions or continuations of any such Patents; in each case, to the extent each such Patent: [ * ]. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 b) [ * ] shall mean [ * ]. 

c) [ * ] shall mean any [ * ] pursuant to which XenoPort: (1) [ * ]; or (2) [ * ]. 

d) [ * ] shall mean [ * ] that: (1) constitute [ * ] Psoriasis Indications and/or MS Indications in the Territory;
or (2) represent [ * ] MS Indication; [ * ] will not include: (i) [ * ]. 
 To the extent that any [ *
] Psoriasis Indications and/or MS Indications in the Territory and other intellectual property, undertakings or subject matter [ * ] a Psoriasis Indication or an MS Indication), then, for the purposes [ * ] for Psoriasis
Indications and/or MS Indications in the Territory and such other intellectual property, undertakings or subject matter, [ * ]. 

ARTICLE III 
 GOVERNANCE

 3.1 Joint Steering Committee. [ * ] after the Effective Date, the Parties shall establish a committee (the
“Joint Steering Committee” or “JSC”) to oversee the development, Marketing Approval, manufacturing, and commercialization of the Compound and Products for the Territory. 

(a) Composition. The JSC will consist of [ * ] from each Party, and at least [ * ] from each Party [ * ]. In case
a representative of a Party is unavailable for a scheduled JSC meeting, upon reasonable notice to the other Party, such Party may substitute in place of such representative for such meeting, a competent person who is authorized by such Party to act
on matters that will be presented to the JSC at such meeting. Either Party may also replace its respective JSC representatives at any time with prior notice to the other Party; provided that the criteria for composition of the JSC set forth in the
first sentence of this Section 3.1(a) continues to be satisfied following any such replacement. 
 (b) Meetings. The JSC shall
meet at least once each calendar half year during the term of this Agreement, unless otherwise agreed by the Parties or such other frequency as Parties reasonably mutually agree. Such meeting(s) shall be in person, alternating between each
Party’s (or its Affiliate’s) facilities in the Territory, unless otherwise mutually agreed to in advance and in writing by the Parties, for example to conduct such meeting via teleconference, video conference or by other mutually agreeable
means. At the discretion of each Party, other representatives of XenoPort or DRL may attend JSC meetings as non-voting observers. Each Party shall bear its own personnel and travel costs and expenses relating to such Party’s participation in
JSC meetings. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (c) Responsibility. The JSC shall: (a) review and discuss material matters in
connection with the development, manufacturing, and regulatory activities of the Compound and Products by or under the authority of each Party, provided that, in the case of XenoPort, XenoPort shall provide to the JSC and DRL information relating to
development, manufacturing, regulatory or other activities conducted with respect to the Compound and/or Products for the ROW Territory only to the extent that it has the right to do so; (b) review and discuss DRL’s Development Plan,
including any updates, modifications or additions thereto submitted to XenoPort and the JSC pursuant to Section 4.2(b) below; (c) oversee the implementation of the Development Plan; (d) review and discuss protocols for any clinical
trials involving a Product being conducted by or under the authority of DRL in the Territory or in the ROW Territory for the purpose of seeking or obtaining Marketing Approval for such Product in the Territory; (e) review and discuss the
summaries of any regulatory filings for Product in the Territory (including the precise wording of any Product label) and any regulatory filings pertaining to clinical trials involving a Product conducted by or under the authority of DRL in the ROW
Territory; (f) facilitate the exchange of Data and other information and/or materials between the Parties as provided in this Agreement; (g) review and discuss DRL’s and/or its Affiliates’ manufacturing plans for the Compound and
Product; (h) review and discuss the Commercialization Plan, including any updates, modifications or additions thereto submitted to XenoPort and the JSC pursuant to Section 5.1(a) below, and review and discuss the progress of DRL and/or its
Affiliates thereunder; and (i) undertake and/or approve such other matters as are allocated to the authority of the JSC under this Agreement, or otherwise agreed by the Parties. 

(d) Decisions. It is understood that the purpose of the JSC is to provide a forum for discussion and exchange of information between
the Parties, as provided in this Agreement, and the JSC [ * ]. If the Parties are unable to mutually agree on a resolution with respect to any matter referred to the Senior Executives under this Section 3.1(d) above, DRL shall not
proceed (or authorize any of its Affiliates or any other person or entity to proceed) with a disputed course of action unless and until such dispute is resolved. 

(e) Scope of Governance. Notwithstanding the creation of the JSC, each Party shall retain the rights, powers and discretion granted to
it hereunder, and the JSC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein or the Parties expressly so agree in writing. The JSC shall not have the power to amend
or modify this Agreement, and its decisions shall not be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JSC are only those specific issues that are expressly
provided in this Agreement to be decided by the JSC. 
 3.2 Withdrawal. Notwithstanding Section 3.1 above, it is understood that
XenoPort’s participation in the JSC is not an obligation of, or a deliverable to be provided by, XenoPort under this Agreement and that such participation is a right of XenoPort that XenoPort may exercise or

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
waive, in its discretion. At any time and for any reason, XenoPort shall have the right to withdraw from participation in the JSC upon notice to DRL referencing this Section 3.2, which
notice shall be effective immediately upon receipt (“Withdrawal Notice”). Following the issuance of a Withdrawal Notice, the JSC shall dissolve and neither Party shall be obligated to provide any further updates to the other party
with respect to the matters set forth in Section 3.1(c) above. 
 3.3 General Communications. DRL shall keep XenoPort reasonably
informed as to its (and its Affiliates’ and sublicensees’) progress and activities relating to the manufacture, development and commercialization of Products for the Territory (including with respect to regulatory matters and meetings
with, or inspections by, Regulatory Authorities and the results thereof or any reports or notices issued in connection therewith), by way of updates to the JSC, at its meetings and as otherwise specified in this Agreement, or as reasonably requested
by XenoPort. In connection therewith, DRL shall provide XenoPort with such information regarding such progress and activities under the Development Plan or otherwise relating to the Compound and Products, as XenoPort may reasonably request from time
to time. [ * ]. 
 ARTICLE IV 

DEVELOPMENT 
 4.1
Development. 
 (a) In the Territory. Subject to Section 3.1(d) above, DRL shall be responsible for: (a) conducting,
and shall use Diligent Efforts to conduct, such applicable preclinical studies and clinical trials and to obtain such regulatory approvals, including Marketing Approvals and pricing and/or reimbursement approvals, as may be necessary to
commercialize Product [ * ] in the Territory; and (b) shall use Diligent Efforts to manufacture the Compound and Product as appropriate to support such clinical trials and regulatory approvals for Products for the Territory. Without
limiting the foregoing, DRL agrees to use Diligent Efforts to conduct clinical trials to support, and to obtain, as soon as practical, Marketing Approval for a Product [ * ] in the Territory and to achieve the milestones set forth in
Section 6.3. DRL agrees to timely report adverse events/experiences as defined in the SDEA which may occur in the conduct of these activities. It is understood and agreed that all such development and manufacturing efforts shall be [ *
], and shall be conducted in accordance with the Development Plan described in Section 4.2 of this Agreement. Notwithstanding the foregoing, the Parties agree that XenoPort shall [ * ], and upon [ * ] after the Execution Date
in the performance of such study [ * ]. The ongoing preclinical carcinogenicity studies described in Exhibit 4.1(a) shall not be revised after the Execution Date by XenoPort without DRL’s consent. 

(i) For [ * ], DRL shall promptly consult with the FDA regarding obtaining Marketing Approval [ * ]. In the event (A) the
FDA [ * ] or (B) DRL [ * ]. Unless DRL provides notice as set forth in the preceding sentence of this Section 4.1(i), DRL shall use Diligent Efforts to obtain such regulatory approvals, including Marketing Approvals and
pricing and/or reimbursement approvals, as may be necessary to commercialize [ * ] Product [ * ] in the Territory. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (b) Outside the Territory. XenoPort or its licensee(s) shall be solely responsible for all
development, manufacturing and regulatory activities and expenses with respect to the Compound and Product for the ROW Territory. 
 4.2
DRL Development Plan. 
 (a) [ * ], DRL shall provide the JSC with a plan for its development of Product for the Territory for
use in the Field for the JSC’s review and discussion (such plan, the “Development Plan”). Such Development Plan shall, at a minimum, outline all activities reasonably necessary for the development of the Compound and Product
for the Territory in order to obtain Marketing Approval for Product [ * ] in the Territory, including any necessary preclinical and clinical trials. 

(b) DRL agrees to provide to the JSC for its review updated written versions of the Development Plan [ * ], and also any modification
or addition to the Development Plan within a reasonable period of time prior to adoption and implementation thereof. 
 4.3 Change in
Formulation. Before modifying or creating a new formulation or dosage form of a Product, or developing the Compound in combination with another active ingredient, DRL shall discuss the proposed modifications or development with XenoPort at the
JSC. 
 4.4 Conduct of Activities. DRL shall conduct, and, if applicable, shall cause its Affiliates and sublicensees to conduct, all
activities under the Development Plan in compliance in all material respects with all Applicable Laws and in accordance with good scientific and clinical practices, applicable under the Applicable Laws of the country in which such activities are
conducted. DRL shall provide XenoPort with prompt notice of any alleged violations of Applicable Laws, and any material issues relating to the development or manufacture of the Compound and Products. 

4.5 Exchange of Data and Know-How. 

(a) By XenoPort. After the Effective Date, XenoPort shall provide DRL with [ * ], including, [ * ]. Notwithstanding the
foregoing, in no event shall XenoPort be obligated to provide [ * ]. If XenoPort, at its discretion, [ * ]. 
 (b) By Each
Party. During the term of this Agreement, each Party shall provide to the other Party, in a timely fashion and as promptly as possible, [ * ]. 

(c) Use; Disclosure. DRL may use and disclose XenoPort Know-How to its Affiliates or Third Parties only as required to obtain Marketing
Approval for Products in the 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
Territory and/or as necessary in performing its obligations and exercising its rights under and in accordance with this Agreement, [ * ]. DRL may not use any Data or XenoPort Know-How (and
shall cause its any Third Party to whom DRL discloses any XenoPort Know-How and its Affiliates not to use Data or XenoPort Know-How) outside the Territory, except as required to manufacture the Compound or Products or to conduct clinical trials
involving a Product in accordance with this Agreement, nor for any compound or products other than the Compound and Products. XenoPort may only use, and disclose to Affiliates and/or Third Parties, DRL Know-How provided by DRL as is reasonably
necessary to (i) manufacture the Compound or Products solely for commercialization for the ROW Territory or for use in clinical trials or manufacturing activities conducted in the Territory in accordance with Section 2.1 above;
(ii) develop and/or commercialize the Compound and Product for the ROW Territory; (iii) develop and/or commercialize the Compound and Product for the Territory after termination of this Agreement in accordance with Section 12.2;
and/or (iv) with respect to the Compound and Product, as necessary under Applicable Laws, including for cross referencing drug master files or other regulatory filings by XenoPort and/or Third Parties for use in the ROW Territory. 

(d) Provision of Data to JSC. Upon request by the JSC, DRL shall promptly provide the JSC with summaries in reasonable detail of all
Data generated or obtained in the course of activities conducted under DRL’s Development Plan. 
 4.6 Regulatory Matters. 

(a) Assignment of Regulatory Filings. [ * ] the Effective Date, XenoPort shall provide DRL full copies of [ * ] XenoPort
shall also assign or cause to be assigned to DRL such [ * ]; provided, however, that, prior to [ * ] in connection with its activities under this Agreement. 

(b) Responsibility for Regulatory Filings. Except as provided in Section 4.6(a) above, DRL shall be responsible [ * ] for
filing, obtaining and maintaining approvals for the development and commercialization of the Compound and each Product in the Territory, including any such IND, NDA or Marketing Approval, as well as pricing or reimbursement approvals in the
Territory and for any regulatory filings required in connection with clinical trials for Products conducted by or under the authority of DRL in the ROW Territory in accordance within this Agreement. 

4.7 Regulatory Cooperation. DRL shall [ * ]. Without limiting the foregoing, DRL shall also provide to XenoPort a copy of any
material documents, information and correspondence submitted to, or received from, the FDA or any other Regulatory Authority relating to activities conducted by or under the authority of DRL or any of its Affiliates involving the Compound or a
Product as soon as reasonably practicable, together with summaries thereof, to the extent such summaries exist. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 4.8 Sharing of Regulatory Filings. Without limiting Section 4.5 above, each Party
shall permit the other to access, and shall provide the other Party with sufficient rights to reference and use in association with exercising its rights and performing its obligations under this Agreement (including the right of XenoPort to
commercialize the Product in the ROW Territory), all of such Party’s, and, in the case of DRL, its Affiliates’ and, to the extent a Party has the right to do so and subject to Section 10.5 if applicable, its licensees’ Data,
regulatory filings and regulatory communications associated with any submissions of NDAs or other regulatory approvals for the Compound or a Product in such Party’s respective territory (i.e., in the Territory, in the case of DRL and in the ROW
Territory, in the case of XenoPort). 
 ARTICLE V 

COMMERCIALIZATION AND PROMOTION 

5.1 Commercialization 

(a) In the Territory. Subject to Section 3.1(d) above, DRL and/or its Affiliate(s), shall have the sole right to launch,
manufacture and commercialize Products in the Territory, [ * ] and DRL shall use Diligent Efforts to launch a Product as soon as practicable in the Territory [ * ]. 

(i) Notwithstanding the foregoing, [ * ], DRL shall provide to the JSC, for its review and discuss, an initial commercialization plan
setting forth the strategy for the commercialization of the Products in the Territory during the term of this (such plan, as presented to the JSC and as updated as provided in this Section 5.1(a)(i) below, the “Commercialization
Plan”). The Commercialization Plan shall set forth at least estimated launch dates, and sales forecasts, including at least one year and three year sales forecasts and a high-level marketing plan for Products for all approved indications.
DRL agrees to provide to the JSC, for its review and discussion, updated versions of the Commercialization Plan [ * ] in writing, including any material modification or addition to the Commercialization Plan [ * ] prior to adoption and
implementation thereof. 
 (b) Outside the Territory. XenoPort and/or its licensee(s) shall have the sole right to launch,
manufacture and commercialize Products outside the Territory in its sole discretion. 
 5.2 Reporting; Adverse Drug Reactions. 

(a) [ * ] following the Effective Date, XenoPort will provide a draft Safety Data Exchange Agreement (SDEA) which shall be negotiated by
the Parties in good faith and the Parties will enter into a Safety Data Exchange Agreement that more specifically sets forth the obligations of each Party with respect to the exchange of safety information and will require the Parties to comply with
a standard operating procedure set forth therein governing the collection, investigation, reporting and exchange of safety information with respect to the Compound and Products, including 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
but not limited to adverse events, product quality, and product complaints, sufficient to permit each Party (and in the case of XenoPort, any of its licensees of the Compound and Products outside
the Territory) to comply with their respective legal obligations, all in accordance with Applicable Law. The SDEA must be completed and agreed to prior to DRL’s commencement of any clinical trials involving a Product. The SDEA will be promptly
updated if required by changes in Applicable Law. Each Party shall keep the other Party informed about any adverse events of which such Party (or in the case of DRL, any of its Affiliates) becomes aware or is informed regarding the use of Product in
or outside the Territory. As between the Parties, DRL shall be responsible for reporting all adverse events/experiences with respect to activities involving the Compound and/or Product conducted by or under the authority of DRL to the appropriate
Regulatory Authorities, and XenoPort shall be responsible for reporting all adverse events/experiences with respect to activities involving the Compound and/or Product conducted by or under its authority (other than by or under the authority of DRL)
to the appropriate Regulatory Authorities, in accordance with the appropriate laws and regulations of the relevant countries and authorities. DRL shall ensure that its Affiliates comply with such safety reporting obligations. Each Party will
designate a pharmacovigilance liaison to be responsible for communicating with the other Party regarding the reporting of adverse events/experiences. 

(b) Without limiting Section 5.2(a), [ * ], each Party shall establish and thereafter maintain a safety database with respect to
the Compound and Products in such Party’s territory (i.e., in the case of DRL, the Territory, and in the case of XenoPort, the ROW Territory), and shall provide the other Party with a copy of the data included in such safety database. The SDEA
shall include provisions to facilitate and ensure that each Party has sufficient information to maintain such a database. 
 ARTICLE VI

 PAYMENTS 
 6.1
Initial License Fee. In partial consideration of the costs incurred by XenoPort in connection with the research and development of Product and in exchange for the rights granted herein, DRL shall pay to XenoPort an initial license fee in the
amount of Forty Seven Million Five Hundred Thousand Dollars ($47,500,000) on the Effective Date. XenoPort will issue an invoice to DRL for the Initial license fee amount on the Effective Date. The initial license fee set forth in this
Section 6.1 shall not be refundable or creditable against any future milestone payments, royalties or other payments by DRL to XenoPort under this Agreement. 

6.2 Inventory Payment. DRL shall pay to XenoPort an inventory payment in the amount of Two Million Five Hundred Thousand Dollars
($2,500,000) [ * ] after the Delivery Date (as defined in Section 8.1(a)). The inventory payment set forth in this Section 6.2 shall not be refundable or creditable against any future milestone payments, royalties or other payments
by DRL to XenoPort under this Agreement, except to the extent expressly provided in Section 8.1 below. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 6.3 Milestone Payments. 

(a) Milestone Payments. In addition, DRL shall pay to XenoPort the milestone payments set out below following the first achievement by
DRL, or any of its Affiliates, of the corresponding milestone set out below, in accordance with this Section 6.3 and the payment provisions in Article 7: 
  

			
	Milestone Event	  	Milestone Payment
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]

 (b) Reports and Payments. DRL shall notify XenoPort in writing promptly [ * ] with regard to
Milestone Events [ * ] and [ * ] with regard to Milestone Events [ * ], after the achievement of each milestone set out in Section 6.3(a) by DRL or any of its Affiliates, and shall pay the appropriate milestone payment [
* ] as provided in Section 7.1. Any milestone payable by DRL pursuant to this Section 6.3 shall be made no more than once with respect to the achievement of each milestone set out in Section 6.3(a) by DRL, or any of its
Affiliates, and in no event shall the aggregate amount to be paid by DRL under this Section 6.3 exceed Four Hundred Forty Million Dollars ($440,000,000). For the avoidance of doubt, the milestone payments set forth in this Section 6.3
shall not be refundable and shall not be creditable against future milestone payments, royalties or other payments to XenoPort under this Agreement. For the avoidance of doubt, [ * ]. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 6.4 Royalty Payments. 

(a) Royalty Rate – [ * ]. Subject to the terms and conditions of this Agreement, in further consideration of the rights
granted to DRL under this Agreement, DRL shall pay to XenoPort royalties at the rate set out below on the Net Sales of [ * ] Product(s) in the Territory: 
  

			
	Annual Net Sales of [ * ] Product(s) in the United States	  	Royalty Rate
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]

 (b) Royalty Rate – [ * ]. Subject to the terms and conditions of this Agreement, in further
consideration of the rights granted to DRL under this Agreement, DRL shall pay to XenoPort royalties at the rate set out below on Net Sales of [ * ] Product(s) in the Territory: 

 

			
	Annual Net Sales of [ * ] Product(s) in the United States	  	Royalty Rate
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]

 (c) Discounting. DRL and its Affiliates shall set prices and discounts for Product in the Territory in
the best interest of the commercial success of the Products in the Territory and not for the interest of their other products and services. Without limiting the foregoing, if DRL and/or any of its Affiliates sells any Product to a Third Party who
also purchases other products or services from such entities, DRL and its Affiliates agree not to discount or price Products in a manner that would disadvantage Products in order to benefit sales or prices of such other products or services offered
to such Third Party. However, the foregoing provisions in this Section 6.4(c) shall not be construed to dictate to DRL and/or its Affiliates any resale prices for Product in the Territory. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (d) Royalty Term. 

(i) DRL’s obligations to pay royalties under Section 6.4 (“Royalty Term”) shall commence [ * ] on the [ *
] Product in the Territory and shall continue until the later to occur of: (A) [ * ] Product; (B) the expiration of the last to expire Valid Claim [ * ] in the Territory [ * ]; and (C) expiration of all
Regulatory Exclusivity with respect to [ * ] in the Territory. 
 (ii) [ * ], if (A) a Generic Product [ * ]
Product in the Territory, and (B) for [ * ], and (C) the [ * ]; then the royalty rate payable pursuant to Section 6.4(a) or (b), as applicable, on Net Sales of such Product in Territory shall [ * ] such Net Sales
during such then-current calendar quarter. 
 (iii) The Parties acknowledge and agree that the royalty payments (including the royalty
rates and term for such royalty payments) set forth in Section 6.4 are to be made in consideration for the licenses and rights granted by XenoPort to DRL with respect to [ * ], and have been agreed to by the Parties for the purpose of
reflecting and advancing their mutual convenience, including the ease of calculation of such royalties and the payment of such royalties by DRL to XenoPort. 

(e) Reports and Royalty Payment. [ * ] each calendar quarter, DRL shall deliver to XenoPort a report setting out in reasonable
detail the information necessary to calculate the royalty payments due under this Section 6.4 with respect to Net Sales made in that calendar quarter, including the following, in each case, [ * ]: 

(i) units of [ * ] Product(s) and [ * ] Product(s) sold in the Territory during the relevant calendar quarter; 

(ii) gross sales of Products in the Territory in the relevant calendar quarter; 

(iii) Net Sales in the relevant calendar quarter in the Territory; and 

(iv) all relevant deductions or credits due to DRL in accordance with the terms of this Agreement. 

Any amounts due under Section 6.4(a) and (b) for such calendar quarter shall accompany such statement. 

ARTICLE VII 
 PAYMENTS;
BOOKS AND RECORDS 
 7.1 Payment Method. For all payments covered under this Agreement, XenoPort will issue an invoice to DRL for
each of such payments. All payments under this Agreement shall be 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
made by bank wire transfer in immediately available funds to an account designated by the Party to which such payments are due. Any payments or portions thereof due under this Agreement that are
not paid by the date such payments are due under this Agreement shall bear interest at a rate equal to: [ * ]. This Section 7.1 shall in no way limit any other remedies available to the Parties. All amounts owed by DRL to XenoPort
hereunder shall be paid by an entity resident in Switzerland from a bank account located in Switzerland. 
 7.2 Taxes. 

(a) Withholding Taxes. If laws or regulations require withholding by DRL of any taxes imposed upon XenoPort on account of any initial
license fees, milestone and/or royalties and/or other payments paid under this Agreement, such taxes shall be timely paid by DRL to the proper taxing authorities. Official receipts of payment of any withholding tax shall be secured and sent to
XenoPort as evidence of such payment. The Parties will exercise their reasonable efforts to ensure that any withholding taxes imposed are reduced or eliminated as far as possible under the provisions of any applicable tax treaty, and shall cooperate
in filing any forms required for such reduction. If any withholding taxes are imposed with respect to any initial license fees, milestone and/or royalties and/or other payments payable by DRL to XenoPort under this Agreement, DRL shall pay to
XenoPort such additional amount as is necessary to ensure that the amount actually received by XenoPort with respect to such payment, free and clear of any withholding taxes (including any such withholding taxes imposed on such additional amount),
shall equal the amount of the payment that would have been received if no such withholding taxes applied. 
 (b) In the event DRL is
required to pay any withholding tax under Section 7.2(a) of this Agreement, both Parties will work together in good faith to minimize the amount of such withholding taxes to be paid by DRL. XenoPort shall make reasonable efforts to take credit
or refund of withholding taxes paid by DRL by filing tax returns, as may be reasonably required, to claim the tax refund or credit. If XenoPort is successful in getting a refund or credit of such tax amount, then, after deducting any expenses
thereof, shall provide refund or credit to DRL promptly following receipt of such credit or refunds. 
 (c) Indirect Taxes. All
payment amounts specified in this Agreement are exclusive of value added taxes, sales taxes, consumption taxes and other similar taxes (the “Indirect Taxes”). If any Indirect Taxes are chargeable in respect of any payments, the
paying Party shall pay such Indirect Taxes at the applicable rate in respect of such payments following receipt, where applicable, of an Indirect Taxes invoice in the appropriate form issued by the receiving Party in respect of those payments. The
Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes. If the Indirect Taxes originally paid or otherwise borne
by the paying Party are in whole or in part subsequently determined not to have been chargeable, reasonable steps will be taken by the receiving Party to apply for a refund of these overpaid Indirect Taxes from the applicable governmental authority
or other fiscal authority and any amount of undue Indirect Taxes 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
repaid by such authority to the receiving Party will be transferred to the paying Party [ * ]. In the event that a government authority retroactively determines that a payment made by the
paying Party to the receiving Party pursuant to this Agreement should have been subject to Indirect Taxes, and the receiving Party is required to remit such Indirect Taxes to the government authority, the receiving Party will have the right
(i) to invoice the paying Party for such amount (which shall be payable by the paying Party [ * ]) or (ii) to pursue reimbursement by any other available remedy. 

7.3 U.S. Dollars. All dollar amounts specified in, and all payments made under this Agreement, shall be in U.S. dollars. 

7.4 Records; Inspection. DRL shall keep, and cause its Affiliates to keep, complete, true and accurate books of accounts and records
for the purpose of determining the amounts payable to XenoPort pursuant to this Agreement. Such books and records shall be kept for [ * ]. Such records will be open for inspection during [ * ], by an independent auditor chosen by [
* ] for the purpose of verifying the amounts payable by DRL hereunder. Such inspections may be made [ * ], at reasonable times and [ * ] written notice. Such records [ * ] shall be subject to [ * ]. The independent
auditor from the audit firm of international repute [ * ], shall be obligated to execute a reasonable confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section 7.4 shall be at the expense
of [ * ], unless a variation or error producing [ * ] for a period covered by the inspection is established, in which case all reasonable costs relating to the inspection for such period and any [ * ] amounts that are discovered
shall be paid by [ * ], together with interest on such [ * ] amounts at the rate set forth in Section 7.1 above. If the audit establishes that [ * ] period covered by the audit, then such [ * ] amount shall be
credited against [ * ] under this Agreement after the completion of the audit. The Parties will endeavor in such inspection to minimize disruption of DRL’s normal business activities to the extent reasonably practicable. 

ARTICLE VIII 

MANUFACTURING AND SUPPLY 

8.1 Transfer of Existing Inventory and Stability Studies. 

(a) [ * ] XenoPort shall provide to DRL certificates of analysis (“CoAs”) for the quantities of Compound and Product
included in the Existing Inventory, together with any additional information pertaining to the Existing Inventory in XenoPort’s possession that has been reasonably requested by DRL prior to the Execution Date. DRL shall [ * ] the CoAs
for the Existing Inventory from XenoPort to notify XenoPort of DRL’s acceptance of the Existing Inventory; provided that if DRL fails to so notify XenoPort [ * ], DRL shall be deemed to have accepted the Existing Inventory (such notice
or deemed notice, the “Existing Inventory Acceptance Notice”). [ * ] XenoPort’s [ * ] of the Existing Inventory Acceptance Notice from DRL or the Effective Date, [ * ] the “Delivery Date”),
all XenoPort’s right, title and interest in and to the Existing Inventory, shall be, and is hereby, conveyed and assigned by XenoPort to DRL, and all such Existing Inventory shall be 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
deemed to have been delivered to DRL under this Agreement as of such date. DRL [ * ] to DRL from and after the Delivery Date and shall thereafter remain with DRL, notwithstanding that
certain Third Parties may continue to have possession of the Existing Inventory pursuant to agreements between such Third Party and XenoPort. In addition, on and from the Delivery Date, DRL shall [ * ] conduct of the stability studies of the
Compound and Product ongoing as of the Execution Date and being performed by each of the Third Parties identified on Exhibit 1.13 (each such Third Party, a “XenoPort CMO” and such studies, the “Stability
Studies”). 
 (b) [ * ] the Delivery Date, XenoPort agrees to provide each XenoPort CMO with written notice that, as between
the relevant XenoPort CMO, DRL and XenoPort: (i) if such XenoPort CMO has possession of any Existing Inventory, title to the Existing Inventory within such XenoPort CMO’s possession has passed to DRL [ * ] XenoPort of the Existing
Inventory in such XenoPort CMO’s possession [ * ] DRL [ * ] the Delivery Date, and (ii) DRL [ * ] conduct of those of the Stability Studies [ * ] by such XenoPort CMO. XenoPort shall provide to DRL a copy of
each such notice [ * ] to each XenoPort CMO. 
 (c) If DRL provides XenoPort with an Existing Inventory Acceptance Notice, DRL shall:
(i) [ * ] the Existing Inventory held by each XenoPort CMO, [establish a new] storage [ * ] relevant XenoPort CMO with respect to the storage of such Existing Inventory, and (ii) [ * ] the XenoPort CMOs [ * ]
DRL [ * ] the Stability Studies, including [ * ], in each case, [ * ] the Delivery Date. [ * ] XenoPort shall cooperate with DRL and [ * ] DRL to [ * ] the applicable quantities of Existing Inventory and
[ * ] the Stability Studies [ * ] XenoPort’s [ * ] relevant XenoPort CMO; provided that DRL agrees [ * ] XenoPort to each XenoPort CMO in connection with (i) the storage of such Existing Inventory [ * ]
and/or the performance of any services relating to the same (including, without limitation, services relating to the handling, delivery or disposal of such Existing Inventory), and/or (ii) the performance of the Stability Studies [ * ].
Any such amounts shall be paid by DRL to XenoPort [ * ] receipt of an invoice from XenoPort therefor. 
 (d) XenoPort represents and
warrants to DRL [ * ] that, to its knowledge: (i) the storage of such Existing Inventory [ * ] and/or the performance of any handling, delivery or disposal services by each XenoPort CMO relating to the same have been
conducted in compliance in all material respects with all Applicable Laws; (ii) the performance of the Stability Studies [ * ] by each such XenoPort CMO has been conducted in compliance in all material respects with all Applicable Laws;
and (iii) the quantities of Compound, MMF, and Product specified in Exhibit 1.13 reflect the quantities of such items held at the relevant XenoPort CMO, as reported by such XenoPort CMO to XenoPort. 

(e) DRL acknowledges and agrees that, unless otherwise agreed to by XenoPort in writing: (i) all of XenoPort’s obligations with
respect to the storage of the Existing Inventory at each XenoPort CMO, and/or the performance of any activities relating thereto, and the continuation of the Stability Studies shall terminate [ * ] the Delivery Date; (ii) XenoPort shall
have no further obligations to DRL with respect to the storage of the Existing Inventory, and/or the performance of 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
any activities relating thereto and/or with respect to the Stability Studies, [ * ]; and (iii) in any event, XenoPort’s obligations with respect to all such activities [ *
] shall be limited as described in this Agreement (including this Section 8). 
 (f) If, [ * ] DRL establishes that
(i) any quantities of the Existing Inventory specified on Exhibit 1.13 were less than the actual quantities of Compound, MMF or Product included in the Existing Inventory being held at the relevant XenoPort CMO [ * ] or
(ii)(A) any quantities of Compound, MMF or Product included in the Existing Inventory do not conform to the applicable specification therefor set out in Exhibit 8.1(f), (B) such failure to conform to the applicable
specifications has not been not caused by any negligence, or failure to comply with Applicable Law or such specifications (including retesting the Existing Inventory as part of the Stability Studies) on the part of DRL or any of its Affiliates or
any person storing or otherwise handling the applicable items on DRL’s or its Affiliate’s behalf, (C) the failure to conform is identified [ * ] and (D) DRL or one of its Affiliates has not determined to (or actually used)
use such portion of the Existing Inventory in human clinical trials; then, in the case of each of clauses (i) and (ii) above, DRL may notify XenoPort (and shall include in such notice [ * ] description of the issue). [ * ]
such notice to XenoPort, DRL shall have the right to deduct from future milestone payments due to XenoPort under Section 6.3, an amount equal to XenoPort’s manufacturing cost of the quantity of Existing Inventory that satisfies the
requirements of clause (i) or (ii) above. The foregoing shall be DRL’s sole remedy with respect to any quantities of the Existing Inventory that are inaccurate [ * ] or that do not conform to the applicable specifications and
in no event shall DRL be entitled under this Section 8.1(f) to deduct [ * ] from milestone payments otherwise due to XenoPort under Section 6.3 above. For the avoidance of doubt, DRL shall not have the right to assert that XenoPort
is in material breach of this Agreement, nor to seek to terminate this Agreement under Section 11.2 below, if any quantities of the Existing Inventory actually held by a XenoPort CMO [ * ] are different to the applicable quantities
specified in Exhibit 1.13 or fail to conform the applicable specifications therefor [ * ]. 
 (g) EXCEPT AS EXPRESSLY SET
FORTH IN THIS SECTION 8.1 ABOVE, XENOPORT MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO [ * ], INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OR AS TO THE CONDITION, VALUE OR QUALITY OF [ * ]. 
 8.2 Transfer of Manufacturing and Supply Responsibilities. [ * ]
DRL shall assume responsibility [ * ] for manufacturing and supply of the Compound and Products for use and/or sale by or under the authority of DRL in accordance with this Agreement. XenoPort agrees to [ * ] the Third Party suppliers
that manufactured Compound and/or Product for XenoPort’s Phase II Trial, and shall [ * ] and DRL. The Parties acknowledge and agree that XenoPort shall not be obligated to assign or transfer to DRL any contracts with any such Third Party
supplier or any other XenoPort CMO. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 8.3 Manufacturing and Supply for the Territory. [ * ], as between the Parties: 

(a) Subject to the terms and conditions of this Agreement, during the Term, DRL shall have the exclusive right to manufacture the Compound and
the Products for the purposes of commercial sale of Products in the Territory and to satisfy the development activities in the Development Plan that are conducted in accordance with this Agreement; except that XenoPort shall have the non-exclusive
right to manufacture the Compound and Products at locations within the Territory solely for use and/or sale in the ROW Territory or for use in development activities in the Territory being conducted by or under the authority of XenoPort to support
or obtain Marketing Approval for Products in a jurisdiction(s) within the ROW Territory. It is understood that XenoPort [ * ] DRL with respect to any of the foregoing activities. 

(b) During the Term, each Party agrees that it will not, and in the case of DRL, it will cause its Affiliates not to, enter into any
manufacturing agreements with Third Parties which expressly prohibits the other Party (or, in the case of XenoPort, XenoPort’s licensees) from purchasing the Compound or Product from the same Third Party supplier. 

ARTICLE IX 

CONFIDENTIALITY 
 9.1
Confidential Information. Except as expressly provided in this Agreement, the Parties agree that the receiving Party shall not publish or otherwise disclose and shall not use for any purpose any information furnished to it by the other Party
hereto pursuant to this Agreement (collectively, “Confidential Information”). Notwithstanding the foregoing, Confidential Information shall not include information that, in each case as demonstrated by written documentation: 

(a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure or, as shown by
written documentation, was developed by the receiving Party prior to its disclosure by the disclosing Party; 
 (b) was generally available
to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally available
to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 

(d) was subsequently lawfully disclosed to the receiving Party by a person other than the disclosing Party, and who did not directly or
indirectly receive such information from disclosing Party; or 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (e) is developed by the receiving Party without use of or reference to any Confidential
Information disclosed by the disclosing Party. 
 9.2 Permitted Disclosures. Notwithstanding the provisions of Section 9.1 above
and subject to Sections 9.3 and 9.4 below, each Party hereto may use and disclose the other Party’s Confidential Information to its Affiliates, licensees, contractors and any other Third Parties to the extent such use and/or disclosure is
reasonably necessary to exercise the rights granted to it, or reserved by it, under this Agreement (including in the case of XenoPort, in connection with the development, manufacture and/or commercialization of the Compound and/or Products for
outside the Territory), prosecuting or defending litigation, complying with Applicable Laws, submitting information to tax or other governmental authorities or conducting clinical trials hereunder with respect to any Product. If a Party is required
by law or regulations to make any such disclosure of the other Party’s Confidential Information, to the extent it may legally do so, it will give reasonable advance notice to such other Party of such disclosure and, save to the extent
inappropriate in the case of patent applications or otherwise, will use its good faith efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise). For any other
disclosures of the other Party’s Confidential Information, including to Affiliates, licensees, contractors and/or other Third Parties, a Party shall ensure that the recipient thereof is bound by a written confidentiality agreement as materially
protective of such Confidential Information as this Article 9. 
 9.3 Confidential Terms. Each Party agrees not to disclose to
any Third Party [ * ], except each Party may disclose [ * ] Notwithstanding the foregoing, the Parties [ * ]. 
 9.4
Publication of Product Information. [ * ] Products [ * ] the Product [ * ] relating to the Compound and/or Products [ * ] the Parties. The contribution of each Party shall be noted in all publications or
presentations by acknowledgment or co-authorship, whichever is appropriate. 
 9.5 Publicity Review. The Parties acknowledge the
importance of supporting each other’s efforts to publicly disclose results and significant developments regarding the Compound and Products for the Territory and other activities pursuant to this Agreement that may reflect the terms of this
Agreement or information that [ * ], beyond what is required by Applicable Law, and each Party may make such disclosures from time to time [ * ]. Such disclosures may include, without limitation, achievement of milestones, significant
events in the development and regulatory process, commercialization activities and the like. When a Party [ * ] elects to make any such public disclosure under this Section 9.5, it will [ * ]. The principles to be observed in such
disclosures shall be accuracy, compliance with Applicable Law, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the [ * ] Party’s business.
Accordingly, the [ * ] Party shall [ * ] disclosure that complies with such principles. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 9.6 Prior Non-Disclosure Agreements. Upon execution of this Agreement, the terms of this
Article 9 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties with respect to information relating to the Compound, Products and/or the business or operations of a Party. Any such information
disclosed under such prior agreements shall be deemed disclosed under this Agreement. 
 ARTICLE X 

INTELLECTUAL PROPERTY 

10.1 Ownership of Inventions. As between the Parties, all rights, title and interest in and to all inventions and other intellectual
property made (a) solely by personnel of DRL or any of its Affiliates in connection with this Agreement (“DRL IP”) shall be solely owned by DRL; (b) solely by personnel of XenoPort or any of its Affiliates in connection
with this Agreement shall be solely owned by XenoPort; and (c) jointly by personnel of XenoPort and DRL (or their respective Affiliates) in connection with this Agreement (“Jointly-Owned IP”) shall be jointly owned by XenoPort
and DRL. DRL hereby grants to XenoPort a non-exclusive, worldwide, irrevocable, fully paid-up license, with the right to sublicense, under any Improvement Patents to make, have made, use, sell, offer for sale, import, practice and otherwise exploit
such Improvements, subject to the exclusive rights granted to DRL under this Agreement with respect to the Compound and Products in the Territory. As used herein, “Improvement Patents” means any Patent and any patent rights in
inventions made by or under authority of DRL in connection with the research, development and/or commercialization of any Compound and/or Product that pertains to the Compound and/or Product and/or compositions, use, formulations, manufacture,
packaging and/or testing of the Compound and/or Product, including Patents and patent rights within the DRL IP and DRL’s interest in any Jointly-Owned IP (“Improvements”). 

10.2 Prosecution and Maintenance of XenoPort Patents. 

(a) XenoPort Patent Rights. XenoPort shall, in its sole discretion and expense, control all Prosecution and Maintenance of Patents
included in the XenoPort Patents [ * ], XenoPort shall [ * ]. For the purposes of this Section 10.2, “Prosecution and Maintenance” (including variations such as “Prosecute and Maintain”) shall
mean, with respect to a Patent, the preparing, filing, prosecuting and maintenance of such Patent, as well as re-examinations, reissues and requests for Patent term extensions and the like with respect to such Patent, together with the conduct of
interferences, the defense of oppositions and other similar proceedings with respect to a Patent. 
 (b) DRL Patents and Jointly-Owned
Patents. DRL shall, in its sole discretion and expense, control all Prosecution and Maintenance of all Patents included within DRL IP, including Improvement Patents. Prosecution and Maintenance of any Patent included within Jointly-Owned IP, and
[ * ]. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (c) Cooperation. Each Party shall cooperate with the other Party in connection with its
Prosecution and Maintenance activities undertaken as set forth this Section 10.2, including: (i) making available in a timely manner any documents or information as the other Party reasonably requests to facilitate Prosecution and
Maintenance of the XenoPort Patents, Patents included within DRL IP, and Patents included within Jointly-Owned IP; and (ii) if and as appropriate, signing (or causing to have signed), at the reasonable request of the other Party, all documents
relating to the Prosecution and Maintenance of the XenoPort Patents and, during the Term, Patents included within DRL IP, and Patents included within Jointly-Owned IP. Each Party shall [ * ] provide to the other Party all information
reasonably requested with regard to its Prosecution and Maintenance activities pursuant to this Section 10.2. Each Party shall hold all information disclosed to it under this Section as Confidential Information. 

10.3 Enforcement. 
 (a)
Notice. Subject to the provisions of this Section 10.3, in the event that DRL [ * ] that any XenoPort Patents in the Territory are infringed by a Third Party, or any of the XenoPort Patents are subject to a declaratory judgment
action in the Territory arising from such infringement, in each case with respect to the manufacture, sale or use of a product containing a Compound (an “Infringing Product”), DRL shall [ * ] notify XenoPort. XenoPort shall
have the initial right (but not the obligation), [ * ] to enforce the XenoPort Patents with respect to such infringement or defend any declaratory judgment action with respect thereto in the Territory (for purposes of this Section 10.3,
an “Enforcement Action”). DRL shall, [ * ] have the right to join in as a party plaintiff [ * ] and, in any event, at all times shall give reasonable assistance to XenoPort with respect to such Enforcement Action. [
* ] XenoPort shall keep DRL reasonably informed of the progress of any such Enforcement Action. [ * ]XenoPort agrees not to settle any Enforcement Action, or make any admissions or assert any position in such Enforcement Action, [ *
] with respect to the Compound and Products in the Territory, [ * ]. 
 (b) Initiating Enforcement Actions. In the event
that, [ * ] XenoPort fails to initiate an Enforcement Action to enforce the XenoPort Patents against [ * ] infringement by a Third Party in the Territory, which infringement consists of the manufacture, sale or use of an Infringing
Product in the Field in the Territory, [ * ], DRL may initiate an Enforcement Action against such infringement [ * ]; provided however that if the Infringing Product is the subject of a paragraph IV certification under the Hatch
Waxman statute, 21 U.S.C. §355(j)(2)(A)(vii)(IV) or any successor provision thereto (“Paragraph IV Certification”), XenoPort shall [ * ] initiate such Enforcement Action; provided further that if any applicable
XenoPort Patent contains claims directed to subject matter other than the Compound or Product, or a method of use or manufacture of the Compound or a Product, DRL shall [ * ]. [ * ] XenoPort shall cooperate in such Enforcement Action
[ * ]. DRL shall keep XenoPort [ * ] informed of the progress of any such Enforcement Action. XenoPort shall, [ * ] have the right to join in as a party plaintiff and to give [ * ] assistance to such Enforcement Action.
DRL agrees not to settle any Enforcement Action, or make any admissions or assert any 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
position in such Enforcement Action, in a manner that would materially adversely affect the validity, enforceability or scope of any XenoPort Patents or any Patents controlled by XenoPort
relating to the Compound or Product (or any method of use or manufacture of any of the foregoing) outside the Territory [ * ]. 
 (c)
Recovery. DRL and XenoPort shall [ * ] associated with any litigation against infringers undertaken pursuant to Section 10.3(b) above or settlement thereof [ * ]. 

(d) Cooperation. The Parties shall keep one another informed of the status of their respective activities regarding any litigation or
settlement thereof concerning any Enforcement Actions described in this Section 10.3 controlled by such Party and shall assist one another and cooperate in any such litigation at the other’s reasonable request (including joining as a party
plaintiff to the extent necessary and requested by the other Party). 
 10.4 Third Party Infringement Claims. If the manufacture or
use of the Compound or the manufacture, use or sale of a Product in the Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent infringement against XenoPort or DRL (or their respective Affiliates or licensees)
(collectively, “Infringement Actions”), such Party shall [ * ] notify the other Party hereto in writing. The Party subject to such Infringement Action shall have the right to direct and control the defense thereof; provided,
however, that the other Party may participate in the defense and/or settlement thereof [ * ]. In any event, the Party that is subject to the Infringement Action agrees to keep the other Party hereto [ * ] informed of all material
developments in connection with any such Infringement Action. The Party who is subject to the Infringement Action agrees not to settle such Infringement Action, or make any admissions or assert any position in such Infringement Action, in a manner
that would adversely affect the other Party’s rights with respect to the Compound or a Product in such other Party’s territory (i.e., in the case of DRL, the Territory, and in the case of XenoPort, the ROW Territory) or the manufacture or
use of the Compound or manufacture, use or sale of any Product in such other Party’s respective territory, [ * ]. To the extent an Infringement Action is initiated during the Term, [ * ]. 

10.5 XenoPort IP Acquired after the Execution Date. If, after the Execution Date, XenoPort acquires from a Third Party subject matter
within the XenoPort Patents, and/or XenoPort Know-How, as applicable, (“Third Party IP”) that is subject to royalty or other payment obligations to such Third Party, then the following shall apply. The licenses granted under
Section 2.1 above with respect to such Third Party IP shall be subject [ * ] the XenoPort Patents, and/or XenoPort Know-How, as applicable, hereunder. 

10.6 Patent Marking. DRL agrees to mark appropriately, and ensure that its Affiliates appropriately mark, all patented Product that it
sells or distributes pursuant to this Agreement in accordance with the applicable patent statutes or regulations in the Territory to enable recovery of all damages or remedies available with respect to infringement of XenoPort Patents or any other
Patents controlled by DRL relating to the Compound or Product. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 10.7 Regulatory Data Protection. 

(a) To the extent required or permitted by Applicable Law, the Parties will use Diligent Efforts to promptly, accurately and completely list,
with the applicable Regulatory Authorities during the Term all applicable XenoPort Patents, and/or any Patents that are Controlled by DRL or its Affiliates, for any Product and that the Parties intend, or have begun, to commercialize in the
Territory and that have become the subject of an NDA submitted to FDA, such listings to include all Orange Book listings required under the Hatch-Waxman Act (regardless of which Party is the sponsor of record of the NDA at such time). 

(b) In connection with such listings, the Parties will meet to evaluate and identify all applicable Patents that are Controlled by each Party.
DRL [ * ] the listing of all applicable Patents for any Product Controlled by DRL, and XenoPort [ * ] listing of any XenoPort Patent.  

10.8 Product Trademarks. DRL shall not use, nor authorize the use of, the Product Trademarks except in the Territory, and agrees not to
file or register the Product Trademarks, or any trademarks confusingly similar to the Product Trademarks, in any jurisdiction within the ROW Territory. DRL shall own, and shall be entitled to register, all Product Trademarks in the Territory in
connection with packaging, marketing, promoting, distributing and selling Product(s), including all goodwill accruing from the use of such Product Trademarks in the Territory. XenoPort shall not knowingly take any action that would materially
adversely affect the value of the Product Trademarks in the Territory. 
 ARTICLE XI 

TERM, TERMINATION AND CONDITIONS TO OBLIGATIONS 

11.1 Term. This Agreement shall commence on the Execution Date, and unless terminated earlier as provided in this Article 11,
shall continue in full force and effect on a Product-by-Product basis until DRL has no remaining payment obligations to XenoPort with respect to such Product (the “Term”). Upon expiration (but not an earlier termination) of this
Agreement, DRL shall [ * ] such Product in the Territory. 
 11.2 Breach. Either Party to this Agreement may terminate this
Agreement in the event the other Party shall have materially breached or defaulted in the performance of any of its obligations hereunder, and such default shall have continued for [ * ] after written notice thereof was provided to the
breaching Party by the non-breaching Party; provided, however, that if such breach is capable of being cured but cannot be cured within such [ * ] period and the breaching Party initiates actions to cure such breach within such [ * ]
period and thereafter diligently pursues such actions, then upon written notice by the non-breaching Party to the non-breaching Party describing actions being taken to cure the applicable breach, the breaching Party shall have an additional period,
but in no event longer than [ * ], to cure such breach. Any such termination shall become effective at the end of the applicable period unless the breaching Party has cured any such breach or default prior to the expiration of the applicable
period. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 11.3 Termination For Convenience. DRL may terminate this Agreement in its entirety for any
reason: (a) upon sixty (60) days’ prior written notice to XenoPort prior to the First Commercial Sale; and (b) upon one hundred eighty (180) days’ prior written notice to XenoPort following the First Commercial Sale.

 11.4 Termination for Patent Challenge. XenoPort shall have the right to terminate this Agreement upon notice to DRL in the event
that DRL, or any Affiliate or sublicensee of DRL, or any Third Party assigned or designated by DRL or any of its Affiliates, [ * ] in connection with a challenge to the validity, enforceability, scope, inventorship or ownership of any of the
XenoPort Patents, or any other Patents controlled by XenoPort in the ROW Territory relating to the Compound or a Product, in any court or tribunal or before the United States Patent and Trademark Office or, any other patent office or in any
arbitration proceeding, including in connection with an opposition proceeding, re-examination, or other post-grant proceeding, unless such challenge is withdrawn [ * ]. 

11.5 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by either Party are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S.
Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other
country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the
Party that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the
non-subject Party’s possession, shall be promptly made available to it (a) upon any such commencement of a bankruptcy proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects
to continue to perform all of its obligations under this Agreement, or (b) if not made available under clause (a) above when required, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon
written request therefor by the non-subject Party. 
 11.6 Conditions to Obligations of DRL and XenoPort. As provided in
Section 16.1 below, the rights and obligations of each of DRL and XenoPort pursuant to Articles 2 through 8 (excluding Section 8.1(a), 8.1(d) and 8.1(e)) and Article 10 shall not take effect until the HSR Clearance Date

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
and shall further be subject to the fulfillment by each Party, or waiver by the other Party, on or prior to the Effective Date, of the following conditions: 

(a) The representations and warranties of each Party contained in Article 13 of this Agreement shall be true and correct in all respects (in
the case of any representation or warranty qualified by materiality) or in all material respects (in the case of any representation or warranty not qualified by materiality) as of the Effective Date with the same effect as though made at and as of
such date (except those representations and warranties that address matters only as of a specified date, which shall be true and correct in all respects as of that specified date). 

(b) Each Party will have received from the other Party a certificate, signed by a duly authorized officer of such other Party, certifying that
the condition set forth in Section 11.6(a) has been satisfied. 
 ARTICLE XII 

EFFECT OF TERMINATION 

12.1 Accrued Obligations. The expiration or termination of this Agreement for any reason shall not release either Party from any
liability that, at the time of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination, nor will any termination of this Agreement preclude either Party from
pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. 
 12.2
Rights on Termination. This Section 12.2 shall apply upon any termination of DRL’s rights under this Agreement in its entirety, excluding only termination of this Agreement pursuant to Section 11.2 for XenoPort’s breach.

 (a) Wind-down Period. 

(i) Development. In the event there are any on-going clinical trials of Product for the Territory and/or any on-going formulation
studies (e.g. stability studies) of Product for the Territory, to the extent so requested by XenoPort, DRL agrees to either promptly transition such clinical trials and/or formulation studies to XenoPort (or its designee), or continue to conduct
such clinical trials and/or formulation studies, at DRL’s own expense, and otherwise in accordance with the terms and conditions of this Agreement in effect prior to its termination. 

(ii) Commercialization. To avoid a disruption in the supply of Product to patients in the Territory if this Agreement expires or is
terminated after the First Commercial Sale of Product in the Territory, DRL and its Affiliates shall continue to distribute all Products for which Marketing Approval has been obtained in the Territory in accordance with the terms and conditions of
this Agreement, [ * ]. Notwithstanding any other provision of this Agreement, [ * ] XenoPort shall have the right to engage one or more other distributor(s) and/or licensee(s) of the Compound and/or Products in all or part of the
Territory. Any Product sold or disposed by DRL and its 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
Affiliates in the Territory [ * ] shall be subject to the applicable payment obligations under Articles 6 and 7 above. [ * ] expiration or termination of this Agreement (or if
applicable and at XenoPort’s election, [ * ]), DRL shall notify XenoPort of any quantity of the Compound and/or Product remaining in DRL’s inventory and, [ * ] DRL shall transfer to XenoPort (or its designee) all right, title
and interest in and to any such quantities of the Compound and/or Product [ * ]. 
 (b) Assignment of Regulatory Filings and
Marketing Approvals. At XenoPort’s [ * ], DRL shall, at its expense, assign or cause to be assigned to XenoPort or its designee [ * ] all regulatory filings and registrations (including INDs, NDAs and Marketing Approvals) for
the Compound and/or any Product in the Territory, including any such regulatory filings and registrations made or owned by its Affiliates. In each case, unless otherwise required by any Applicable Law or requested by XenoPort, the foregoing
assignment (or availability) shall [ * ] such expiration or termination of this Agreement. In addition, DRL shall, [ * ] provide to XenoPort (in electronic form, to the extent the same exists in electronic form) a copy of all Data and
DRL Know-How pertaining to the Compound and/or Product (including all development plans, life cycle management plans, medical education materials and/or commercialization plans), to the extent not previously provided to XenoPort, and XenoPort shall
have the right to use (and authorize the use of), and to disclose, all such Data and other DRL Know-How following expiration or termination of this Agreement. 

(c) Supply. DRL shall [ * ] transition to XenoPort, upon XenoPort’s request, any arrangements with any contractor from
which DRL had arranged to obtain a supply of the Compound or Product for use or sale in the Territory. In any event, DRL shall continue to provide to (or procure for) XenoPort Compound and/or Products [ * ]. The [ * ] continued supply
of Compound and/or Products to XenoPort pursuant to the transition supply terms of this Section 12.2(c) shall [ * ]. Without limiting the foregoing provisions of this Section 12.2(c), DRL shall, [ * ] provide to XenoPort [
* ] all DRL Know-How pertaining to the manufacture of the Compound and Products to the extent not previously provided to XenoPort during the Term or pursuant to Section 12.2(b), and XenoPort shall have the right to use (and authorize the
use of) and to disclose all such DRL Know-How in connection with the manufacture of the Compound and Products following expiration or termination of this Agreement. Further, [ * ] DRL shall [ * ] to XenoPort (and/or its designated
contract manufacturer(s)) DRL’s (or its relevant Third Party contract manufacturer’s) personnel with expertise in manufacturing any Compound and/or Products [ * ] to allow XenoPort (and/or its designated contract manufacturer(s)) to
implement the manufacture of such Compound and/or Products at their facilities [ * ]. 
 (d) Transition. DRL shall [ *
] XenoPort and/or its designee to effect a smooth and orderly transition in the development, sale and on-going marketing, promotion and commercialization of the Compound and Product in the Territory. Without limiting the foregoing, DRL shall
conduct [ * ] activities to be conducted under Section 12.2. In addition, DRL shall refer all inquiries received by DRL [ * ] regarding the Compound or Products to XenoPort or its designee. Further, DRL shall [ * ] its
Affiliates shall transition all Compound and Products back to XenoPort in the manner set forth in this Section 12.2 as if such Affiliate were named herein. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (e) Licenses; Assignment. DRL hereby grants to XenoPort an exclusive, worldwide,
royalty-free license, with the right to grant and authorize sublicenses, under any DRL Know-How, and/or any Patents owned or Controlled by DRL or its Affiliates [ * ] in connection with, the development, manufacture and/or commercialization
of the Compound and/or Product for the purposes of making, having made, using, developing, importing, selling, distributing, marketing, promoting and otherwise commercializing the Compound, product containing Compound and/or Product in or outside
the Territory. Upon the effective date of a termination, DRL agrees to assign and does hereby assign to XenoPort, DRL’s right, title, and interest in and to the Product Trademarks in the Territory, and all goodwill accruing from the use of such
Product Trademarks, and DRL shall cease all use of the Product Trademarks. 
 (f) Return of Materials. Except for any Product in
DRL’s inventory that is transferred to XenoPort as set forth in Section 12.2(a)(ii), [ * ] DRL shall, [ * ] destroy all tangible items comprising, bearing or containing any Data provided by XenoPort and/or any Product
Trademarks, including any samples, literature, sales and promotional aids relating to the Compound and/or Products (“Product Materials”) and Confidential Information of XenoPort, that is in DRL’s possession, and provide
written certification of such destruction, or prepare such tangible items of Product Materials and Confidential Information for shipment to XenoPort, as XenoPort may direct [ * ]. 

12.3 Termination by DRL under Section 11.2. If this Agreement is terminated by DRL in accordance with Section 11.2 by reason
of XenoPort’s material uncured breach, then the only provisions of this Agreement that will survive such termination are [ * ]  

(a) [ * ]. 
 12.4
Survival. Upon the expiration or termination of this Agreement, all rights and obligations of the Parties under this Agreement shall terminate except as expressly provided in Sections 12.1, 12.2 and 12.3 above and those rights and obligations
of the Parties under the following Articles and Sections: [ * ]. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 ARTICLE XIII 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

13.1 General Representations. Each Party hereby represents and warrants to the other Party as of the Execution Date as follows: 

(a) Duly Organized. Such Party is a corporation duly organized, validly existing and is in good standing under the laws of the
jurisdiction of its incorporation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to
have such would prevent such Party from performing its obligations under this Agreement. 
 (b) Due Execution; Binding Agreement.
This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party have been duly authorized by all necessary corporate action
and do not and will not: (i) require any consent or approval of its stockholders; (ii) to such Party’s knowledge, violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body
or administrative or other agency having jurisdiction over such Party; nor (iii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which such Party is a party or by which it is bound.

 (c) Debarment. Such Party has not been debarred and is not subject to debarment and neither it nor any of its Affiliates have
knowingly used, nor will knowingly use in any material capacity, in connection with the activities directed to the development, manufacturing or commercialization of the Compound or Product for the Territory, any person or entity who has been
debarred pursuant to Section 306 of the FDCA, or who is subject of a conviction described in such Section 306. Further, during the term of this Agreement, such Party agrees to inform the other Party in writing promptly if it or any person
or entity who is performing activities directed to the development, manufacturing or commercialization of the Compound or Product for the Territory hereunder is debarred or is the subject of a conviction described in such Section 306, or if any
action, suit, claim, investigation or legal administrative proceeding is pending or, to such Party’s knowledge, is threatened, relating to the debarment of such Party, its Affiliates or any person or entity used in any material capacity by such
Party or its Affiliates in connection with the activities directed to the development, manufacturing or commercialization of the Compound or Product for the Territory. 

(d) False Statements. Neither such Party, nor any officer, employee or agent of such Party, has made, or, during the term of this
Agreement, will make an untrue statement of a material fact to the FDA with respect to the Compound or Product (whether in any submission to such Regulatory Authority or otherwise), or has knowingly failed or will knowingly fail to disclose a
material fact required to be disclosed to the FDA with respect to the Compound or Product. 
 (e) Anti-Bribery; Anti-Corruption. To
the extent applicable, each Party has complied, and will comply, in all material respects with all Applicable Laws pertaining to bribery, corruption and prohibited business practices of and has not, and will not, engage in any actions in relation to
transactions that are in violation of such Applicable Laws, including, to the extent applicable, Prevention of Corruption Act, 1988, Foreign Corrupt Practices Act, 1977 and UK Bribery Act 2010. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 13.2 Representations, Warranties and Covenants of XenoPort. XenoPort represents, warrants
and covenants to DRL that, as of the Execution Date: 
 (a) it Controls the XenoPort IP, and it has the full right and authority to grant
the rights and licenses as provided herein; 
 (b) it has not previously granted, nor will it grant during the Term, any right, license or
interest in or to the XenoPort IP, or any portion thereof, that is in conflict with the rights or licenses granted to DRL under this Agreement; 

(c) to its knowledge, there are no Patents Controlled by XenoPort in the Territory not included in the XenoPort Patents that claim composition
of matter (including, product by process), method of manufacture or use in the Field of the Compound or Product; 
 (d) to its knowledge,
the research, development, manufacture, sale, offer for sale, import or export of the Compound or the Non-Equivalent Product described in clause (a) of Section 1.26, in each case, as they exist as of the Execution Date, does not infringe a
claim of a Patent nor misappropriate any other intellectual property rights of any Third Party; 
 (e) to its knowledge, none of the
XenoPort Patents are invalid or unenforceable, all fees required to be paid to applicable governmental patent offices in the Territory as of the Execution Date in order to prosecute or maintain such XenoPort Patents have been paid on or before the
due date for payment, and all such XenoPort Patents have been filed and maintained in a manner consistent with XenoPort’s standard practice in the Territory; 

(f) there are no actual, pending, or, to its knowledge, alleged or threatened actions, suits, claims, interference or governmental
investigations in the Territory involving the Compound, the Product, or the XenoPort IP, by or against XenoPort, or any of its Affiliates. In particular, to its best knowledge, there is no pending or threatened product liability action nor
intellectual property right litigation in the Territory in relation to the Compound; 
 (g) except for any filings that may be made by
XenoPort with the FTC and DOJ pursuant to the Hart-Scott-Rodino Act and subject to satisfaction of the HSR Conditions as described in Article 16, all necessary consents, approvals and authorizations of all Regulatory Authorities, other
governmental authorities and other persons or entities required to be obtained by XenoPort in order to enter into this Agreement have been obtained; and 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (h) to its knowledge, there is no actual, pending, alleged or threatened infringement or
misappropriation by a Third Party in the Territory of any of the XenoPort Patents or the XenoPort Know-How. 
 13.3 Representations and
Warranties of DRL. DRL represents and warrants to XenoPort that, as of the Execution Date: 
 (a) it has the full right and authority to
grant the rights granted herein; 
 (b) all necessary consents, approvals and authorizations of all Regulatory Authorities, other
governmental authorities and other persons or entities required to be obtained by DRL in order to enter into this Agreement have been obtained; and 

(c) DRL does not have any knowledge that any of XenoPort’s representations and warranties set forth in Sections 13.1 and 13.2 above
are inaccurate. 
 13.4 Notice Obligations Between Execution Date and Effective Date. Each Party shall [ * ] notify the other
Party if any representation or warranty made by it in this Article 13 becoming untrue or inaccurate in any material respect during the period commencing on the Execution Date and ending on the Effective Date; provided, however, that the
delivery of any notice pursuant to this Section 13.4 shall not in and of itself be deemed to limit or modify such receiving Party’s payment or other obligations under this Agreement. For the avoidance of doubt, if the Effective Date
occurs, the delivery of a notice by XenoPort to DRL pursuant to this Section 13.4 shall not, and shall not be deemed to, modify DRL’s obligations to pay the entire amounts specified in Section 6.1 and Section 6.2 above (with
respect to Section 6.2, provided that DRL issues an Existing Inventory Acceptance Notice pursuant to Section 8.1(a) above). 

13.5 DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY
WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OR VALIDITY OF ANY PATENTS ISSUED OR PENDING. 

ARTICLE XIV 

INDEMNIFICATION 
 14.1
Indemnification of XenoPort. DRL shall indemnify and hold harmless each of XenoPort, its Affiliates and licensees and their respective directors, officers and employees and the successors and assigns of any of the foregoing (the
“XenoPort Indemnitees”), from and against any and all liabilities, damages, penalties, fines, costs, expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Liabilities”) from any
claims, actions, suits or proceedings brought by 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
a Third Party (a “Third Party Claim”) incurred by any XenoPort Indemnitee, arising from, or occurring as a result of: (a) the developing, making, having made, use,
marketing, distribution, import, export and/or sale of the Compound and/or Products by or under the authority of DRL on or after the Effective Date, including, without limitation, any Third Party Claim alleging product liability, manufacturing,
packaging or labeling defect, failure to warn, or any similar action relating to the formulation (to the extent such formulation of a Product was developed after the Effective Date), manufacture, use or safety of those Products sold or provided by
or under authority of DRL (a “Product Liability Claim”) (b) the storage of the Existing Inventory by any XenoPort CMO on or after the Delivery Date and/or any activities or services performed on or after the Delivery Date by a
XenoPort CMO relating to such Existing Inventory, or (c) any material breach of any representations, warranties or covenants by DRL in Section 13 above; except to the extent such Third Party Claims fall within the scope of XenoPort’s
indemnification obligations set forth in Section 14.2 below. 
 14.2 Indemnification of DRL. XenoPort shall indemnify and
hold harmless each of DRL, and its Affiliates and their respective directors, officers and employees and the successors and assigns of any of the foregoing (the “DRL Indemnitees”), from and against any and all Liabilities from any
Third Party Claims incurred by any DRL Indemnitee, arising from, or occurring as a result of: (a) the developing, making, having made, use, marketing, distribution, import, export and/or sale of any Compound and/or Product by XenoPort or its
Product licensee(s) (other than DRL or any Person under DRL’s authority), including, without limitation, any Third Party Claim alleging product liability, manufacturing, packaging or labeling defect, failure to warn, or any similar action
relating to the formulation (to the extent such formulation was developed before the Effective Date), manufacture, use or safety of those Products sold or provided by or under authority of XenoPort or its Product licensee(s), (b) the storage of
the Existing Inventory by any XenoPort CMO on or before the Delivery Date and/or any activities or services performed on or before the Delivery Date by a XenoPort CMO relating to such Existing Inventory, or (c) any material breach of any
representations, warranties or covenants by XenoPort in Article 13 above. 
 14.3 Procedure. Except with respect to Third Party
infringement claims subject to Section 10.3 above, a Party that intends to claim indemnification under Article 14 (the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) in writing of any
Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense and/or settlement thereof. The indemnity arrangement in Article 14 shall not apply to amounts paid
in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the
Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under Article 14, but
the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability that it may have to any Indemnitee otherwise than under Article 14. The Indemnitee under Article 14 shall cooperate fully with the
Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 14.4 Insurance. Each Party shall secure and maintain in effect during the term of
this agreement, and [ * ] insurance policy(ies) underwritten by a reputable insurance company and having [ * ] for exposures related to pharmaceutical products (including the Compound and Products) and their development, manufacture
and/or commercialization. Such policies shall include coverage for [ * ]. Upon request by a Party, certificates of insurance evidencing the coverage required above shall be provided by the other Party to the requesting Party. 

14.5 LIMITATION OF LIABILITY. EXCEPT WITH RESPECT TO (A) EACH PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 14.1 OR
SECTION 14.2, (B) EITHER PARTY’S BREACH OF ITS OBLIGATIONS UNDER SECTION 2.3, OR (C) EITHER PARTY’S BREACH OF ITS OBLIGATIONS UNDER SECTION 2.5, AS APPLICABLE, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE
LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS THAT ARE CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, WILLFUL MISCONDUCT,
STRICT LIABILITY OR OTHERWISE, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF. 

ARTICLE XV 
 DISPUTE
RESOLUTION 
 15.1 Senior Executives. In the event of any dispute between the Parties arising out of or in connection with this
Agreement, either Party may, by written notice to the other, have such dispute referred to the Senior Executives of the Parties for attempted resolution by good faith negotiations [ * ] and, in such event, each Party shall cause its
representative to meet and be available to attempt to resolve such issue. Notwithstanding the foregoing, neither Party shall be obligated to negotiate [ * ]. If the Parties should resolve such dispute or claim, a memorandum setting forth
their agreement will be prepared and signed by both Parties if requested by either Party. 
 15.2 Jurisdiction. Any dispute,
controversy or claim with respect to the breach, interpretation, performance or enforcement of this Agreement not resolved pursuant to Section 15.1 shall be subject to the exclusive jurisdiction of the state and federal courts in New York City,
New York. Each Party hereby (a) submits, and irrevocably consents, to the exclusive jurisdiction and venue of such courts for the resolution of such disputes and (b) agrees that process shall be served upon such Party in the manner set
forth in Section 17.7, and that service in such manner shall constitute valid and sufficient service of process. Each Party hereby waives the defense of any inconvenient forum for the maintenance of any action or proceeding in such jurisdiction
for such 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
purpose and covenants not to assert or plead any objection that such Party might otherwise have to such jurisdiction, venue, and process. Each Party hereby agrees not to commence any legal
proceedings relating to or arising out of this Agreement or the transactions contemplated hereby in any jurisdiction or courts other than as provided in this Section 15.2. Notwithstanding the foregoing, a Party will be entitled to seek
enforcement of a judgment entered pursuant to this Section 15.2 in any court having competent jurisdiction thereof where enforcement is deemed necessary. 

15.3 Interim Relief. Notwithstanding anything in this Article 15 to the contrary, DRL and XenoPort shall each have the right to apply
to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other similar interim or conservatory relief, as necessary to protect the right or property of such Party. 

ARTICLE XVI 

HART-SCOTT-RODINO 
 16.1
Hart-Scott-Rodino Act Compliance. Notwithstanding anything to the contrary in this Agreement, this Agreement shall be binding upon the Parties as of the Execution Date; however, the provisions of Articles 2 through 8 (excluding
Section 8.1(a), 8.1(d) and 8.1(e)) and Article 10 shall not take effect until the HSR Clearance Date. As used herein, the “HSR Clearance Date” shall mean such time as: (a) the Parties shall have complied with all
applicable requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended the (“Hart-Scott-Rodino Act”); (b) the waiting period under the Hart-Scott-Rodino Act shall have expired or been early terminated;
(c) no judicial or administrative proceeding opposing consummation of all or any part of this Agreement shall be pending; (d) no injunction (whether temporary, preliminary or permanent) prohibiting consummation of the transactions
contemplated by this Agreement or any material portion hereof shall be in effect; and (e) no requirements or conditions shall have been formally requested or imposed by the DOJ or FTC in connection therewith that are not reasonably and mutually
satisfactory to the Parties (collectively, the “HSR Conditions”). In the event that the HSR Conditions are not met [ * ], then either Party may terminate this Agreement upon notice, in which case, notwithstanding any
provisions that are stated to survive under Section 13.3 above, all provisions of this Agreement shall terminate and be of no force or effect whatsoever, except only that any liability of either Party for failing to comply this Article 16 shall
survive. 
 16.2 HSR Filing. Both Parties shall promptly file following execution of this Agreement their respective pre-merger
notification and report forms with the Federal Trade Commission (“FTC”) and the Department of Justice (“DOJ”) pursuant to the Hart-Scott-Rodino Act, which forms shall specifically request early termination of the
initial Hart-Scott-Rodino Act waiting period. DRL shall pay the filing fee. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 16.3 Cooperation. 

(a) The Parties shall [ * ] obtain [ * ] clearance required under the Hart-Scott-Rodino Act for the consummation of this
Agreement and the transactions contemplated herein and shall keep each other apprised of the status of any communications with, and any inquiries or requests for additional information from, the FTC and the DOJ and shall comply [ * ] with any
such inquiry or request; provided, however, that neither Party shall be required to consent to the divestiture or other disposition of any of its or its Affiliates’ assets or to consent to any other structural or conduct remedy, and each Party
and its Affiliates shall have no obligation to contest, administratively or in court, any ruling, order or other action of the FTC or DOJ or any third party respecting the transactions contemplated by this Agreement. 

(b) The Parties hereto commit to instruct their respective counsel to cooperate with each other and [ * ] facilitate and expedite the
identification and resolution of any such issues and, consequently, the expiration of the applicable Hart-Scott-Rodino Act waiting period. In the context of this Section 16.3, [ * ] counsel’s undertaking: (a) to keep each other
appropriately informed of communications received from and submitted to personnel of the reviewing antitrust authority; and (b) to confer with each other regarding appropriate contacts with and responses to personnel of the FTC or DOJ. 

ARTICLE XVII 
 GENERAL
PROVISIONS 
 17.1 Force Majeure. If the performance of any part of this Agreement (except for any payment obligation under this
Agreement) by either Party is prevented, restricted, interfered with or delayed by reason of force majeure (including, fire, flood, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism, strike, lockout or other labor
disturbance or acts of God), the Party so affected shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall
use its reasonable efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

17.2 Governing Law. This Agreement and all questions regarding its validity or interpretation, or the breach or performance of this
Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, without reference to conflict of law principles. The U.N. Convention on the Sale of Goods shall not apply to this Agreement. 

17.3 Waiver of Breach. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a
written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s
rights at a later time to enforce the same. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or term. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 17.4 Modification. No amendment or modification of any provision of this Agreement shall
be effective unless in writing signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set
forth in an agreement in writing and signed by a duly authorized representative of each Party. 
 17.5 Severability. In the event any
payment or other provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original
intent of the Parties and all other provisions of this Agreement shall remain in full force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such payment or
other provision in any other jurisdiction. In the event a Party seeks to avoid a payment or other provision of this Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, the other Party shall have the right to
terminate this Agreement upon [ * ] written notice to the asserting Party, unless such assertion is eliminated and the effect of such assertion cured within such [ * ] period. Any termination in accordance with the foregoing shall be
deemed a termination pursuant to Section 11.3 if the Party who made the assertion was DRL, and shall be deemed a termination under Section 11.2 by reason of a breach by XenoPort, if XenoPort is the Party who made such assertion. 

17.6 Entire Agreement. This Agreement (including the Exhibits attached hereto) constitutes the entire agreement between the Parties
relating to its subject matter and supersedes all prior or contemporaneous agreements, understandings or representations, either written or oral, between XenoPort and DRL with respect to such subject matter. 

17.7 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices and other communications between the
Parties relating to, and all written documentation to be prepared and provided under, this Agreement shall be in the English language: (a) delivered personally; (b) sent by registered or certified mail (return receipt requested and postage
prepaid); (c) sent by express courier service providing evidence of receipt, postage pre-paid where applicable; or (d) sent by facsimile (receipt verified and a copy promptly sent by another permissible method of providing notice described
in paragraphs (b), (c) or (d) above), to the following addresses of the Parties or such other address for a Party as may be specified by like notice: 
  

			
	 To XenoPort:
  

XenoPort, Inc.
 3410 Central Expressway

Santa Clara, CA 95051
 Telephone: (408) 616-7200

Facsimile: (408) 616-7211
 Attention: Secretary
	  	 To DRL:
  

Dr. Reddy’s Laboratories SA
 Elisabethenanlage 11

CH - 4051 Basel
 Switzerland

T : +41 (0) 61 271 4754
 F : +41 (0) 61 271 4755

Attention: [ * ]

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

			
	 With a copy to:
  

Wilson, Sonsini, Goodrich & Rosati
 650 Page Mill Road

Palo Alto, CA 94304
 Telephone: (650) 493-9300

Facsimile: (650) 493-6811
 Attention: [ * ]
	  	 With a copy to:
  

Dr. Reddy’s Laboratories SA
 Elisabethenanlage 11

CH - 4051 Basel
 Switzerland

T : +41 (0) 61 271 4754
 F : +41 (0) 61 271 4755

Attention: RGC – Europe

 Any notice required or permitted to be given concerning this Agreement shall be effective [ * ] or [
* ] whichever is earlier. 
 17.8 Assignment. This Agreement shall not be assignable by either Party to any Third Party hereto
without the written consent of the other Party hereto; except either Party may assign this Agreement without the other Party’s consent to an entity that acquires substantially all of the business or assets of the assigning Party, whether by
merger, acquisition or otherwise, provided that the Party to whom this Agreement is assigned assumes this Agreement in writing or by operation of law. In addition, either Party shall have the right to assign this Agreement to an Affiliate upon
written notice to the non-assigning Party; provided that the assigning Party guarantees the performance of this Agreement by such Affiliate; and further provided that if the non-assigning Party reasonably believes such assignment could result in
material adverse tax consequences to the non-assigning Party, such assignment shall not be made without the non-assigning Party’s consent. Subject to the foregoing, this Agreement shall inure to the benefit of each Party, its successors and
permitted assigns. A Party assigning this Agreement shall provide written notice of any assignment to the other Party [ * ]. Any assignment of this Agreement in contravention of this Section 17.8 shall be null and void. 

17.9 Effects of XenoPort Change of Control. In the event of a XenoPort Change of Control, the following provisions of this
Section 17.9 shall apply: 
 (a) XenoPort Intellectual Property. All XenoPort Patents and XenoPort Know-How Controlled by
XenoPort immediately prior to such XenoPort Change of Control shall continue to be XenoPort Patents and XenoPort Know-How for purposes of this Agreement. 

(b) Existing Acquirer Intellectual Property. Patents, know-how and other intellectual property and subject matter that were Controlled
by the entity acquiring XenoPort or such entity’s affiliates that were not Affiliates of XenoPort prior to such XenoPort Change of 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
Control (such entity together with such affiliates, collectively, the “Acquirer Entities”) shall not be included within the XenoPort Patents, XenoPort Know-How, the Compound or a
Product and such Change of Control shall not provide DRL with a license, rights or access to any such pre-existing Patents, know-how and other intellectual property and subject matter. 

(c) Independent Intellectual Property. Patent rights, know-how and other intellectual property or subject matter that, following such
XenoPort Change of Control, are developed, made or otherwise acquired or Controlled by the Acquirer Entities without use of DRL’s Confidential Information, or any of the then-existing XenoPort Patents or confidential XenoPort Know-How in the
Territory, shall not be included within the XenoPort Patents, XenoPort Know-How, the Compound or a Product and such Change of Control shall not provide DRL with a license, rights or access to any such independently developed or acquired Patents,
know-how and other intellectual property and subject matter. 
 (d) Limitation on Exclusivity Obligations. The Acquirer Entity to
which this Agreement, [ * ]. 
 17.10 No Partnership or Joint Venture. Nothing in this Agreement is intended, or shall be
deemed, to establish a joint venture or partnership between XenoPort and DRL. Neither Party to this Agreement shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party,
or to bind the other Party to any contract, agreement or undertaking with any Third Party. 
 17.11 Interpretation. The captions to
the several Articles and Sections of this Agreement are not a part of this Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall
be deemed to be followed by the phrase “without limitation” or like expression; (b) the singular shall include the plural and vice versa; (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable;
(d) the word “will” shall be construed as having the same meaning and effect as the word “shall”; (e) provision of information, documents or material to the JSC shall mean provision of such information, documents or
material to each Parties’ representatives to the JSC and, unless timing is otherwise specified, shall occur reasonably in advance of the next scheduled JSC meeting; and (f) each reference in this Agreement to the conduct of activities or
exercise of rights “by or under the authority of DRL” shall be deemed to include and apply to any Affiliates of DRL who may use or practice any of the intellectual property rights included in the XenoPort Patents and/or XenoPort Know-How
and/or that may otherwise be involved in the activities relating to the Compound or any Product. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under U.S. Generally Accepted Accounting
Principles, or other generally accepted cost accounting principles in the United States, but only to the extent consistent with its usage and the other definitions in this Agreement. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 17.12 Export Laws. Notwithstanding anything to the contrary contained herein, all
obligations of XenoPort and DRL are subject to prior compliance with the export regulations of the United States or any other relevant country and such other Applicable Laws in effect in the United States or any other relevant country as may be
applicable, and to obtaining all necessary approvals required by the applicable agencies of the governments of the United States and any other relevant countries. XenoPort and DRL shall cooperate with each other and shall provide assistance to the
other as reasonably necessary to obtain any required approvals. 
 17.13 Counterparts. This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Signatures to this Agreement delivered by facsimile or other form of electronic transmission (e.g., portable document
format (PDF)) will be deemed binding as originals. 
 [Remainder of page intentionally left blank; signature page follows] 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth
above. 
  

			
	XENOPORT, INC.
		
	BY:	 	 /s/ William G. Harris

	NAME:	 	William G. Harris
	TITLE:	 	Senior Vice President of Finance and Chief Financial Officer
	
	DR. REDDY’S LABORATORIES, S.A.
		
	BY:	 	 /s/ Sameer Natu

	NAME:	 	Sameer Natu
	TITLE:	 	Senior Director & Head Finance (Europe)
	
	DR. REDDY’S LABORATORIES, S.A.
		
	BY:	 	 /s/ Vishwas Muthyala

	NAME:	 	Vishwas Muthyala
	TITLE:	 	Director & Head

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 1.6 

Compound 
  

 
  

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 1.13 

Existing Inventory 

Drug Product 
  

									
	 Material
	  	Lot/Batch Number	 	Amount (kg)	 	Location	 	DOM
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	
	API
	
	 API

					
	 Description
	  	Lot#	 	Amount (kg)	 	Location	 	DOM
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

 XenoPort CMOs 

[ * ] 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 1.22 

MMF 
  

 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 1.41 

XenoPort Patents 
 [ * ] 

 

															
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

															
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
								
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]	 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

															
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 		 		 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

															
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]
								
	 [ * ]
	  		 		 		 		 		 		 	
								
	 Country
	  	Appl. #	 	Filing Date	 	Publ. #	 	Publ. Date	 	Patent #	 	Issue Date	 	Status
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 2.5(b) 

[ * ] Patents 
  

															
	Country	  	Appl. #	  	Filing Date	  	Publ. #	  	Publ. Date	  	Patent #	  	Issue Date	  	Status
	 [ * ]
	  	[ * ]	  	[ * ]	  		  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 4.1(a) 

Ongoing Carcinogenicity Studies 
  

	1.	[ * ] 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 8.1(f) 

Existing Inventory Specifications 

Provided by [ * ] 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 9.3 

Press Release 
 (See
attached.) 

					
	

	 		 	

 For Immediate Release 

Dr. Reddy’s Laboratories and XenoPort Enter Into a 

U.S. Licensing Agreement for XP23829 

Dr. Reddy’s Laboratories Plans to Develop XP23829 in 

Psoriasis and Multiple Sclerosis 
 Hyderabad,
India, and Santa Clara, CA — March 28, 2016 — Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to
which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical entity, XP23829. Dr. Reddy’s Laboratories plans to develop XP23829
as a potential treatment for moderate-to-severe chronic plaque psoriasis and relapsing forms of multiple sclerosis (MS). 
 Under the terms of the
agreement, Dr. Reddy’s Laboratories will receive exclusive U.S. rights to develop and commercialize XP23829 for all indications. In exchange for these rights, XenoPort will receive a $47.5 million up-front payment and an additional $2.5
million for transfer of certain clinical trial materials to Dr. Reddy’s Laboratories. XenoPort will also be eligible to receive up to $190 million upon the achievement by Dr. Reddy’s Laboratories of certain regulatory milestones,
which could be achieved over a period of several years. In addition, XenoPort will be eligible to receive up to $250 million upon the achievement of commercial milestones, and up to mid-teens royalty payments based on potential net sales of XP23829
in the United States. 
 Dr. Mark Jackson, M.D., clinical professor of medicine, Dermatology, University of Louisville, stated, “Based on
today’s available treatments, physicians need additional oral medications that are both safe and effective for patients with psoriasis. Fumaric acid esters possess a unique anti-inflammatory mechanism of action and have been used to treat
psoriasis in Germany for over 20 years. XP23829, a novel fumaric acid ester, has the potential to be a meaningful treatment option for patients with moderate-to-severe psoriasis.” 

“We see this compound complementing our internal development and focus to bring novel and relevant solutions to our providers,” said Raghav Chari,
executive vice president, Proprietary Products Group, Dr. Reddy’s Laboratories. Further, XP23829 could enable Promius Pharma, a wholly owned marketing arm of Dr. Reddy’s that is focused on dermatology and neurology, to address
the needs of a substantial portion of the 1.5 million moderate-to-severe psoriasis patients in the United States.” 
 “We are very pleased to
announce this agreement with Dr. Reddy’s Laboratories,” said Vincent J. Angotti, chief executive officer, XenoPort, Inc. “As one of our key objectives for 2016, we were interested in finding a strong partner that would recognize
the opportunity of this innovative therapy that we believe will make a significant difference in the lives of psoriasis and MS patients. We are now fully focused on our HORIZANT® (gabapentin
enacarbil) Extended-Release Tablets commercialization effort.” 

 The agreement is subject to review by the U.S. Government under the Hart-Scott-Rodino (HSR) Antitrust
Improvements Act, as amended, and will become effective only after clearing HSR review. 
 About XP23829 

XP23829 is an investigational drug discovered by XenoPort. It is a novel, oral fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).
Fumaric acid ester compounds have shown immuno-modulatory and neuroprotective effects in cell-based systems and preclinical models of disease. TECFIDERA, which is approved for relapsing forms of MS in the United States and relapsing-remitting MS in
the European Union and FUMADERM, which is approved in Germany for psoriasis, are based on another MMF prodrug known as dimethyl fumarate (DMF). XP23829 is protected by a U.S. composition-of-matter patent that currently has an expiration date of
2029. 
 In September 2015, XenoPort announced results of a Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic
plaque-type psoriasis. 
 About Psoriasis 
 Psoriasis is
a chronic, systemic, inflammatory disease that manifests in the skin and/or joints. It typically manifests as thick scaling red plaques, with variable morphology and distribution, resulting from an unusually high rate of skin cell growth. There is
no cure for psoriasis, and treatment often requires complex medical intervention. The main cause of psoriasis is uncertain, but it is thought to be caused by autoimmunity, genetic predisposition and environmental factors. 

Psoriasis is the most prevalent autoimmune disease in the United States with as many as 7.5 million Americans suffering from the condition. It is
estimated that approximately 1.5 million adults in the United States are considered to have moderate-to-severe psoriasis and between 150,000 and 260,000 new cases of psoriasis are diagnosed each year. 

About MS 
 MS is a chronic and progressive
neurodegenerative disease in which the body’s immune system attacks the myelin protein that wraps around nerve fibers. The disease typically strikes between the ages of 20 to 40 years, and because it is progressive in nature, disability
accumulates over time and can lead to permanent impairment of mobility, cognition and the ability for self-care. 
 Although the exact prevalence is not
known, it is estimated that approximately 250,000 to 350,000 people in the United States have been diagnosed with MS and that approximately one million people worldwide suffer from MS. 

 About Dr. Reddy’s 

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and
innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are dermatology, gastro-intestinal, cardiovascular, diabetology, neurology, oncology, pain management and
anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com. 

About XenoPort 
 XenoPort, Inc. is a biopharmaceutical
company focused on commercializing HORIZANT in the United States. XenoPort has entered into a clinical trial agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under which the NIAAA has initiated a clinical trial
evaluating HORIZANT as a potential treatment for patients with alcohol use disorder. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc.
XenoPort has granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Indivior PLC for all indications. It has granted exclusive U.S. rights for the
development and commercialization of its clinical-stage oral product candidate, XP23829, to Dr. Reddy’s Laboratories. XenoPort’s other clinical-stage product candidate, XP21279, is a prodrug of levodopa that is a potential treatment
for patients with idiopathic Parkinson’s disease. 
 To learn more about XenoPort, please visit the website at www.XenoPort.com. 

Dr. Reddy’s Disclaimer 
 This press release may
include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “believe,” “could,” “intend,” “plans,”
“potential,” “will” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends,
(iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related
integration issues. 

 XenoPort Forward-Looking Statements 

This press release contains “forward-looking” statements, including, without limitation, all statements related to the anticipated effectiveness of
XenoPort’s license agreement with Dr. Reddy’s Laboratories; Dr. Reddy’s Laboratories’ future clinical development program for XP23829; the therapeutic and commercial potential of XP23829; and XenoPort’s receipt of
potential future regulatory and commercial milestone payments, as well as potential royalty payments, and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be
forward-looking statements. Words such as “believe,” “could,” “intend,” “plans,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These
forward-looking statements are based upon XenoPort’s current expectations. Forward-looking statements involve risks and uncertainties. XenoPort’s actual results and the timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and uncertainties, which include, without limitation:[risks related to the ability of the parties to obtain clearance under the Hart-Scott-Rodino Antitrust Improvements Act, as amended; the
difficulty and uncertainty of pharmaceutical product development and the uncertain results and timing of clinical trials and other studies, including the risk that success in preclinical testing and early clinical trials does not ensure that later
clinical trials will be successful; the uncertainty of the FDA approval process and other regulatory requirements; the uncertain therapeutic and commercial value of XP23829; XenoPort’s dependence on collaborative partners, including the risks
that if Dr. Reddy’s Laboratories were to breach or terminate the license agreement or otherwise fail to successfully develop and commercialize XP23829 thereunder and in a timely manner, XenoPort would not obtain the anticipated financial
and other benefits of the license agreement and the clinical development or commercialization of XP23829 could be delayed or terminated; as well as risks related to future opportunities and plans, including the uncertainty of future financial and
operating results. These and other risk factors are discussed under the heading “Risk Factors” in XenoPort’s Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-K for the year
ended December 31, 2015, filed with the Securities and Exchange Commission on February 26, 2016. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. 

 

			
	Dr. Reddy’s Laboratories	  	
	IR Contact	  	Media Contact
	Kedar Upadhye	  	Calvin Printer
	Phone: +91-40-6683 4297	  	Phone: +91.40.4900 2121
	Email: kedaru@drredys.com	  	Email: calvinprinter@drreddys.com
		
	XenoPort IR and Media Contact	  	
	Jackie Cossmon	  	
	Phone: 408-616-7220	  	
	Email: ir@XenoPort.comEX-10.1

 Exhibit 10.1 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 EXECUTION VERSION 

 
 Initial Regional Manufacturing 

Agreement 
  

Entered into by 
 The Coca-Cola
Company, 
 a Delaware corporation, 

and 
 Coca-Cola Bottling Co.
Consolidated, 
 a Delaware corporation, 

with Effective Date of April 29, 2016 

 TABLE OF CONTENTS 
  

					
	1 RECITALS	  	 	1	  
		
	2 DEFINITIONS	  	 	1	  
		
	3 AUTHORIZATION FOR BOTTLER TO PURCHASE CONCENTRATES AND TO MANUFACTURE AUTHORIZED COVERED BEVERAGES	  	 	3	  
		
	4 AUTHORIZATION FOR BOTTLER TO SELL AND SUPPLY AUTHORIZED COVERED BEVERAGES	  	 	4	  
		
	5 COMPANY AND BOTTLER RIGHTS AND OBLIGATIONS REGARDING THE TRADEMARKS	  	 	5	  
		
	6 REFORMULATION AND DISCONTINUATION OF THE CONCENTRATES	  	 	6	  
		
	7 TERRITORIAL LIMITATIONS AND TRANSSHIPPING	  	 	6	  
		
	8 [RESERVED.]	  	 	6	  
		
	9 EFFECT OF NEW OR AMENDED MANUFACTURING AGREEMENTS WITH OTHER REGIONAL PRODUCING BOTTLERS	  	 	6	  
		
	10 OBLIGATIONS OF BOTTLER AS TO MANUFACTURE OF OTHER BEVERAGE PRODUCTS	  	 	7	  
		
	11 WARRANTIES OF COMPANY RELATING TO MANUFACTURE AND QUALITY OF THE CONCENTRATE	  	 	8	  
		
	12 OBLIGATIONS AND WARRANTIES OF BOTTLER RELATING TO MANUFACTURE AND QUALITY OF THE AUTHORIZED COVERED BEVERAGES	  	 	8	  
		
	13 OBLIGATIONS OF COMPANY AND BOTTLER RELATING TO RECALL OF AUTHORIZED COVERED BEVERAGES	  	 	11	  
		
	14 OBLIGATIONS OF BOTTLER RELATING TO MANUFACTURE OF AUTHORIZED COVERED BEVERAGES, SYSTEM GOVERNANCE, INVESTMENT, MANAGEMENT, REPORTING AND PLANNING ACTIVITIES	  	 	12	  
		
	15 PRICING AND OTHER CONDITIONS OF PURCHASE AND SALE OF CONCENTRATES	  	 	13	  
		
	16 OWNERSHIP AND CONTROL OF BOTTLER	  	 	13	  
		
	17 TERM OF AGREEMENT	  	 	14	  
		
	18 COMMERCIAL IMPRACTICABILITY AND FORCE MAJEURE	  	 	14	  
		
	19 TERMINATION FOR DEFINED EVENTS	  	 	15	  
		
	20 DEFICIENCY TERMINATION	  	 	16	  
		
	21 BOTTLER RIGHT TO CURE	  	 	17	  
		
	22 [RESERVED.]	  	 	19	  

					
		
	23 EFFECT OF BOTTLER’S CBA ON THIS AGREEMENT IN CERTAIN EVENTS	  	 	19	  
		
	24 POST-EXPIRATION AND POST-TERMINATION OBLIGATIONS	  	 	19	  
		
	25 COMPANY’S RIGHT OF ASSIGNMENT	  	 	19	  
		
	26 LITIGATION	  	 	19	  
		
	27 INDEMNIFICATION	  	 	20	  
		
	28 BOTTLER’S INSURANCE	  	 	21	  
		
	29 [RESERVED.]	  	 	21	  
		
	30 INCIDENT MANAGEMENT	  	 	21	  
		
	31 SEVERABILITY	  	 	21	  
		
	32 REPLACEMENT OF CERTAIN PRIOR CONTRACTS, MERGER, AND REQUIREMENTS FOR MODIFICATION	  	 	21	  
		
	33 NO WAIVER	  	 	22	  
		
	34 NATURE OF AGREEMENT AND RELATIONSHIP OF THE PARTIES	  	 	22	  
		
	35 HEADINGS AND OTHER MATTERS	  	 	22	  
		
	36 EXECUTION IN MULTIPLE COUNTERPARTS	  	 	23	  
		
	37 NOTICE AND ACKNOWLEDGEMENT	  	 	23	  
		
	38 CHOICE OF LAW AND VENUE	  	 	25	  
		
	39 CONFIDENTIALITY	  	 	25	  
		
	40 ACTIVE AND COMPLETE ARMS LENGTH NEGOTIATIONS	  	 	26	  
		
	41 RESERVATION OF RIGHTS	  	 	26	  
		
	42 BOTTLER AFFILIATES	  	 	27	  

 TABLE OF EXHIBITS 
  

					
	  

    Exhibit    

 
	  	  

Title
  
	  	  

    Exhibit References by    

Section
  

	  
 A

 
	  	  

Regional Manufacturing Facilities
  
	  	  

2.1.2
  

	  
 B
	  	  

Authorized Covered Beverages
	  	  

2.3
  

9.3
  

  
  

 TABLE OF SCHEDULES 
  

					
	  

    Schedule    

 
	  	  

Title
  
	  	  

    Schedule References by    

Section
  

	 	 	 
	 2.17

 
	  	Related Agreements	  	2.17
	 	 	 
	 2.18

 
	  	[***]	  	2.18
	 	 	 
	 9.4

 
	  	Regional Manufacturing Agreement	  	 2.14

9.4
  

	 	 	 
	 10.1.5

 
	  	Third Party Beverages	  	 10.1.5

10.1.6
  

	 	 	 
	 12.2

 
	  	Technical Requirements	  	12.2
	 	 	 
	 28

 
	  	 Insurance Requirements

 
	  	 28

 

	 	 	 
	32.1.2	  	Agreements Not Affected by this Agreement	  	 32.1.2

32.1.4
  

  
  

 
 [***] – THIS CONFIDENTIAL
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 

 Initial Regional Manufacturing Agreement 

 
  

THIS AGREEMENT IS ENTERED INTO BY THE COCA-COLA COMPANY, A DELAWARE CORPORATION (“COMPANY”), AND COCA-COLA BOTTLING CO. CONSOLIDATED, A
DELAWARE CORPORATION (“BOTTLER”). 
  

	1	 RECITALS 

  

	 	1.1	 Company and Bottler (or one or more Affiliates of Bottler) have entered into one or more Comprehensive Beverage
Agreement(s) (as may be amended, restated or modified from time to time, “Bottler’s CBA”) authorizing Bottler to market, promote, distribute and sell Covered Beverages and Related Products within specific geographic
Territories, subject to the terms and conditions contained in Bottler’s CBA. Capitalized terms used in this Agreement will have the meanings ascribed to them in Bottler’s CBA, unless a different meaning is ascribed under this Agreement;

  

	 	1.2	 Company manufactures and sells, or authorizes others to manufacture and sell, the Concentrates used to
manufacture certain of the Covered Beverages, the formulas for all of which constitute trade secrets owned by Company and which are identified by the Trademarks; 

 

	 	1.3	 Company and Bottler acknowledge that the manufacture of such Covered Beverages is subject to strict production
standards and applicable regulatory requirements; 

  

	 	1.4	 Bottler and Company wish to enter into this Agreement in order to permit Bottler to manufacture, produce and
package (collectively, “manufacture”), at the Regional Manufacturing Facilities, the Authorized Covered Beverages in Authorized Containers both for (i) distribution and sale by Bottler and its Affiliates for their own account;
and (ii) sale by Bottler and its Affiliates to Company and to certain other U. S. Coca-Cola Bottlers in accordance with this Agreement; 

  

	 	1.5	 Bottler has requested an authorization from Company to use the Trademarks in connection with such manufacture of
the Authorized Covered Beverages; and 

  

	 	1.6	 Company is willing to grant the requested authorization to Bottler under the terms and conditions set forth in
this Agreement. 

 COMPANY AND BOTTLER AGREE AS FOLLOWS: 
  

	2	 DEFINITIONS  

  

	 	2.1	 “Agreement” means this Initial Regional Manufacturing Agreement between Bottler and Company, as
amended from time to time. 

  

	 	2.2	 “Authorized Containers” means containers of certain types, sizes, shapes and other
distinguishing characteristics that Company from time to time approves in its sole discretion, subject to Section 12.9, for use by all Regional Producing Bottlers in manufacturing Authorized Covered Beverages at the Regional
Manufacturing Facilities. A list of Authorized Containers for each Authorized Covered Beverage will be provided by Company to Bottler, which list may be amended by additions, deletions or modifications by Company from time to time in its sole
discretion. 

	 	2.3	 “Authorized Covered Beverages” means the Covered Beverages identified on Exhibit B
that all Regional Producing Bottlers are authorized to manufacture in Authorized Containers at their respective regional manufacturing facilities, which Exhibit will be deemed automatically amended to add any Covered Beverage that Company hereafter
authorizes for concentrate-based, cold-fill manufacturing by any U.S. Coca-Cola Bottler, and may otherwise be updated from time to time as mutually agreed by Company and the NPSG. For purposes hereof, cold-fill manufacturing means the process of
manufacturing beverages in which the product is chilled, or equal to or less than ambient temperature, at time of filling and packaging. 

  

	 	2.4	 “Company Owned Manufacturer” means any Affiliate or operating unit of Company located in the
United States that manufactures any of the Authorized Covered Beverages for distribution or sale within the United States. 

  

	 	2.5	 “Concentrates” means the concentrates and/or beverage bases used to manufacture the Authorized
Covered Beverages at the Regional Manufacturing Facilities, the formulas for all of which constitute trade secrets owned by Company and which are identified by the applicable Trademarks. 

 

	 	2.6	 “Effective Date” means April 29, 2016. 

 

	 	2.7	 “Expanding Participating Bottler” has the meaning ascribed to that term under the Comprehensive
Beverage Agreement. 

  

	 	2.8	 “Finished Goods Supply Agreements”: 

 

	 	2.8.1	 “Interim Finished Goods Supply Agreement” means (a) with respect to the Sandston, VA
Regional Manufacturing Facility, the Finished Goods Supply Agreement [Bottler as Producer for CCR Distribution Centers], dated as of January 29, 2016, by and between CCR and Bottler, and (b) with respect to the Baltimore, MD and Silver
Spring, MD Regional Manufacturing Facilities, the Finished Goods Supply Agreement [Bottler as Producer for CCR Distribution Centers], dated as of the Effective Date, by and between CCR and Bottler. 

 

	 	2.8.2	 “NPSG Finished Goods Supply Agreement” means the form of finished goods supply agreement to be
mutually agreed by Company and Bottler, that will provide, among other things, that Bottler’s pricing to other Regional Producing Bottlers will be calculated by Bottler in accordance with the pricing formula set forth in
Section 4.1.2 hereof, which has been determined unilaterally by Company in a manner that, together with other applicable arrangements between Company and Bottler, supports and enables [***], and to strengthen the
competitiveness of the Coca-Cola finished goods production system. 

  

	 	2.8.3	 “Regional Finished Goods Supply Agreement” means the form of finished goods supply agreement to
be mutually agreed by Company and Bottler, that will provide, among other things, that Bottler’s pricing to Expanding Participating Bottlers and Participating Bottlers will be the [***]. 

 

	 	2.9	 [***] 

  

	 	2.10	 “National Product Supply Group” or “NPSG” means The Coca-Cola System
National Product Supply Group, as described more fully in the National Product Supply System Governance Agreement. 

  
 - 2 - 

[***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 

	 	2.11	 “National Product Supply Group Board” or “NPSG Board” means The Coca-Cola
System National Product Supply Group Governance Board, the governing body for the Coca-Cola National Product Supply Group consisting of representatives of Company and all Regional Producing Bottlers, as described more fully in the National Product
Supply System Governance Agreement between Bottler, certain other Regional Producing Bottlers and Company dated as of October 30, 2015. 

  

	 	2.12	 “Participating Bottler” means any U.S. Coca-Cola Bottler that is not a Regional Producing
Bottler or an Expanding Participating Bottler that is party to a Comprehensive Beverage Agreement with Company. 

  

	 	2.13	 “Recipient Bottler” means the U.S. Coca-Cola Bottlers which Bottler is authorized pursuant to
this Agreement to supply with Authorized Covered Beverages manufactured by Bottler at the Regional Manufacturing Facilities. 

  

	 	2.14	 “Regional Manufacturing Facilities” means the manufacturing facilities owned and operated by
Bottler and listed on Exhibit A, which Exhibit will be deemed automatically amended to add any manufacturing facility acquired or built by Bottler after the Effective Date with the approval of the NPSG, and, subject to the requirements
of National Product Supply System Governance Agreement, may be otherwise updated from time to time as mutually agreed by Company and Bottler. 

  

	 	2.15	 “Regional Producing Bottler” means (i) Bottler; (ii) any other Expanding Participating
Bottler that is or becomes a member of the NPSG that Company has authorized, or hereafter authorizes, to manufacture Authorized Covered Beverages under an agreement in substantially the same form as either this Agreement or the Regional
Manufacturing Agreement attached as Schedule 9.4 hereto; and (iii) a Company Owned Manufacturer that is or becomes a member of the National Product Supply Group. 

 

	 	2.16	 [Reserved.] 

  

	 	2.17	 “Related Agreement” means any agreement identified on Schedule 2.17 between
Company and any of Company’s Affiliates and Bottler and any of Bottler’s Affiliates relating to the manufacturing of Authorized Covered Beverages. 

  

	 	2.18	 [***] 

  

	 	2.19	 [***] 

  

	3	 AUTHORIZATION FOR BOTTLER TO PURCHASE CONCENTRATES AND TO MANUFACTURE AUTHORIZED COVERED BEVERAGES 

  

	 	3.1	 Company appoints Bottler as an authorized purchaser of the Concentrates for the purpose of manufacture of the
Authorized Covered Beverages in Authorized Containers at the Regional Manufacturing Facilities. Except as otherwise mutually agreed in writing by Company and Bottler, Company shall not appoint, and shall not consent to any appointment by Coca-Cola
Refreshments USA, Inc. or any of its other Affiliates of, any other Person as an authorized purchaser of the Concentrates for the purposes of manufacture, packaging and distribution of such Authorized Covered Beverages in Authorized Containers for
sale in Bottler’s Territory. 

  
 - 3 - 

[***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 

	 	3.2	 Bottler will purchase its entire requirements of Concentrates for such Authorized Covered Beverages exclusively
from Company and will not use any other syrup, beverage base, concentrate or other ingredient not specified by Company in the manufacture of Authorized Covered Beverages. 

 

	4	 AUTHORIZATION FOR BOTTLER TO SELL AND SUPPLY AUTHORIZED COVERED BEVERAGES  

 

	 	4.1	 With the objective of ensuring that U.S. Coca-Cola Bottlers are able to acquire finished goods from Regional
Producing Bottlers at a price that enables the Coca-Cola Bottler System to be highly competitive in the marketplace, Company authorizes Bottler to sell and supply Authorized Covered Beverages manufactured by Bottler at the Regional Manufacturing
Facilities: 

  

	 	4.1.1	 During the period from the Effective Date through and including December 31, 2016: 

 

	 	4.1.1.1	 To Regional Producing Bottlers in accordance with the terms and conditions of the Interim Finished Goods Supply
Agreement; and 

  

	 	4.1.1.2	 To other U.S. Coca-Cola Bottlers that CCR supplied from the Manufacturing Facilities immediately prior to the
Effective Date, on the terms and conditions applicable to each such supply arrangement. 

  

	 	4.1.2	 To other Regional Producing Bottlers at the price specified in this Section 4.1.2 and in
accordance with the terms and conditions of the NPSG Finished Goods Supply Agreement: 

  

	 	4.1.2.1	 For calendar year 2017, the price shall be [***]. 

 

	 	4.1.2.2	 For calendar year 2018 and thereafter, the price shall be [***]. 

 

	 	4.1.3	 To Expanding Participating Bottlers and Participating Bottlers at the price specified in this
Section 4.1.3 and in accordance with the terms and conditions of the Regional Finished Goods Supply Agreement: 

  

	 	4.1.3.1	 For calendar year 2017, the price shall be [***]. 

 

	 	4.1.3.2	 For calendar year 2018 and thereafter, the price shall be [***]. 

 

	 	4.2	 Company authorizes Bottler to sell and supply Authorized Covered Beverages manufactured by Bottler to Company,
and Bottler agrees to sell to Company Authorized Covered Beverages, at a price equivalent to [***], in quantities sufficient to enable Company to satisfy demand of U.S. Coca-Cola Bottlers that are not Regional Producing Bottlers, Expanding
Participating Bottlers or Participating Bottlers in accordance with sourcing plans developed by the NPSG from time to time. 

  

	 	4.3	 Upon Company’s request, Bottler agrees to advise Company, in accordance with written instructions issued by
Company from time to time, of the amount of the Authorized Covered Beverages in Authorized Containers that are manufactured at the Regional Manufacturing Facilities and sold by Bottler to Company, and, as applicable, to each Regional Producing
Bottler, Expanding Participating Bottler and Participating Bottler; provided, however, that Bottler will not be required to provide Company with duplicate copies of any such information provided to the NPSG that expressly directs the
NPSG to provide such information to Company. 

  
 - 4 - 

[***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 

	5	 COMPANY AND BOTTLER RIGHTS AND OBLIGATIONS REGARDING THE TRADEMARKS  

 

	 	5.1	 Bottler acknowledges and agrees that Company is the sole and exclusive owner of all rights, title and interest in
and to the Trademarks. Company has the unrestricted right, in its sole discretion, to use the Trademarks on the Authorized Covered Beverages and on all other products and merchandise, to determine which Trademarks will be used on which Authorized
Covered Beverages, and to determine how the Trademarks will be displayed and used on and in connection with the Authorized Covered Beverages. Bottler agrees not to dispute the validity of the Trademarks or their exclusive ownership by Company either
during the Term or thereafter, notwithstanding any applicable doctrines of licensee estoppel. 

  

	 	5.2	 Company grants to Bottler only a nonexclusive, royalty-free license to use the Trademarks in connection with the
manufacture of the Authorized Covered Beverages in Authorized Containers at the Regional Manufacturing Facilities and in connection with the sale of such Authorized Covered Beverages to Recipient Bottlers and Company as provided in this Agreement,
and in accordance with standards adopted and issued by Company from time to time, and made available to Bottler through written, electronic, on-line or other form or media, subject to the rights reserved to Company under this Agreement.

  

	 	5.3	 Nothing in this Agreement, nor any act or failure to act by Bottler or Company, will give Bottler any proprietary
or ownership interest of any kind in the Trademarks or in the goodwill associated therewith. 

  

	 	5.4	 Bottler acknowledges and agrees that, as between Company and Bottler, all use by Bottler of the Trademarks will
inure to the benefit of Company. 

  

	 	5.5	 Except as provided in Bottler’s CBA or as otherwise authorized by Company in writing, Bottler must not adopt
or use any name, corporate name, trading name, title of establishment or other commercial designation or logo that includes the words “Coca-Cola”, “Coca”, “Cola”, “Coke”, or any of them, or any word, name or
designation that is confusingly similar to any of them, or any graphic or visual representation of the Trademarks or any other Trademark or intellectual property owned by Company, without the prior written consent of Company, which consent will not
be unreasonably withheld and will be contingent on Bottler’s compliance with Bottler’s CBA and this Agreement. 

  

	 	5.6	 Bottler recognizes that the uniform external appearance of the Trademarks on primary and secondary packaging and
on equipment and materials used under this Agreement is important to the Trademarks, the successful marketing of the Covered Beverages, and the Coca-Cola system. 

 

	 	5.6.1	 Bottler agrees, to the extent such Trademarks are utilized by Bottler in connection with the manufacture of
Authorized Covered Beverages at the Regional Manufacturing Facilities, to accept and, within a reasonable time, apply, any new or modified standards adopted and issued from time to time by Company that are generally applicable, and made available to
Bottler for the design and decoration of trucks and other delivery vehicles, packaging materials, cases, cartons, and other materials and equipment that bear such Trademarks. 

 

	 	5.6.2	 If Company changes such standards, the new standards will apply to all such assets acquired by Bottler for use at
the Regional Manufacturing Facilities or in connection with the manufacture of Authorized Covered Beverages at the Regional Manufacturing Facilities following receipt of Notice of the change in standards to the extent Bottler uses the Trademarks on
such assets, and will be applied to such existing assets in the normal course of Bottler’s business (e.g., trucks would be repainted consistent with normal maintenance cycles). 

  
 - 5 - 

	6	 REFORMULATION AND DISCONTINUATION OF THE CONCENTRATES 

 

	 	6.1	 Company has the sole and exclusive right and discretion to reformulate any of the Concentrates.

  

	 	6.2	 Company has the right to discontinue any Concentrates for any Authorized Covered Beverage that is discontinued or
Transferred in accordance with the terms of Bottler’s CBA and any other agreements between Bottler and Company or their respective Affiliates. 

  

	7	 TERRITORIAL LIMITATIONS AND TRANSSHIPPING 

 

	 	7.1	 Company and Bottler hereby agree that, notwithstanding the provisions of Paragraph 9 of Bottler’s CBA
(or applicable provisions of any other agreements between Bottler and Company or their respective Affiliates), Bottler may supply Authorized Covered Beverages in Authorized Containers manufactured at the Regional Manufacturing Facilities to
Recipient Bottlers in accordance with Section 4 for distribution by such Recipient Bottlers in their respective territories in accordance with their respective Comprehensive Beverage Agreement(s) or other agreements with Company.

  

	 	7.2	 Bottler agrees not to sell, distribute or otherwise transfer any Authorized Covered Beverage manufactured at the
Regional Manufacturing Facilities except, (i) distribution and sale in Bottler’s (or any one or more of its Affiliates’) Territories in accordance with Bottler’s CBA and in other geographic territories in which Bottler and its
Affiliates are authorized to distribute and sell Authorized Covered Beverages by Company or its Affiliates, and (ii) sales of Authorized Covered Beverages in Authorized Containers to Recipient Bottlers or Company in accordance with
Section 4. 

  

	8	 [RESERVED.] 

  

	9	 EFFECT OF NEW OR AMENDED MANUFACTURING AGREEMENTS WITH OTHER REGIONAL PRODUCING BOTTLERS 

  

	 	9.1	 If Company or a Company Affiliate on or after January 29, 2016 (a) enters into a new authorization
agreement to manufacture all or substantially all Authorized Covered Beverages at manufacturing facilities acquired from Company or a Company Affiliate on or after October 30, 2015 in territories in the United States of America with another
Regional Producing Bottler (other than a Company Owned Distributor) that is more favorable to such other Regional Producing Bottler than the terms and conditions of this Agreement in any material respect, or (b) agrees to an amendment of the
terms of a regional manufacturing agreement or other similar agreement authorizing manufacture of all or substantially all Authorized Covered Beverages at manufacturing facilities acquired from Company or a Company Affiliate on or after
October 30, 2015 in territories in the United States with another Regional Producing Bottler (other than a Company Owned Distributor) that is more favorable to such other Regional Producing Bottler than the terms and conditions of this
Agreement in any material respect, then Company will offer such other new agreement or amended agreement, as the case may be (a “New Agreement”), in its entirety, to Bottler. If the New Agreement relates to less than all of the
Authorized Covered Beverages, then the New Agreement offered to Bottler under this Section 9.1 will cover only those Authorized Covered Beverages covered by the New Agreement. 

  
 - 6 - 

	 	9.2	 The foregoing obligation will not apply to any consent, waiver or approval provided under this Agreement or under
any agreement held by another Regional Producing Bottler; provided, however, that Company will not waive or otherwise enter into any agreement with any other Regional Producing Bottler that limits the requirement set forth in
Section 14.1 or any equivalent requirement under any Regional Manufacturing Agreement held by another Regional Producing Bottler. 

  

	 	9.3	 Nothing in Section 9.2 will affect (a) Company’s obligation under
Section 15.2 or (b) Company’s agreement that the list of Covered Beverages identified on Exhibit B will be the same for all Regional Producing Bottlers. 

 

	 	9.4	 If, after the Effective Date, (a) the CBA Conversion (as defined in the Territory Conversion Agreement
between the parties dated September 23, 2015) (as amended, the “Territory Conversion Agreement”) occurs in accordance with the Territory Conversion Agreement or (b) Bottler otherwise enters into the Comprehensive Beverage
Agreement described in Section 1.1 of the Territory Conversion Agreement with respect to all Territories granted to Bottler under Bottler’s CBA (as defined in this Agreement) and all of Bottler’s Legacy Territory (as defined in the
Territory Conversion Agreement), this Agreement shall be amended and restated in the form of the Regional Manufacturing Agreement attached hereto as Schedule 9.4 on and as of the date on which the CBA Conversion or the entry into such
Comprehensive Beverage Agreement occurs. 

  

	 	9.5	 The parties agree to cooperate in taking such other actions as may reasonably be required to further document any
amendments and modifications resulting from the provisions of this Section 9. 

  

	10	 OBLIGATIONS OF BOTTLER AS TO MANUFACTURE OF OTHER BEVERAGE PRODUCTS  

 

	 	10.1	 Bottler covenants and agrees (subject to any requirements imposed upon Bottler under applicable law) not to
manufacture at the Regional Manufacturing Facilities any Beverage, Beverage Component, or other beverage product except for: 

  

	 	10.1.1	 Authorized Covered Beverages, subject to the terms and conditions of this Agreement and any Related Agreement;

  

	 	10.1.2	 Beverages (including Incubation Beverages), Beverage Components and other beverage products, if and to the extent
(a) authorized under any separate written agreement with Company or any of Company’s Affiliates, or (b) otherwise requested by Company or any of its Affiliates; 

 

	 	10.1.3	 Permitted Beverage Products distributed by Bottler or its Affiliates for their own account, subject to the terms
and conditions of Bottler’s or Bottler Affiliate’s CBA; 

  

	 	10.1.4	 Beverages, Beverage Components and other beverage products manufactured by Bottler under license from a third
party brand owner and supplied by Bottler to a Recipient Bottler, subject to the terms and conditions of the Recipient Bottler’s CBA or other bottling and distribution agreements between Company and Recipient Bottler; provided that
Bottler will not supply any such Beverage, Beverage Component or other beverage product manufactured at the Regional Manufacturing Facilities to any Recipient Bottler if Company provides Bottler with Notice that such Beverage, Beverage Component or
other beverage product is not a Permitted Beverage Product under such Recipient Bottler’s CBA (or that is prohibited by other bottling and distribution agreements between Company and Recipient Bottler); provided, further, that
Bottler’s supply of any Beverage, Beverage Component or other beverage product to a Recipient Bottler that is not a Permitted Beverage Product under such Recipient Bottler’s CBA (or that is prohibited by other bottling and distribution
agreements between 

  
 - 7 - 

	 	 
Company and Recipient Bottler) will not be a breach of this Section 10.1.4 unless Company provides Bottler with such Notice and Bottler continues to supply such Beverage to
such Recipient Bottler thereafter in violation of such Notice; 

  

	 	10.1.5	 Beverages, Beverage Components and other beverage products manufactured by Bottler at the Regional Manufacturing
Facilities under license from a third party brand owner and supplied by Bottler to another U.S. Coca-Cola Bottler as of the Effective Date, as specified on Schedule 10.1.5; and 

 

	 	10.1.6	 Beverages, Beverage Components and other beverage products, not otherwise permitted under Sections
10.1.3, 10.1.4, or 10.1.5, manufactured by Bottler at the Regional Manufacturing Facilities under license from a third party brand owner with Company’s prior written consent, which consent will not be unreasonably
withheld and will be specified on Schedule 10.1.5. 

  

	 	10.2	 Notwithstanding anything in Section 10.1 to the contrary, if the NPSG reasonably determines
during product supply system sourcing plan development routines that Bottler should supply any Beverage manufactured by Bottler at the Regional Manufacturing Facilities under license from a third party brand owner to certain Recipient Bottlers
and/or certain other Regional Producing Bottlers in order to optimize the location for production of such Beverages, then Bottler may do so on a temporary basis as reasonably determined by the NPSG (but in any event not to exceed one hundred eighty
(180) days). 

  

	11	 WARRANTIES OF COMPANY RELATING TO MANUFACTURE AND QUALITY OF THE CONCENTRATE  

 

	 	 	 Company agrees and warrants that the Concentrates supplied to Bottler, as well as Company’s package designs and
design specifications of packages and labels authorized by Company for use on Authorized Covered Beverages, shall comply with all food, labeling, health, packaging and all other applicable laws, including the Federal Food, Drug and Cosmetic Act, as
amended (the “Act”), and regulations, and when supplied to Bottler will not be adulterated, contaminated, or misbranded within the meaning of the Act or any other federal, state or local law, rule or regulation applicable thereto.

  

	12	 OBLIGATIONS AND WARRANTIES OF BOTTLER RELATING TO MANUFACTURE AND QUALITY OF THE AUTHORIZED COVERED BEVERAGES 

  

	 	12.1	 Bottler agrees and warrants that Bottler’s handling and storage of the Concentrates and Bottler’s
manufacture, handling, storage, transportation and delivery of the Authorized Covered Beverages, including any Authorized Covered Beverages supplied to Company or any Recipient Bottler, will at all times and in all events: 

 

	 	12.1.1	 be accomplished in accordance with the product, package and equipment quality; food safety; workplace safety; and
environmental sustainability standards, requirements and instructions reasonably established and routinely communicated in writing, including through electronic systems and media, by Company to Bottler from time to time (collectively
“Technical Requirements”); and 

  

	 	12.1.2	 comply with all food, labeling, health, packaging, environmental, safety, sanitation and all other applicable
laws, rules, orders, regulations and requirements of any federal, state, city, county or other local government, including any law, statute, ordinance, rule regulation, order, determination, restrictive covenant or deed restriction that regulates
the use, generation, 

  
 - 8 - 

	 	 
disposal, release, storage or presence at the Regional Manufacturing Facilities of substances based upon corrosiveness, toxicity, carcinogenic properties, radioactivity, environmentally hazardous
or similar characteristics. 

  

	 	12.2	 The Technical Requirements as of the Effective Date are identified on Schedule 12.2, which schedule
will be updated by Company from time to time following discussion with the NPSG and Notice to each Regional Producing Bottler (including any Company Owned Manufacturers). 

 

	 	12.2.1	 Company agrees that all Regional Producing Bottlers will be required to comply with same Technical Requirements;
provided, however, that (i) Company may make limited exceptions in application or enforcement where necessary to prevent undue hardship for a Regional Producing Bottler, which exceptions shall not in any way be deemed to modify
the Technical Requirements and (ii) this Section 12.2.1 shall not in any way effect, limit, or modify any of Bottler’s or Company’s respective rights and obligations under this Agreement, including Bottler’s
obligations under Section 12.1. 

  

	 	12.3	 Bottler represents, warrants and covenants that Bottler possesses, or will possess, prior to the manufacture of
the Authorized Covered Beverages, and will maintain during the Term, such plant or plants, machinery and equipment, qualified technical personnel and trained staff as are capable of manufacturing the Authorized Covered Beverages in Authorized
Containers in accordance with this Agreement and in sufficient quantities to meet fully the demand for the Authorized Covered Beverages in Authorized Containers by Bottler in the Territory in accordance with sourcing plans developed by the NPSG from
time to time. 

  

	 	12.4	 Bottler agrees to use commercially reasonable efforts to meet fully the demand for the Authorized Covered
Beverages in Authorized Containers from Recipient Bottlers in accordance with sourcing plans developed by the NPSG from time to time. 

  

	 	12.5	 Bottler recognizes that increases in the demand for the Authorized Covered Beverages, as well as changes in the
list of Authorized Containers, may, from time to time, require adaptation of its existing manufacturing or packaging equipment or the purchase of additional manufacturing or packaging equipment. Bottler agrees to use commercially reasonable efforts
to make such modifications and adaptations as necessary and to purchase and install such equipment, in time to permit the introduction and manufacture of sufficient quantities of the Authorized Covered Beverages in Authorized Containers, to satisfy
fully the demand for the Authorized Covered Beverages in Authorized Containers in the Territory and to fulfill Bottler’s supply obligations, if any, to Recipient Bottlers, in each case in accordance with sourcing plans developed by the NPSG
from time to time. 

  

	 	12.6	 As of the date the Authorized Covered Beverages in Authorized Containers are shipped by Bottler, the Authorized
Covered Beverages manufactured by Bottler will meet the Technical Requirements and will comply with all applicable laws; provided, however, that Bottler will not be responsible for any failure to comply with the Technical Requirements
or applicable laws to the extent such failure results from the content or design of labels authorized by Company for use on Authorized Covered Beverages. 

  

	 	12.7	 Bottler, in accordance with such instructions as may be given from time to time by Company, will submit to
Company, at Bottler’s expense, samples of the Authorized Covered Beverages and the raw materials used in the manufacture of the Authorized Covered Beverages. Bottler will permit representatives of Company to have access to the premises of
Bottler during ordinary business hours to inspect the plant, equipment, and methods used by Bottler in order to ascertain whether Bottler is complying with the terms of this Section 12, including whether Bottler is complying
strictly with the 

  
 - 9 - 

	 	 
Technical Requirements with respect to the manufacturing, handling and storage of the Authorized Covered Beverages. Bottler will also provide Company with all the information regarding
Bottler’s compliance with the terms of this Section 12, as Company may reasonably request from time to time. 

  

	 	12.8	 Bottler is authorized to use only Authorized Containers in the manufacture of the Authorized Covered Beverages,
and will use only such Authorized Containers, closures, cases, cartons and other packages and labels as will be authorized from time to time by Company for Bottler and will purchase such items only from manufacturers approved by Company, which
approval will not be unreasonably withheld. 

  

	 	12.8.1	 Company will approve three (3) or more manufacturers of such items, if in the reasonable opinion of Company,
there are three (3) or more manufacturers who are capable of producing such items to be fully suitable for the purpose intended and in accordance with the high quality standards and image of excellence of the Trademarks and the Authorized
Covered Beverages. 

  

	 	12.8.2	 Such approval by Company does not relieve Bottler of Bottler’s independent responsibility to assure that the
Authorized Containers, closures, cases, cartons and other packages and labels purchased by Bottler are suitable for the purpose intended, and in accordance with the good reputation and image of excellence of the Trademarks and Covered Beverages (it
being understood and agreed, however, that Bottler will not be responsible for the review or inspection of the content or design of labels authorized by Company for use on Authorized Covered Beverages). 

 

	 	12.9	 Company reserves the right to withdraw from time to time its approval of any of the Authorized Containers upon
six (6) months’ prior Notice to Bottler, and, in such event, the repurchase provisions of Section 24.1.2 will apply to such containers so disapproved that are owned by Bottler. Company will exercise its right to approve,
and to withdraw its approval of, specific Authorized Containers in good faith and after consultation with Bottler so as to permit Bottler to continue to satisfy the demand in Bottler’s Territory as a whole for Authorized Covered Beverages.

  

	 	12.10	 Bottler will use commercially reasonable efforts to maintain at all times a stock of, or have entered into other
alternate supply arrangements to obtain, Authorized Containers, closures, labels, cases, cartons, and other essential related materials bearing the Trademarks, sufficient to satisfy fully the demand for Authorized Covered Beverages in Authorized
Containers in Bottler’s Territory and to fulfill Bottler’s supply obligations, if any, to Recipient Bottlers, in each case in accordance with sourcing plans developed by the NPSG from time to time, and Bottler will not use or authorize any
other Person to use Authorized Containers, or such closures, labels, cases, cartons and other materials, if they bear the Trademarks or contain any Beverages, for any purpose other than the packaging of the Authorized Covered Beverages.

  

	 	12.11	 Bottler agrees not to refill or otherwise reuse nonreturnable containers. 

 

	 	12.12	 The parties acknowledge and agree (a) that Bottler makes the representations, warranties and agreements set
forth in this Section 12 in reliance on Company’s warranty in Section 11 and (b) that the representations, warranties, covenants and agreements contained in this Section 12 relate
solely to Bottler’s activities under this Agreement and the manufacture of Authorized Covered Beverages at the Regional Manufacturing Facilities. 

  
 - 10 - 

	13	 OBLIGATIONS OF COMPANY AND BOTTLER RELATING TO RECALL OF AUTHORIZED COVERED BEVERAGES 

  

	 	13.1	 If Company determines or becomes aware of the existence of any quality or technical problems relating to any
Authorized Covered Beverages manufactured at the Regional Manufacturing Facilities, or any package used for such Authorized Covered Beverage, in Bottler’s Territory, Company will immediately notify Bottler by telephone, facsimile, e-mail or any
other form of immediate communication. This notification will include, to the extent available to Company, (a) the identity and quantities of Authorized Covered Beverages involved, including the specific packages, (b) coding data, and
(c) all other relevant data that will assist in tracing such Authorized Covered Beverages. 

  

	 	13.1.1	 Company may require Bottler to take all necessary action to recall all of such Authorized Covered Beverages, or
any package used for such Authorized Covered, or withdraw immediately such Authorized Covered Beverages from the market or the trade, as the case may be. 

  

	 	13.1.2	 Company will notify Bottler by telephone, facsimile, e-mail or any other form of immediate communication of the
decision by Company to require Bottler to recall such Authorized Covered Beverages or withdraw such Authorized Covered Beverages from the market or trade. 

  

	 	13.2	 If Bottler determines or becomes aware of the existence of quality or technical problems relating to Authorized
Covered Beverages manufactured at the Regional Manufacturing Facilities, then Bottler must immediately notify Company by telephone, e-mail or any other form of immediate communication. This notification must include: (a) the identity and
quantities of Authorized Covered Beverages involved, including the specific packages, (b) coding data, and (c) all other relevant data that will assist in tracing such Authorized Covered Beverages. 

 

	 	13.3	 In the event of a withdrawal or recall of any Authorized Covered Beverage manufactured at the Regional
Manufacturing Facilities or any package used for such Authorized Covered Beverage, that was produced by Bottler and sold to a Recipient Bottler, Bottler will use its commercially reasonable efforts to respond promptly and fairly if a claim is made
by a Recipient Bottler as a result of any such withdrawal or recall. 

  

	 	13.4	 If any withdrawal or recall of any Authorized Covered Beverage manufactured at the Regional Manufacturing
Facilities or any of the packages used therefor is caused by (i) quality or technical defects in the Concentrates, or other materials prepared by Company from which the product involved was prepared by Bottler, or (ii) quality or technical
defects in Company’s designs and design specifications of packages and labels authorized by Company for use on Authorized Covered Beverages (and specifically excluding designs and specifications of other parties and the failure of other parties
to manufacture packages in strict conformity with the designs and specifications of Company), Company will reimburse Bottler for Bottler’s total reasonable expenses incident to such withdrawal or recall, including any payment made by Bottler to
a Recipient Bottler in connection with the specific withdrawal or recall. 

  

	 	13.5	 Conversely, if any withdrawal or recall of Authorized Covered Beverages manufactured at the Regional
Manufacturing Facilities is caused by Bottler’s failure to comply with the Technical Requirements or any applicable laws, rules and regulations (it being understood and agreed that Bottler will not be responsible for any failure to comply with
the Technical Requirements or applicable laws to the extent such failure results from the content or design of labels authorized by Company for use on Authorized Covered Beverages), Bottler will bear its total expenses of such withdrawal or recall
and reimburse Company for Company’s total reasonable expenses incident to such withdrawal or recall. 

  
 - 11 - 

	14	 OBLIGATIONS OF BOTTLER RELATING TO MANUFACTURE OF AUTHORIZED COVERED BEVERAGES, SYSTEM GOVERNANCE,
INVESTMENT, MANAGEMENT, REPORTING AND PLANNING ACTIVITIES 

  

	 	14.1	 Bottler will participate fully in, and comply fully with, the requirements and programs established from time to
time by the NPSG Board; provided, however, that Bottler will not be required to engage in conduct that would result in breach of this Agreement, Bottler’s CBA, or any other agreements between Company and Bottler.

  

	 	14.2	 [Reserved.] 

  

	 	14.3	 [Reserved.] 

  

	 	14.4	 Bottler will maintain the consolidated financial capacity reasonably necessary to assure that Bottler and all
Bottler Affiliates will be financially able to perform their respective duties and obligations under this Agreement. 

  

	 	14.5	 Upon Company’s request, Bottler will provide to Company each year and review with Company an annual and long
range operating plan and budget for Bottler’s business of manufacturing Authorized Covered Beverages at the Regional Manufacturing Facilities, including financials and capital investment budgets to the extent related to the Regional
Manufacturing Facilities, and, if requested by Company, discuss changes in general management and senior management of Bottler’s manufacturing business, except to the extent otherwise prohibited by applicable law. 

 

	 	14.6	 Bottler will: 

  

	 	14.6.1	 Maintain accurate books, accounts and records relating to the purchasing of Concentrate and the manufacture of
Authorized Covered Beverages under this Agreement; and 

  

	 	14.6.2	 Upon Company’s request, provide to Company such operational, financial, accounting, forecasting, planning
and other information, including audited and unaudited detail of cost of goods sold and sales volume for Authorized Covered Beverages to the extent, in the form and manner, as permitted by applicable law and at such times as reasonably required
(a) by Company to determine whether Bottler is performing its obligations under this Agreement; (b) by Company to calculate finished goods pricing under the Interim Finished Goods Supply Agreement, NPSG Finished Goods Supply Agreement or
Regional Finished Goods Supply Agreement and (c) by the NPSG Board for the purpose of implementing, administering, and operating the NPSG, subject to appropriate regulatory firewalls ((a), (b), and (c) collectively, the “Financial
Information”); provided, however, that Bottler will not be required to provide Company with duplicate copies of any compilation of Financial Information provided to the NPSG that expressly directs the NPSG to provide such
compilation to Company. 

  

	 	14.7	 The parties recognize that the Financial Information is critical to the ability of Company and the NPSG to
maintain, promote, and safeguard the overall performance, efficiency, integrity, and competitiveness of the product supply system for Authorized Covered Beverages. 

 

	 	14.8	 Company will hold the Financial Information provided by Bottler in accordance with the confidentiality provisions
of Section 39 and will not use such information for any purpose other than determining compliance with this Agreement, to calculate finished goods pricing under the Interim Finished Goods Supply Agreement, NPSG Finished Goods
Supply Agreement or Regional Finished Goods Supply Agreement, or as necessary to provide to the NPSG, subject to appropriate regulatory firewalls, for the purpose of facilitating the NPSG’s execution of operational responsibilities such
as infrastructure optimization, national sourcing and strategic initiative decisions. 

  
 - 12 - 

	15	 PRICING AND OTHER CONDITIONS OF PURCHASE AND SALE OF CONCENTRATES  

 

	 	15.1	 Subject to Section 15.2, Company reserves the right to establish and to revise at any time, in
its sole discretion, the price of any of the Concentrates sold to Bottler for use in manufacturing Authorized Covered Beverages at the Regional Manufacturing Facilities, the related terms of payment, and the other terms and conditions of supply, any
such revision to be effective immediately upon Notice to Bottler. Bottler acknowledges that information related to pricing of Company’s Concentrates is confidential and will be maintained as such in accordance with
Section 39. 

  

	 	15.2	 If Company exercises its discretion under Section 15.1, the “price” charged by
Company or its Affiliate for any of the Concentrates will be the same as the “price” charged by Company or its Affiliate for such Concentrate, the terms of payment and other terms and conditions of supply will be the same as those applied
by Company for such Concentrates, to each other Regional Producing Bottler (other than a Company Owned Manufacturer) in the United States. 

  

	 	15.3	 For purposes of manufacturing Authorized Covered Beverages at the Regional Manufacturing Facilities, Bottler will
purchase from Company only such quantities of the Concentrates as will be necessary and sufficient to carry out Bottler’s obligations under this Agreement. Bottler will use the Concentrates exclusively for its manufacture of the Authorized
Covered Beverages. Bottler will not sell or otherwise transfer any Concentrates or permit the same to get into the hands of third parties. 

  

	16	 OWNERSHIP AND CONTROL OF BOTTLER  

 

	 	16.1	 Bottler hereby acknowledges the personal nature of Bottler’s obligations under this Agreement, including
with respect to the performance standards applicable to Bottler, the dependence of the Trademarks on proper quality control, and the confidentiality required for protection of Company’s trade secrets and confidential information.

  

	 	16.2	 Bottler represents and warrants to Company that, prior to execution of this Agreement, Bottler has made available
to Company a complete and accurate list of Persons that own more than five percent (5%) of the outstanding securities of Bottler, and/or of any third parties having a right to, or effective power of, control or management of Bottler (whether
through contract or otherwise). 

  

	 	16.3	 [Reserved.] 

  

	 	16.4	 Bottler acknowledges that Company has a vested and legitimate interest in maintaining, promoting and safeguarding
the overall performance, efficiency and integrity of Company’s bottling, distribution and sales system. Bottler therefore covenants and agrees: 

  

	 	16.4.1	 Except as otherwise permitted by Bottler’s CBA, not to assign, transfer or pledge this Agreement or any
interest herein, in whole or in part, whether voluntarily, involuntarily, or by operation of law (including by merger or liquidation), or sublicense its rights under this Agreement, in whole or in part, to any third party or parties, without the
prior written consent of Company; and 

  

	 	16.4.2	 Not to delegate any material element of Bottler’s performance under this Agreement, in whole or in part, to
any third party or parties without the prior written consent of Company. 

  
 - 13 - 

	 	16.5	 Notwithstanding Section 16.4, the following shall be expressly permitted hereunder:

  

	 	16.5.1	 Bottler may, after Notice to Company, assign, transfer or pledge this Agreement or any interest herein, in whole
or in part, or delegate any material element of Bottler’s performance of this Agreement, in whole or in part, to any wholly-owned Affiliate of Bottler; provided that (a) any such Affiliate must agree in writing to be bound by and
comply with the terms and conditions of this Agreement, and (b) any such assignment, transfer, pledge or delegation will not relieve Bottler of any of its obligations under this Agreement; and 

 

	 	16.5.2	 Bottler may engage third party contractors and service providers for the purpose of receiving services relating
to non-core functions (e.g., back-office administrative services, human resources, payroll, information technology services and similar services); provided that (a) Bottler will retain full responsibility to Company for all of
Bottler’s obligations under this Agreement; and (b) Bottler may not subcontract core functions (i.e., manufacturing, market and customer-facing functions) without the prior written consent of Company. 

 

	 	16.6	 Any attempt to take any actions prohibited by Sections 16.4 and 16.5 without
Company’s prior written consent shall be void and shall be deemed to be a material breach of this Agreement, unless such actions are otherwise permitted under Bottler’s CBA. 

 

	17	 TERM OF AGREEMENT 

 

	 	 	 This Agreement will commence on the Effective Date and continue so long as Bottler’s CBA is in effect (the
“Term”). 

  

	18	 COMMERCIAL IMPRACTICABILITY AND FORCE MAJEURE 

 

	 	18.1	 With respect to any one or more Concentrates (the “Affected Products”), as applicable:

  

	 	18.1.1	 The obligation of Company (including any of its Affiliates) to supply Affected Products to Bottler, and
Bottler’s obligation to purchase Affected Products from Company and to manufacture any Authorized Covered Beverages manufactured from such Affected Products, shall be suspended during any period when there occurs a change in applicable laws,
regulations or administrative measures (including any government permission or authorization regarding customs, health or manufacturing, and further including the withdrawal of any government authorization required by any of the parties to carry out
the terms of this Agreement), or issuance of any judicial decree or order binding on any of the parties hereto, in each case in such a manner as to render unlawful or commercially impracticable: 

 

	 	18.1.1.1	 The importation or exportation of any essential ingredients of the Affected Products that cannot be produced in
quantities sufficient to satisfy the demand therefor by existing Company (including any of its Affiliates) facilities in the United States; 

  

	 	18.1.1.2	 The manufacture and distribution of Affected Products to Bottler; or 

 

	 	18.1.1.3	 Bottler’s manufacture of Authorized Covered Beverages using such Affected Products. 

  
 - 14 - 

	 	18.2	 “Force Majeure Event” means any strike, blacklisting, boycott or sanctions imposed by a
sovereign nation or supra-national organization of sovereign nations, however incurred, or any act of God, act of foreign enemies, embargo, quarantine, riot, insurrection, a declared or undeclared war, state of war or belligerency or hazard or
danger incident thereto. 

  

	 	18.3	 Neither Company (including any of its Affiliates) nor Bottler shall be liable for or be subject to any claim for
breach or termination as the result of a failure to perform their respective obligations to purchase or supply Concentrate under this Agreement or to manufacture Authorized Covered Beverages made from such Concentrate in quantities to satisfy demand
of Company and Recipient Bottlers, as applicable, if and to the extent that such failure is caused by or results from a Force Majeure Event; provided, however: 

 

	 	18.3.1	 The party claiming the excuse afforded by this Section 18.3 must use commercially reasonable
efforts to comply with any excused obligations under this Agreement that are impaired by such Force Majeure Event; and 

  

	 	18.3.2	 If Bottler is the party claiming the excuse afforded by this Section 18.3:

  

	 	18.3.2.1	 To the extent that Bottler is unable to remediate the effect on its ability to perform caused by such Force
Majeure Event within three (3) months from the date of the occurrence of the Force Majeure Event, then, 

  

	 	18.3.2.1.1	 Company shall have the right (but not the obligation) upon not less than one (1) month prior Notice to suspend this
Agreement and Related Agreements during the period of time that such Force Majeure Event results in Bottler being unable to perform its obligations under this Agreement. 

 

	 	18.3.2.1.2	 To the extent that Bottler is unable to remediate the effect on its ability to perform caused by such Force Majeure
Event within two (2) years from the date of occurrence of the Force Majeure Event, Company shall have the right to terminate this Agreement. 

  

	19	 TERMINATION FOR DEFINED EVENTS  

 

	 	19.1	 Company may, at Company’s option, terminate this Agreement, subject to the requirements of
Section 23, if any of the following events occur: 

  

	 	19.1.1	 An order for relief is entered with respect to Bottler under any Chapter of Title 11 of the United States Code, as
amended; 

  

	 	19.1.2	 Bottler voluntarily commences any bankruptcy, insolvency, receivership, or assignment for the benefit of creditors
proceeding, case, or suit or consents to such a proceeding, case or suit under the laws of any state, commonwealth or territory of the United States or any country, kingdom or commonwealth or sub-division thereof not governed by the United States;

  

	 	19.1.3	 A petition, proceeding, case, complaint or suit for bankruptcy, insolvency, receivership, or assignment for the benefit
of creditors, under the laws of any state, territory or commonwealth of the United States or any country, commonwealth or sub-division thereof or kingdom not governed by the United States, is filed against Bottler, and such a petition, proceeding,
suit, complaint or case is not dismissed within sixty (60) days after the commencement or filing of such a petition, proceeding, complaint, case or suit or the order of dismissal is appealed and stayed; 

  
 - 15 - 

	 	19.1.4	 Bottler makes an assignment for the benefit of creditors, deed of trust for the benefit of creditors or makes an
arrangement or composition with creditors; a receiver or trustee for Bottler or for any interest in Bottler’s business is appointed and such order or decree appointing the receiver or trustee is not vacated, dismissed or discharged within sixty
(60) days after such appointment or such order or decree is appealed and stayed; 

  

	 	19.1.5	 Any of the Regional Manufacturing Facilities is subject to attachment, levy or other final process for more than twenty
(20) days or any of its equipment or facilities is noticed for judicial or non-judicial foreclosure sale and such attachment, levy, process or sale would materially and adversely affect Bottler’s ability to fulfill its obligations under
this Agreement; or 

  

	 	19.1.6	 Bottler becomes insolvent or ceases to conduct its operations relating to the Regional Manufacturing Facilities in the
normal course of business. 

  

	 	19.1.7	 Any Bottler’s Contract, Bottler’s Bottle Contract, or Master Bottle Contract (as the case may be) for
Coca-Cola, listed on Schedule 32(d) of Bottler’s CBA, between Company and Bottler or their respective Affiliates is terminated by Company under provisions that permit termination without damages due to Bottler’s breach or default,
unless Company agrees in writing that this Section 19.1.7 will not be applied by Company to such termination. 

  

	20	 DEFICIENCY TERMINATION  

 

	 	20.1	 Company may also, at Company’s option, terminate this Agreement, subject to the requirements of
Section 21 and Section 23, if any of the following events of default occur: 

  

	 	20.1.1	 Bottler fails to make timely payment for Concentrate, or of any other material debt owing to Company;

  

	 	20.1.2	 The condition of the facilities or equipment used by Bottler in manufacturing the Authorized Covered Beverages at
the Regional Manufacturing Facilities, as reflected in any data collected by Company or generated by Bottler, or in any audit or inspection conducted by or on behalf of Company, fails to meet the Technical Requirements reasonably established by
Company, and Bottler fails to complete corrective measures approved by Company within the timeframe therefor reasonably established by Company and specified in the applicable Technical Corrective Action Plan; 

 

	 	20.1.3	 Bottler fails to handle the Concentrates or manufacture or handle the Authorized Covered Beverages at the
Regional Manufacturing Facilities in strict conformity with the Technical Requirements and applicable laws, rules and regulations and Bottler fails to complete corrective measures approved by Company within the timeframe therefor reasonably
established by Company; 

  

	 	20.1.4	 Bottler or any Affiliate of Bottler engages in any of the activities prohibited under
Section 10; 

  

	 	20.1.5	 [Reserved]; 

  

	 	20.1.6	 [Reserved]; 

  
 - 16 - 

	 	20.1.7	 Bottler breaches in any material respect any of Bottler’s other material obligations under this Agreement;

  

	 	20.1.8	 Bottler breaches in any material respect any of Bottler’s material obligations under the NPSG Governance
Agreement and such breach is not timely cured; or 

  

	 	20.1.9	 Any event of default occurs under Section XII of Bottler’s CBA that is not timely cured in the manner
provided in Bottler’s CBA. 

  

	 	20.2	 In any such event of default, Company may either exercise its right to terminate under this
Section 20 (subject to Section 21 and Section 23), or pursue any rights and remedies (other than termination) against Bottler with respect to any such event of default; provided, that
Company will not take any action pursuant to this Section 20.2 or Section 21.4 that would limit Bottler’s right to cure under Section 21 of this Agreement or Paragraph 34 of
Bottler’s CBA. 

  

	21	 BOTTLER RIGHT TO CURE  

 

	 	21.1	 Upon the occurrence of any of the events of default enumerated in Section 20, Company will
give Bottler Notice of default. 

  

	 	21.2	 In the case of an event of default due to a material breach by Bottler of its obligations under
Section 12 (other than Sections 12.2 or 12.4) or Section 13: 

  

	 	21.2.1	 Bottler shall have a period of sixty (60) days from receipt of the Notice of default within which to cure
such default, by: 

  

	 	21.2.1.1	 at the instruction of Company and at Bottler’s expense, promptly withdrawing from the market and destroying
any Authorized Covered Beverage that fails to meet the Technical Requirements; 

  

	 	21.2.1.2	 compliance with the “Corrective Action” provision of the Technical Requirements; and

  

	 	21.2.1.3	 implementing a corrective action plan (the “Technical Corrective Action Plan”), to be negotiated
in good faith and agreed to by Company and Bottler, that reasonably meets the applicable requirements of the “Corrective Action” provision of the Technical Requirements (which Technical Corrective Action Plan may, by mutual agreement of
the parties, provide for actions to be taken after expiration of the cure periods specified herein). 

  

	 	21.2.2	 If such default has not been cured within such initial sixty (60) day period (or such extended period, if
any, provided for under a Technical Corrective Action Plan), then Bottler must cure such default within a second period of sixty (60) days (or such extended period, if any, provided for under a Technical Corrective Action Plan) during which
period Company may, by giving Bottler further Notice to such effect, suspend sales to Bottler of Concentrates and require Bottler to cease manufacture of Authorized Covered Beverages at the Regional Manufacturing Facilities and the supply and sale
of Authorized Covered Beverages from the Regional Manufacturing Facilities by Bottler to Recipient Bottlers; provided, however, that if Bottler has throughout the first and second cure periods strictly complied with
Section 13 (Recall) and Section 30 (Incident Management), then such suspension of Concentrate sales and cessation of manufacture and supply shall be limited to the Regional Manufacturing Facilities in which the
default occurred. 

  
 - 17 - 

	 	21.2.3	 If such default has not been cured during such second period of sixty (60) days (or such extended period, if
any, provided for under a Technical Corrective Action Plan), then Company may terminate this Agreement, by giving Bottler Notice to such effect, effective immediately; provided, however, that if Bottler has throughout the first and
second cure periods strictly complied with Section 13 (Recall) and Section 30 (Incident Management), then Bottler will have a third period of sixty (60) days (or such extended period, if any, provided for
under a Technical Corrective Action Plan) within which to cure the default. 

  

	 	21.2.4	 If such default has not been cured during any such third period of sixty (60) days (or such extended period,
if any, provided for under a Technical Corrective Action Plan), then Company may terminate this Agreement, by giving Bottler notice to such effect, effective immediately. 

 

	 	21.3	 In the case of an event of default other than those specified in Section 21.2:

  

	 	21.3.1	 Within sixty (60) days of receipt of such Notice, Bottler will provide Company with a corrective action plan
(the “Non-Technical Corrective Action Plan”). The Non-Technical Corrective Action Plan must provide for correction of all issues identified in the Notice of default within one (1) year or less from the date on which the
Non-Technical Corrective Action Plan is provided to Company. 

  

	 	21.3.2	 Company will negotiate in good faith with Bottler the terms of the Non-Technical Corrective Action Plan.

  

	 	21.3.3	 If Company and Bottler fail to agree on a Non-Technical Corrective Action Plan within sixty (60) days of
Bottler’s tender of such plan, Bottler must cure the default described in the Notice of default within one (1) year of Bottler’s receipt of the Notice of default. If Bottler fails to cure the default described in the Notice of default
within one (1) year of Bottler’s receipt of the Notice, the default will be deemed not to have been cured. 

  

	 	21.3.4	 If Company and Bottler timely agree on a Non-Technical Corrective Action Plan, but Bottler fails to implement the
agreed Non-Technical Corrective Action Plan to Company’s reasonable satisfaction within the time period specified by the Non-Technical Corrective Action Plan, the default will be deemed not to have been cured. 

 

	 	21.3.5	 In the event of an uncured default under this Section 21.3, Company may, by giving Bottler
further Notice of termination, terminate this Agreement and require Bottler to cease manufacturing Authorized Covered Beverages at the Regional Manufacturing Facilities. 

 

	 	21.4	 The provisions of this Section 21 (including any cure) will not limit Company’s right to
pursue remedies under this Agreement on account of Bottler’s default, other than (a) termination of this Agreement under Section 20, (b) cessation of Company’s performance of its obligations under this
Agreement, or (c) rescission. 

  

	 	21.5	 In the case of a breach by Bottler or one of its Affiliates of its obligations under this Agreement (other than
an event of default specified by Section 21.2), such breach will be deemed to be cured for purposes of this Section 21 if Bottler (or its Affiliate) has terminated the acts or omissions described in such Notice
of breach, and has taken reasonable steps under the circumstances to prevent the recurrence of such breach. 

  
 - 18 - 

	22	 [RESERVED.]  

  

	23	 EFFECT OF BOTTLER’S CBA ON THIS AGREEMENT IN CERTAIN EVENTS 

 

	 	23.1	 Upon any termination of Bottler’s CBA by Company, Company will concurrently terminate this Agreement unless
otherwise agreed in writing by the parties. 

  

	24	 POST-EXPIRATION AND POST-TERMINATION OBLIGATIONS 

 

	 	24.1	 Upon the termination of this Agreement, except to the extent provided in any other agreement between Bottler and
Company (or one of Company’s Affiliates): 

  

	 	24.1.1	 Bottler shall not thereafter continue to manufacture any of the Authorized Covered Beverages in Authorized
Containers at the Regional Manufacturing Facilities or to make any use of the Trademarks or Authorized Containers, or any closures, cases or labels bearing the Trademarks in connection with the manufacture of Authorized Covered Beverages at the
Regional Manufacturing Facilities; and 

  

	 	24.1.2	 Bottler shall forthwith deliver all materials used by Bottler exclusively for the manufacturing of the Authorized
Covered Beverages in Authorized Containers at the Regional Manufacturing Facilities, including Concentrates, usable returnable or any nonreturnable containers, cases, closures, and labels bearing the Trademarks, still in Bottler’s possession or
under Bottler’s control, to Company or Company’s nominee, as instructed, and, upon receipt, Company shall pay to Bottler a sum equal to the reasonable market value of such supplies or materials. Company will accept and pay for only such
articles as are, in the opinion of Company, in first-class and usable condition, and all other such articles shall be destroyed at Bottler’s expense. Containers, closures and all other items bearing the name of Bottler, in addition to the
Trademarks, that have not been purchased by Company shall be destroyed without cost to Company, or otherwise disposed of in accordance with instructions given by Company, unless Bottler can remove or obliterate the Trademarks therefrom to the
satisfaction of Company. The provisions for repurchase contained this Section 24.1.2 shall apply with regard to any Authorized Container approval of which has been withdrawn by Company under Section 12.10,
except under circumstances under which this Agreement is terminated by Company in accordance with Section 20. 

  

	25	 COMPANY’S RIGHT OF ASSIGNMENT 

 

	 	 Company may assign any of its rights and delegate all or any of its duties or obligations under this Agreement to one or
more of its Affiliates; provided, however, that any such assignment or delegation will not relieve Company from any of its contractual obligations under this Agreement. 

 

	26	 LITIGATION 

  

	 	26.1	 Company reserves and has the sole and exclusive right and responsibility to institute any civil, administrative
or criminal proceedings or actions, and generally to take or seek any available legal remedy it deems desirable, for the protection of its reputation, the Trademarks, and other intellectual property rights, as well as for the Concentrates, and to
defend any action affecting these matters. 

  
 - 19 - 

	 	26.2	 At the request of Company, Bottler will render reasonable assistance in any such action, including, if requested
to do so in the sole discretion of Company, allowing Bottler to be named as a party to such action. However, no financial burden will be imposed on Bottler for rendering such assistance. 

 

	 	26.3	 Bottler shall not have any claim against Company or its Affiliates as a result of such proceedings or action or
for any failure to institute or defend such proceedings or action. 

  

	 	26.4	 Bottler must promptly notify Company of any litigation or proceedings instituted or threatened against Bottler
affecting these matters. 

  

	 	26.5	 Bottler must not institute any legal or administrative proceedings against any third party that may affect the
interests of Company in the Trademarks without the prior written consent of Company, which consent Company may grant or withhold in its sole discretion. 

  

	 	26.6	 Bottler will consult with Company on all product liability claims, proceedings or actions brought against Bottler
in connection with the Authorized Covered Beverages and will take such action with respect to the defense of any such claim or lawsuit as Company may reasonably request in order to protect the interests of Company in the Authorized Covered Beverages
or the goodwill associated with the Trademarks. 

  

	27	 INDEMNIFICATION 

 

	 	27.1	 Company will indemnify, protect, defend and hold harmless each of Bottler and its Affiliates, and their
respective directors, officers, employees, shareholders, owners and agents, from and against all claims, liabilities, losses, damages, injuries, demands, actions, causes of action, suits, proceedings, judgments and expenses, including reasonable
attorneys’ fees, court costs and other legal expenses (collectively, “Losses”), to the extent arising from, connected with or attributable to: (a) Company’s manufacture of the Concentrates (except to the extent
arising from matters for which Bottler is responsible under Section 13.5 or Section 27.2); (b) the breach by Company of any provision this Agreement; (c) Bottler’s use, in accordance with this
Agreement and Company guidelines respecting use of Company intellectual property, of the Trademarks or of package labels; or (d) the inaccuracy of any warranty or representation made by Company herein or in connection herewith. None of the
above indemnities shall require Company to indemnify, protect, defend or hold harmless any indemnitee with respect to any claim to the extent such claim arises from, is connected with or is attributable to the negligence or willful misconduct of
such indemnitee. 

  

	 	27.2	 Bottler will indemnify, protect, defend and hold harmless each of Company and its Affiliates, and their
respective directors, officers, employees, shareholders, owners and agents, from and against all Losses to the extent arising from, connected with or attributable to: (a) Bottler’s manufacture of the Authorized Covered Beverages at the
Regional Manufacturing Facilities (except to the extent arising from matters for which Company is responsible under Section 13.4 or Section 27.1); (b) the breach by Bottler of any provision of this
Agreement; or (c) the inaccuracy of any warranty or representation made by Bottler herein or in connection herewith. None of the above indemnities shall require Bottler to indemnify, protect, defend or hold harmless any indemnitee with respect
to any claim to the extent such claim arises from, is connected with or is attributable to the negligence or willful misconduct of such indemnitee. 

  

	 	27.3	 Neither party will be obligated under this Section 27 to indemnify the other party for Losses
consisting of lost profits or revenues, loss of use, or similar economic loss, or for any indirect, special, incidental, consequential or similar damages (“Consequential Damages”) arising out of or in connection with the performance
or non-performance of this Agreement (except to the extent that an indemnified third party claim asserted against a party includes Consequential Damages). 

  
 - 20 - 

	28	 BOTTLER’S INSURANCE 

 

	 	 Bottler will obtain and maintain a policy of insurance with insurance carriers in such amounts and against such risks as
would be maintained by a similarly situated company of a similar size and giving full and comprehensive coverage both as to amount and risks covered in respect of matters referred to in Section 27 (including Bottler’s
indemnity of Company contained therein) and will on request produce evidence satisfactory to Company of the existence of such insurance. Compliance with this Section 28 will not limit or relieve Bottler from its obligations under
Section 27. In addition, Bottler will satisfy the insurance requirements specified on Schedule 28. 

  

	29	 [RESERVED.]  

  

	30	 INCIDENT MANAGEMENT 

 

	 	30.1	 Company and Bottler recognize that incidents may arise that can threaten the reputation and business of Bottler and/or
negatively affect the good name, reputation and image of Company and the Trademarks. 

  

	 	30.2	 In order to address such incidents, including any questions of quality of the Authorized Covered Beverages that
may occur, Bottler will designate and organize an incident management team and inform Company of the members of such team. 

  

	 	30.3	 Bottler further agrees to cooperate fully with Company and such third parties as Company may designate and
coordinate all efforts to address and resolve any such incident consistent with procedures for crisis management that may be issued to Bottler by Company from time to time. 

 

	31	 SEVERABILITY 

  

	 	 	 If any provision of this Agreement is or becomes legally ineffective or invalid, the validity or effect of the remaining
provisions of this Agreement shall not be affected; provided that the invalidity or ineffectiveness of such provision shall not prevent or unduly hamper performance hereunder or prejudice the ownership or validity of the Trademarks.

  

	32	 REPLACEMENT OF CERTAIN PRIOR CONTRACTS, MERGER, AND REQUIREMENTS FOR MODIFICATION 

 

	 	32.1	 As to all matters and things herein mentioned, the parties agree: 

 

	 	32.1.1	 [Reserved]; 

  

	 	32.1.2	 This Agreement, together with the National Product Supply System Governance Agreement and the documents
implementing and governing the NPSG and the NPSG Board set forth the entire agreement between Company and Bottler with respect to the subject matter hereof, and all prior understandings, commitments or agreements relating to such matters between the
parties or their predecessors-in-interest (including the Initial Regional Manufacturing Agreement, dated as of January 29, 2016) are of no force or effect and are cancelled hereby; provided, however, that any written
representations made by either party upon which the other party relied in entering into this Agreement will remain binding to the extent identified on Schedule 32.1.2; 

  
 - 21 - 

	 	32.1.3	 Any waiver, amendment or modification of this Agreement or any of its provisions, and any consents given under
this Agreement will not be binding upon Bottler or Company unless made in writing, signed by an officer or other duly qualified and authorized representative of Company or by a duly qualified and authorized representative of Bottler; and

  

	 	32.1.4	 Except as expressly provided in this Agreement, this Section 32.1 is not intended to affect in
any way the rights and obligations of Bottler (or any of its Affiliates) or Company (or any of its Affiliates) under Bottler’s CBA or the agreements listed in Schedule 32.1.2. 

 

	33	 NO WAIVER 

  

	 	 Failure of Company or Bottler (including any of their respective Affiliates) to exercise promptly any right herein
granted, or to require strict performance of any obligation undertaken herein by the other party, will not be deemed to be a waiver of such right or of the right to demand subsequent performance of any and all obligations herein undertaken by
Bottler or by Company. 

  

	34	 NATURE OF AGREEMENT AND RELATIONSHIP OF THE PARTIES 

 

	 	34.1	 Bottler is an independent contractor and is not an agent of, or a partner or joint venturer with, Company.

  

	 	34.2	 Each of Company and Bottler agree that it will neither represent, nor allow itself to be held out as an agent of,
or partner or joint venturer with the other (including any of its Affiliates). 

  

	 	34.3	 Bottler and Company do not intend to create, and this Agreement will not be construed to create, a partnership,
joint venture, agency, or any form of fiduciary relationship. Each party covenants and agrees never to assert that a partnership, joint venture or fiduciary relationship exists or has been created under or in connection with this Agreement and the
Related Agreements. There is no partnership, joint venture, agency, or any form of fiduciary relationship existing between Bottler and Company, but if it there is determined or found to be a partnership, joint venture, or agency, then Bottler and
Company expressly disclaim all fiduciary duties that might otherwise exist under applicable law. 

  

	 	34.4	 Nothing in this Agreement, express or implied, is intended or will be construed to give any Person, other than
the parties to this Agreement and their successors and permitted assigns, any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained in this Agreement. This Agreement does not, and is not intended
to, confer any rights or remedies upon any Person other than Bottler and Company. 

  

	35	 HEADINGS AND OTHER MATTERS 

 

	 	35.1	 The headings herein are solely for the convenience of the parties and will not affect the interpretation of this
Agreement. 

  

	 	35.2	 As used in this Agreement, the phrase “including” means “including, without limitation” in
each instance. 

  
 - 22 - 

	 	35.3	 References in this Agreement to Sections are to the respective Sections of this Agreement, and references to
Exhibits and Schedules are to the respective Exhibits and Schedules of this Agreement as they may be amended from time to time. 

  

	36	 EXECUTION IN MULTIPLE COUNTERPARTS  

 

	 	 The parties may execute this Agreement in counterparts, each of which is deemed an original and all of which only
constitute one original. 

  

	37	 NOTICE AND ACKNOWLEDGEMENT 

 

	 	37.1	 Notices. 

  

	 	37.1.1	 Requirement of a Writing and Permitted Methods of Delivery. Each party giving or making any notice, request, demand or
other communication (each, a “Notice”) pursuant to this Agreement must give the Notice in writing and use one of the following methods of delivery, each of which for purposes of this Agreement is a writing: 

 

	 	37.1.1.1	 personal delivery; 

  

	 	37.1.1.2	 Registered or Certified Mail, in each case, return receipt requested and postage prepaid; 

 

	 	37.1.1.3	 nationally recognized overnight courier, with all fees prepaid; 

 

	 	37.1.1.4	 facsimile; or 

  

	 	37.1.1.5	 e-mail (followed by delivery of an original by another delivery method provided for in this Section).

  

	 	37.1.2	 Addressees and Addresses. Each party giving a Notice must address the Notice to the appropriate person at the receiving
party (the “Addressee”) at the address listed below or to another Addressee or at another address designated by a party in a Notice pursuant to this Section. 

Company: 
 The
Coca-Cola Company 
 One Coca-Cola Plaza 

Atlanta, Georgia 30313 

	 	Attention:	 EVP & President CCNA [or such other title as may be applicable to Company’s most senior officer for North
America operations] 

 Email: jdouglas@coca-cola.com 

With a copy to: 
 The Coca-Cola Company 
 One Coca-Cola Plaza 

Atlanta, Georgia 30313 
 Attention: General Counsel

 Email: bgoepelt@coca-cola.com 

  
 - 23 - 

 and 

King & Spalding LLP 
 1180 Peachtree
Street NE 
 Atlanta, Georgia 30309 
 Attention:
 William G. Roche 
                   Anne M. Cox 

Email: broche@kslaw.com 

            acox@kslaw.com 

Bottler: 
 Coca-Cola Bottling Co. Consolidated

 4100 Coca Cola Plaza 
 Charlotte, North
Carolina 28211 
 Attention:     Lawrence K. Workman, Jr., Vice President 

Email:           kent.workman@ccbcc.com 

With a copy to: 
 Moore & Van Allen PLLC

 100 North Tryon Street 
 Suite 4700 

Charlotte, North Carolina 28202 
 Attention:
        John V. McIntosh 

                         E.
Beauregarde Fisher III 
 Email:     johnmcintosh@mvalaw.com 

                beaufisher@mvalaw.com 

 

	 	37.1.3	 Effectiveness of a Notice. Except as specifically provided elsewhere in this Agreement, a Notice is effective only if
the party giving or making the Notice has complied with Sections 37.1.1 and 37.1.2 and if the Addressee has received the Notice. A Notice is deemed to have been received as follows: 

 

	 	37.1.3.1	 If a Notice is delivered in person, when delivered to the Addressee. 

 

	 	37.1.3.2	 If delivered by Registered or Certified Mail, upon receipt by Addressee, as indicated by the date on the signed
receipt. 

  

	 	37.1.3.3	 If delivered by nationally recognized overnight courier service, one Business Day after deposit with such courier
service. 

  

	 	37.1.3.4	 If sent by e-mail, when sent (if followed promptly by delivery of an original by another delivery method provided
for in this Section). 

  

	 	37.1.3.5	 If the Addressee rejects or otherwise refuses to accept the Notice, or if the Notice cannot be delivered because
of a change in address for which no Notice was given, then upon the rejection, refusal or inability to deliver. 

  
 - 24 - 

	 	37.1.3.6	 Despite the other clauses of this Section 37.1.3, if any Notice is received after 5:00 p.m. on
a Business Day where the Addressee is located, or on a day that is not a Business Day where the Addressee is located, then the Notice is deemed received at 9:00 a.m. on the next Business Day where the Addressee is located. 

 

	 	37.2	 If Bottler’s signature or acknowledgment is required or requested with respect to any document in connection
with this Agreement and any employee or representative authorized by Bottler “clicks” in the appropriate space on the website designated by Company or takes such other action as may be indicated by Company, Bottler shall be deemed to have
signed or acknowledged the document to the same extent and with the same effect as if Bottler had signed the document manually; provided, however, that no such signature or acknowledgment shall amend or vary the terms and conditions of
this Agreement. 

  

	 	37.3	 Bottler acknowledges and agrees that Bottler has the ability and knowledge to print information delivered to
Bottler electronically, or otherwise knows how to store that information in a way that ensures that it remains accessible to Bottler in an unchanged form. 

  

	38	 CHOICE OF LAW AND VENUE  

 

	 	38.1	 This Agreement shall be interpreted, construed and governed by and in accordance with the laws of the State of
Georgia, United States of America, without giving effect to any applicable principles of choice or conflict of laws, as to contract formation, construction and interpretation issues, and the federal trademark laws of the United States of America as
to trademark matters. 

  

	 	38.2	 The parties agree that any lawsuit commenced in connection with, or in relation to, this Agreement must be
brought in a United States District Court, if there is any basis for federal court jurisdiction. If the party bringing such action reasonably concludes that federal court jurisdiction does not exist, then the party may commence such action in any
court of competent jurisdiction. 

  

	39	 CONFIDENTIALITY 

 

	 	39.1	 In the performance of this Agreement, each party may disclose to the other party certain Proprietary Information.
The Proprietary Information of the Disclosing Party will remain the sole and exclusive property of the Disclosing Party or a third party providing such information to the Disclosing Party. The disclosure of the Proprietary Information to the
Receiving Party does not confer upon the Receiving Party any license, interest, or right of any kind in or to the Proprietary Information, except as expressly provided under this Agreement. 

 

	 	39.2	 At all times and notwithstanding any termination or expiration of this Agreement or any amendment hereto, the
Receiving Party agrees that it will hold in strict confidence and not disclose to any third party the Proprietary Information of the Disclosing Party, except as approved in writing by the Disclosing Party. The Receiving Party will only permit access
to the Proprietary Information of the Disclosing Party to those of its or its Affiliates’ employees or authorized representatives having a need to know and who have signed confidentiality agreements or are otherwise bound by confidentiality
obligations at least as restrictive as those contained in this Agreement (including external auditors, attorneys and consultants). 

  

	 	39.3	 The Receiving Party will be responsible to the Disclosing Party for any third party’s use and disclosure of
the Proprietary Information that the Receiving Party provides to such third party in accordance with this Agreement. The Receiving Party will use at least the same degree of care it would use to protect its own Proprietary Information of like
importance, but in any case with no less than a reasonable degree of care, including maintaining information security standards specific to such information as set forth in this Agreement. 

  
 - 25 - 

	 	39.4	 If the Receiving Party is required by a Governmental Authority or applicable law to disclose any of the
Proprietary Information of the Disclosing Party, the Receiving Party will (a) first give Notice of such required disclosure to the Disclosing Party (to the extent permitted by applicable law), (b) if requested by the Disclosing Party, use
reasonable efforts to obtain a protective order requiring that the Proprietary Information to be disclosed be used only for the purposes for which disclosure is required, (c) if requested by the Disclosing Party, take reasonable steps to allow
the Disclosing Party to seek to protect the confidentiality of the Proprietary Information required to be disclosed, and (d) disclose only that part of the Proprietary Information that, after consultation with its legal counsel, it determines
that it is required to disclose. 

  

	 	39.5	 Each party will immediately notify the other party in writing upon discovery of any loss or unauthorized use or
disclosure of the Proprietary Information of the other party. 

  

	 	39.6	 The Receiving Party will not reproduce the Disclosing Party’s Proprietary Information in any form except as
required to accomplish the intent of this Agreement. Any reproduction of any Proprietary Information by the Receiving Party will remain the property of the Disclosing Party and must contain any and all confidential or proprietary Notices or legends
that appear on the original, unless otherwise authorized in writing by the Disclosing Party. 

  

	 	39.7	 Neither party will communicate any information to the other party in violation of the proprietary rights of any
third party. 

  

	 	39.8	 Upon the earlier of termination of this Agreement, written request of the Disclosing Party, or when no longer
needed by the Receiving Party for fulfillment of its obligations under this Agreement, the Receiving Party will, if requested by the Disclosing Party, either: (a) promptly return to the Disclosing Party all documents and other tangible
materials representing the Disclosing Party’s Proprietary Information, and all copies thereof in its possession or control, if any; or (b) destroy all tangible copies of the Disclosing Party’s Proprietary Information in its possession
or control, if any, in each case, except to the extent that such action would violate applicable regulatory or legal requirements. Each party’s counsel may retain one copy of documents and communications between the Parties as necessary for
archival purposes or regulatory purposes. 

  

	40	 ACTIVE AND COMPLETE ARMS LENGTH NEGOTIATIONS 

 

	 	 The parties acknowledge and agree that the terms and conditions of this Agreement have been the subject of active and
complete negotiations, and that such terms and conditions must not be construed in favor of or against any party by reason of the extent to which a party or its professional advisors may have participated in the preparation of this Agreement.

  

	41	 RESERVATION OF RIGHTS 

 

	 	 As relates to the Territories and the Regional Manufacturing Facilities, Company reserves all rights not expressly
granted to Bottler under this Agreement or Bottler’s CBA. 

  
 - 26 - 

	42	 BOTTLER AFFILIATES 

 

	 	 Bottler hereby absolutely, unconditionally and irrevocably guarantees that any actions taken by any of Bottler’s
Affiliates pursuant to this Agreement will be taken in accordance with all applicable requirements set forth herein to the same extent as if such actions had been taken by Bottler. Bottler acknowledges and agrees that any breach of this Agreement by
any Affiliate of Bottler shall be considered a breach by Bottler for all purposes hereof. 

 [Signature page(s) follow] 

  
 - 27 - 

 IN WITNESS WHEREOF, COMPANY AT ATLANTA, GEORGIA, AND BOTTLER AT CHARLOTTE, NORTH CAROLINA, HAVE CAUSED
THESE PRESENTS TO BE EXECUTED IN TRIPLICATE BY THE DULY AUTHORIZED PERSON OR PERSONS ON THEIR BEHALF ON THE EFFECTIVE DATE. 
  

			
	 THE COCA-COLA COMPANY
  

	By:	 	 /s/ J. Alexander M. Douglas, Jr.

		 	Authorized Representative
	  

COCA-COLA BOTTLING CO. CONSOLIDATED

 

	By:	 	 /s/ Lawrence K. Workman, Jr.

		 	Authorized Representative

  
 [Signature Page to Initial Regional Manufacturing
Agreement] 

 EXHIBIT A 

Regional Manufacturing Facilities 
  

	1.	 Sandston, VA 

  

	2.	 Baltimore, MD 

  

	3.	 Silver Spring, MD 

 EXHIBIT B 

Authorized Covered Beverages 
 The
following Beverages and all SKUs, packages, flavor, calorie and other variations (e.g., Sprite Cranberry, Sprite Zero Cranberry) of each such Beverage offered by Company that are identified by the primary Trademark that also identifies such Beverage
or any modification of such primary Trademark, such as, e.g., the primary Trademark used in conjunction with a prefix, a suffix or other modifier: 
 Coca-Cola 

Caffeine Free Coca-Cola 
 Diet Coke 

Diet Coke with Lime 
 Diet Coke with Splenda® 
 Caffeine free Diet Coke 

Coca-Cola Life 
 Coca-Cola Zero 

caffeine free Coca-Cola Zero 
 Cherry Coke 

Diet Cherry Coke 
 Cherry Coke Zero 

Vanilla Coke 
 Diet Vanilla Coke 

Vanilla Coke Zero 
 Barq’s 

Diet Barq’s 
 DASANI 

DASANI Plus 
 DASANI Sparkling 

Fanta 
 Fanta Zero 

Fresca 
 Mello Yello 

Mello Yello Zero 
 PiBB Xtra 

PiBB Zero 
 Seagram’s ginger ale 

Seagram’s mixers 
 Seagram’s seltzer water 

Sprite 
 Sprite Zero 

TaB 
 VAULT 

VAULT Zero 
 Delaware Punch 

 FUZE 
 FUZE iced tea 

FUZE Juices 
 FUZE Refreshments 

FUZE slenderize 

 Schedule 2.17 

Related Agreements 
  

	1.	 Interim Finished Goods Supply Agreement. 

 Schedule 2.18 

[***] 
 [***] 

[***] 
 [***] 

[***] 
  

	
	  
 [***]

 
 [***]

 
 [***]

 

  
 [***] – THIS CONFIDENTIAL
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 

 [***] 

[***] 
 [***] 

 
  
  

  
 [***] – THIS
CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 

 Schedule 9.4 

Regional Manufacturing Agreement 
 See attached. 

 Regional Manufacturing Agreement 

Entered into by The Coca-Cola Company, 

a Delaware corporation, and 

                       
     , a                      

corporation, with Effective Date of 

                  
    , 20    . 
  

 TABLE OF CONTENTS 
  

							
	 1.
	 	RECITALS	  	 	1	  
			
	 2.
	 	DEFINITIONS	  	 	1	  
			
	 3.
	 	AUTHORIZATION FOR BOTTLER TO PURCHASE CONCENTRATES AND TO MANUFACTURE AUTHORIZED COVERED BEVERAGES	  	 	4	  
			
	 4.
	 	AUTHORIZATION FOR BOTTLER TO SELL AND SUPPLY AUTHORIZED COVERED BEVERAGES	  	 	4	  
			
	 5.
	 	COMPANY AND BOTTLER RIGHTS AND OBLIGATIONS REGARDING THE TRADEMARKS	  	 	5	  
			
	 6.
	 	REFORMULATION AND DISCONTINUATION OF THE CONCENTRATES	  	 	6	  
			
	 7.
	 	TERRITORIAL LIMITATIONS AND TRANSSHIPPING	  	 	6	  
			
	 8.
	 	ACQUIRED MANUFACTURING RIGHTS	  	 	6	  
			
	 9.
	 	EFFECT OF NEW OR AMENDED MANUFACTURING AGREEMENTS WITH OTHER REGIONAL PRODUCING BOTTLERS	  	 	7	  
			
	 10.
	 	OBLIGATIONS OF BOTTLER AS TO MANUFACTURE OF OTHER BEVERAGE PRODUCTS	  	 	7	  
			
	 11.
	 	WARRANTIES OF COMPANY RELATING TO MANUFACTURE AND QUALITY OF THE CONCENTRATE	  	 	9	  
			
	 12.
	 	OBLIGATIONS AND WARRANTIES OF BOTTLER RELATING TO MANUFACTURE AND QUALITY OF THE AUTHORIZED COVERED BEVERAGES	  	 	9	  
			
	 13.
	 	OBLIGATIONS OF COMPANY AND BOTTLER RELATING TO RECALL OF AUTHORIZED COVERED BEVERAGES	  	 	11	  
			
	 14.
	 	OBLIGATIONS OF BOTTLER RELATING TO MANUFACTURE OF AUTHORIZED COVERED BEVERAGES, SYSTEM GOVERNANCE, INVESTMENT, MANAGEMENT, REPORTING AND PLANNING ACTIVITIES	  	 	12	  
			
	 15.
	 	PRICING AND OTHER CONDITIONS OF PURCHASE AND SALE OF CONCENTRATES	  	 	14	  
			
	 16.
	 	OWNERSHIP AND CONTROL OF BOTTLER	  	 	15	  
			
	 17.
	 	TERM OF AGREEMENT	  	 	16	  
			
	 18.
	 	COMMERCIAL IMPRACTICABILITY AND FORCE MAJEURE	  	 	16	  
			
	 19.
	 	TERMINATION FOR DEFINED EVENTS	  	 	18	  
			
	 20.
	 	DEFICIENCY TERMINATION	  	 	18	  
			
	 21.
	 	BOTTLER RIGHT TO CURE	  	 	19	  
			
	 22.
	 	BOTTLER’S RIGHTS AND OBLIGATIONS WITH RESPECT TO SALE OF ITS BUSINESS	  	 	21	  
			
	 23.
	 	EFFECT OF THIS AGREEMENT ON BOTTLER’S CBA IN CERTAIN EVENTS	  	 	21	  
			
	 24.
	 	POST-EXPIRATION AND POST-TERMINATION OBLIGATIONS	  	 	22	  
			
	 25.
	 	COMPANY’S RIGHT OF ASSIGNMENT	  	 	22	  
			
	 26.    
	 	LITIGATION	  	 	22	  

							
	 27.    
	 	INDEMNIFICATION	  	 	23	  
			
	 28.
	 	BOTTLER’S INSURANCE	  	 	24	  
			
	 29.
	 	LIMITATION ON BOTTLER REPRESENTATIONS OR DISCLOSURES REGARDING AUTHORIZED COVERED BEVERAGES	  	 	24	  
			
	 30.
	 	INCIDENT MANAGEMENT	  	 	24	  
			
	 31.
	 	SEVERABILITY	  	 	25	  
			
	 32.
	 	REPLACEMENT OF CERTAIN PRIOR CONTRACTS, MERGER, AND REQUIREMENTS FOR MODIFICATION	  	 	25	  
			
	 33.
	 	NO WAIVER	  	 	26	  
			
	 34.
	 	NATURE OF AGREEMENT AND RELATIONSHIP OF THE PARTIES	  	 	26	  
			
	 35.
	 	HEADINGS AND OTHER MATTERS	  	 	26	  
			
	 36.
	 	EXECUTION IN MULTIPLE COUNTERPARTS	  	 	26	  
			
	 37.
	 	NOTICE AND ACKNOWLEDGEMENT	  	 	26	  
			
	 38.
	 	CHOICE OF LAW AND VENUE	  	 	29	  
			
	 39.
	 	CONFIDENTIALITY	  	 	29	  
			
	 40.
	 	ACTIVE AND COMPLETE ARMS LENGTH NEGOTIATIONS	  	 	30	  
			
	 41.
	 	RESERVATION OF RIGHTS	  	 	30	  
			
	 42.
	 	BOTTLER AFFILIATES	  	 	30	  

 TABLE OF EXHIBITS 
  

					
	  

    Exhibit    

 
	  	  

Title
  
	  	  

    Exhibit References by    

Section
  

	 	 	 
	A	  	Regional Manufacturing Facilities	  	 2.13

8.1
  

	 	 	 
	B	  	Authorized Covered Beverages	  	 2.3

9.3
  

	 	 	 
	[C]	  	[Finished Goods Supply Agreements]	  	 [2.8]

 

 TABLE OF SCHEDULES 
  

					
	  

    Schedule    
	  	  

Title
	  	  

    Schedule References by    

Section
  

	  
 2.17

 
	  	  

Related Agreements
  
	  	  

2.17
  

	  
 2.18

 
	  	  

[***]
  
	  	  

2.18
  

	  
 10.1.5
	  	  

Third Party Beverages
	  	  

10.1.5
10.1.6
  

	  
 12.2

 
	  	  

Technical Requirements
  
	  	  

12.2
  

	  
 28

 
	  	  

Insurance Requirements
	  	  

28

	  
 32.1.2
	  	  

Agreements Not Affected by this Agreement
	  	  

32.1.2
 32.1.4

 

 [***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 

 Regional Manufacturing Agreement 

 
 THIS AGREEMENT IS ENTERED INTO BY THE
COCA-COLA COMPANY, A DELAWARE CORPORATION (“COMPANY”), AND
                                , A
                                 CORPORATION (“BOTTLER”). 

 

	1.	 RECITALS 

  

	1.1.	 Company and Bottler (or one or more Affiliates of Bottler) have entered into one or more Comprehensive Beverage
Agreement(s) (as may be amended, restated or modified from time to time, “Bottler’s CBA”) authorizing Bottler to market, promote, distribute and sell Covered Beverages and Related Products within specific geographic
Territories, subject to the terms and conditions contained in Bottler’s CBA. Capitalized terms used in this Agreement will have the meanings ascribed to them in Bottler’s CBA, unless a different meaning is ascribed under this Agreement;

  

	1.2.	 Company manufactures and sells, or authorizes others to manufacture and sell, the Concentrates used to
manufacture certain of the Covered Beverages, the formulas for all of which constitute trade secrets owned by Company and which are identified by the Trademarks; 

 

	1.3.	 Company and Bottler acknowledge that the manufacture of such Covered Beverages is subject to strict production
standards and applicable regulatory requirements; 

  

	1.4.	 Bottler and Company wish to enter into this Agreement in order to permit Bottler to manufacture, produce and
package (collectively, “manufacture”), at the Regional Manufacturing Facilities, the Authorized Covered Beverages in Authorized Containers both for (i) distribution and sale by Bottler and its Affiliates for their own account
in accordance with Bottler’s CBA; and (ii) sale by Bottler and its Affiliates to Company and to certain other U. S. Coca-Cola Bottlers in accordance with this Agreement; 

 

	1.5.	 Bottler has requested an authorization from Company to use the Trademarks in connection with such manufacture of
the Authorized Covered Beverages; 

  

	1.6.	 Company is willing to grant the requested authorization to Bottler under the terms and conditions set forth in
this Agreement; and 

  

	1.7.	 Company and Bottler are parties to certain pre-existing contracts, some of which are identified in
Bottler’s CBA Exhibit D under which Company has previously authorized Bottler (or one or more Affiliates of Bottler) to manufacture in certain authorized containers, and market, promote, distribute and sell, Coca-Cola and other beverages
marketed under Company’s trademarks. All such pre-existing contracts are amended, restated and superseded by this Agreement and Bottler’s CBA, as of the Effective Date, to the extent provided in Section 32.

 COMPANY AND BOTTLER AGREE AS FOLLOWS: 

	2.	 DEFINITIONS 

  

	2.1.	 “Agreement” means this Regional Manufacturing Agreement between Bottler and Company, as amended from
time to time. 

	2.2.	 “Authorized Containers” means containers of certain types, sizes, shapes and other distinguishing
characteristics that Company from time to time approves in its sole discretion, subject to Section 12.9, for use by all Regional Producing Bottlers in manufacturing Authorized Covered Beverages. A list of Authorized Containers for
each Authorized Covered Beverage will be provided by Company to Bottler, which list may be amended by additions, deletions or modifications by Company from time to time in its sole discretion. 

 

	2.3.	 “Authorized Covered Beverages” means the Covered Beverages identified on Exhibit B, that
all Regional Producing Bottlers are authorized to manufacture in Authorized Containers at their respective regional manufacturing facilities, which Exhibit will be deemed automatically amended to add any Covered Beverage that Company hereafter
authorizes for concentrate-based, cold-fill manufacturing by any U.S. Coca-Cola Bottler, and which may otherwise be updated from time to time as mutually agreed by Company and the NPSG. For purposes hereof, cold-fill manufacturing means the process
of manufacturing beverages in which the product is chilled, or equal to or less than ambient temperature, at time of filling and packaging. [Note to Draft: Authorization to manufacture Incubation Beverages and fountain syrups to be covered under
separate agreements.] 

  

	2.4.	 “Company Owned Manufacturer” means any Affiliate or operating unit of Company located in the United
States that manufactures any of the Authorized Covered Beverages for distribution or sale within the United States. 

  

	2.5.	 “Concentrates” means the concentrates and/or beverage bases used to manufacture the Authorized Covered
Beverages, the formulas for all of which constitute trade secrets owned by Company and which are identified by the applicable Trademarks. 

  

	2.6.	 “Effective Date” means
                                        .

  

	2.7.	 “Expanding Participating Bottler” has the meaning ascribed to that term under the Comprehensive
Beverage Agreement. 

  

	2.8.	 “Finished Goods Supply Agreement”: [Note to Draft: Definitions to be updated as necessary as a result of
impact of conversion of Bottler’s legacy territory. Parties to discuss attaching NPSG Finished Goods Supply Agreement and Regional Finished Goods Supply Agreement as Exhibit C when finalized.] 

 

	 	2.8.1.	 “NPSG Finished Goods Supply Agreement” means [the form of finished goods supply agreement to be mutually
agreed by Company and Bottler, that will provide, among other things, that Bottler’s pricing to other Regional Producing Bottlers will be calculated by Bottler in accordance with the pricing formula set forth in Section 4.1.2
hereof, which has been determined unilaterally by Company in a manner that supports and enables [***], and to strengthen the competitiveness of the Coca-Cola finished goods production system.] 

 

	 	2.8.2.	 “Regional Finished Goods Supply Agreement” means the form of finished goods supply agreement to be mutually
agreed by Company and Bottler, that will provide, among other things that Bottler’s pricing to Expanding Participating Bottlers and Participating Bottlers will be the [***]. 

  
 -2- 

[***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 

	2.9.	 [***] 

  

	2.10.	 “National Product Supply Group” or “NPSG” means The Coca-Cola System National Product
Supply Group, as described more fully in the National Product Supply System Governance Agreement. 

  

	2.11.	 “National Product Supply Group Board” or “NPSG Board” means The Coca-Cola System
National Product Supply Group Governance Board, the governing body for the Coca-Cola National Product Supply Group consisting of representatives of Company and all Regional Producing Bottlers, as described more fully in the National Product Supply
System Governance Agreement between Bottler, certain other Regional Producing Bottlers and Company dated as of October 30, 2015. 

  

	2.12.	 “Participating Bottler” means any U.S. Coca-Cola Bottler that is not a Regional Producing Bottler or an
Expanding Participating Bottler that is party to a Comprehensive Beverage Agreement with Company. 

  

	2.13.	 “Recipient Bottler” means the U.S. Coca-Cola Bottlers which Bottler is authorized pursuant to this
Agreement to supply with Authorized Covered Beverages manufactured by Bottler. 

  

	2.14.	 “Regional Manufacturing Facilities” means the manufacturing facilities owned and operated by Bottler
and listed on Exhibit A, which Exhibit will be deemed automatically amended to add any manufacturing facility acquired or built by Bottler after the Effective Date with the approval of the NPSG, and, subject to the requirements of
National Product Supply System Governance Agreement, may otherwise be updated from time to time as mutually agreed by Company and Bottler. 

  

	2.15.	 “Regional Producing Bottler” means (i) Bottler; (ii) any other Expanding Participating
Bottler that is a member of the NPSG that Company has authorized to manufacture Authorized Covered Beverages in accordance with a regional manufacturing authorization agreement with terms and conditions that are substantially similar to those of
this Agreement (or that are substantially similar to the form of regional manufacturing authorization agreement the parties previously entered into); and (iii) a Company Owned Manufacturer that is a member of the National Product Supply Group.

  

	2.16.	 [Reserved.] 

  

	2.17.	 “Related Agreement” means any agreement identified on Schedule 2.17 between
Company and any of Company’s Affiliates and Bottler and any of Bottler’s Affiliates relating to the manufacturing of Authorized Covered Beverages. 

  

	2.18.	 [***] 

  
 -3- 

[***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 

	2.19.	 [***] 

  

	3.	 AUTHORIZATION FOR BOTTLER TO PURCHASE CONCENTRATES AND TO MANUFACTURE AUTHORIZED COVERED BEVERAGES

  

	3.1.	 Company appoints Bottler as an authorized purchaser of the Concentrates for the purpose of manufacture of the
Authorized Covered Beverages in Authorized Containers at the Regional Manufacturing Facilities. Except as otherwise mutually agreed in writing by Company and Bottler, Company shall not appoint, and shall not consent to any appointment by Coca-Cola
Refreshments USA, Inc. or any of its other Affiliates of, any other Person as an authorized purchaser of the Concentrates for the purposes of manufacture, packaging and distribution of such Authorized Covered Beverages in Authorized Containers for
sale in Bottler’s First Line Territory or in Bottler’s Sub-Bottling Territory, respectively. 

  

	3.2.	 Bottler will purchase its entire requirements of Concentrates for such Authorized Covered Beverages exclusively
from Company and will not use any other syrup, beverage base, concentrate or other ingredient not specified by Company in the manufacture of Authorized Covered Beverages. 

 

	4.	 AUTHORIZATION FOR BOTTLER TO SELL AND SUPPLY AUTHORIZED COVERED BEVERAGES [Note to Draft:
Section 4 is subject to modification as provided in the CCNA Exchange Letter Agreement dated [            ], 2016.] 

 

	4.1.	 With the objective of ensuring that U.S. Coca-Cola Bottlers are able to acquire finished goods from Regional
Producing Bottlers at a price that enables the Coca-Cola Bottler System to be highly competitive in the marketplace, Company authorizes Bottler to sell and supply Authorized Covered Beverages manufactured by Bottler: 

 

	 	4.1.1.	 To other Regional Producing Bottlers at the price specified in this Section 4.1.1 and in accordance
with the terms and conditions of the NPSG Finished Goods Supply Agreement: 

  

	 	4.1.1.1.	 For calendar year 2017, the price shall be [***]. 

 

	 	4.1.1.2.	 For calendar year 2018 and thereafter, the price shall be [***]. 

 

	 	4.1.2.	 To Expanding Participating Bottlers and Participating Bottlers at the price specified in this
Section 4.1.2 and in accordance with the terms and conditions of the Regional Finished Goods Supply Agreement: 

  

	 	4.1.2.1.	 For calendar year 2017, the price shall be [***]. 

 

	 	4.1.2.2.	 For calendar year 2018 and thereafter, the price shall be [***]. 

  
 -4- 

[***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 

	4.2.	 Company authorizes Bottler to sell and supply Authorized Covered Beverages manufactured by Bottler to Company,
and Bottler agrees to sell to Company Authorized Covered Beverages, at a price equivalent to [***], in quantities sufficient to enable Company to satisfy demand of U.S. Coca-Cola Bottlers that are not Regional Producing Bottlers, Expanding
Participating Bottlers or Participating Bottlers in accordance with sourcing plans developed by the NPSG from time to time. 

  

	4.3.	 Upon Company’s request, Bottler agrees to advise Company, in accordance with written instructions issued by
Company from time to time, of the amount of the Authorized Covered Beverages in Authorized Containers that are manufactured and sold by Bottler to Company, and, as applicable, to each Regional Producing Bottler, Expanding Participating Bottler and
Participating Bottler; provided, however, that Bottler will not be required to provide Company with duplicate copies of any such information provided to the NPSG that expressly directs the NPSG to provide such information to Company.

  

	5.	 COMPANY AND BOTTLER RIGHTS AND OBLIGATIONS REGARDING THE TRADEMARKS 

 

	5.1.	 Bottler acknowledges and agrees that Company is the sole and exclusive owner of all rights, title and interest in
and to the Trademarks. Company has the unrestricted right, in its sole discretion, to use the Trademarks on the Authorized Covered Beverages and on all other products and merchandise, to determine which Trademarks will be used on which Authorized
Covered Beverages, and to determine how the Trademarks will be displayed and used on and in connection with the Authorized Covered Beverages. Bottler agrees not to dispute the validity of the Trademarks or their exclusive ownership by Company either
during the Term or thereafter, notwithstanding any applicable doctrines of licensee estoppel. 

  

	5.2.	 Company grants to Bottler only a nonexclusive, royalty-free license to use the Trademarks in connection with the
manufacture of the Authorized Covered Beverages in Authorized Containers at the Regional Manufacturing Facilities and in connection with the sale of such Authorized Covered Beverages to Recipient Bottlers and Company as provided in this Agreement,
and in accordance with standards adopted and issued by Company from time to time, and made available to Bottler through written, electronic, on-line or other form or media, subject to the rights reserved to Company under this Agreement.

  

	5.3.	 Nothing in this Agreement, nor any act or failure to act by Bottler or Company, will give Bottler any proprietary
or ownership interest of any kind in the Trademarks or in the goodwill associated therewith. 

  

	5.4.	 Bottler acknowledges and agrees that, as between Company and Bottler, all use by Bottler of the Trademarks will
inure to the benefit of Company. 

  

	5.5.	 Except as provided in Bottler’s CBA or as otherwise authorized by Company in writing, Bottler must not adopt
or use any name, corporate name, trading name, title of establishment or other commercial designation or logo that includes the words “Coca-Cola”, “Coca”, “Cola”, “Coke”, or any of them, or any word, name or
designation that is confusingly similar to any of them, or any graphic or visual representation of the Trademarks or any other Trademark or intellectual property owned by Company, without the prior written consent of Company, which consent will not
be unreasonably withheld and will be contingent on Bottler’s compliance with Bottler’s CBA and this Agreement. 

  
 -5- 

[***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 

	5.6.	 Bottler recognizes that the uniform external appearance of the Trademarks on primary and secondary packaging and
on equipment and materials used under this Agreement is important to the Trademarks, the successful marketing of the Covered Beverages, and the Coca-Cola system. 

 

	 	5.6.1.	 Bottler agrees, to the extent such Trademarks are utilized by Bottler in connection with the manufacture of Authorized
Covered Beverages, to accept and, within a reasonable time, apply, any new or modified standards adopted and issued from time to time by Company that are generally applicable, and made available to Bottler for the design and decoration of trucks and
other delivery vehicles, packaging materials, cases, cartons, and other materials and equipment that bear such Trademarks. 

  

	 	5.6.2.	 If Company changes such standards, the new standards will apply to all such assets acquired by Bottler following receipt
of Notice of the change in standards to the extent Bottler uses the Trademarks on such assets, and will be applied to such existing assets in the normal course of Bottler’s business (e.g., trucks would be repainted consistent with normal
maintenance cycles). 

  

	6.	 REFORMULATION AND DISCONTINUATION OF THE CONCENTRATES 

 

	6.1.	 Company has the sole and exclusive right and discretion to reformulate any of the Concentrates.

  

	6.2.	 Company has the right to discontinue any Concentrates for any Authorized Covered Beverage that is discontinued or
Transferred in accordance with the terms of Bottler’s CBA. 

  

	7.	 TERRITORIAL LIMITATIONS AND TRANSSHIPPING 

 

	7.1.	 Company and Bottler hereby agree that, notwithstanding the provisions of Section 10 of Bottler’s
CBA, Bottler may supply Authorized Covered Beverages in Authorized Containers to Recipient Bottlers in accordance with Section 4 for distribution by such Recipient Bottlers in their respective territories in accordance with their
respective Comprehensive Beverage Agreement(s) or other agreements with Company. 

  

	7.2.	 Bottler agrees not to sell, distribute or otherwise transfer any Authorized Covered Beverage except,
(i) distribution and sale in Bottler’s (or any one or more of its Affiliates’) Territories in accordance with Bottler’s CBA, and (ii) sales of Authorized Covered Beverages in Authorized Containers to Recipient Bottlers or
Company in accordance with Section 4. 

  

	8.	 ACQUIRED MANUFACTURING RIGHTS 

 

	8.1.	 If, after the Effective Date, Bottler acquires from another U.S. Coca-Cola Bottler the right to manufacture any
of the Authorized Covered Beverages, then, unless otherwise agreed in writing by Company and Bottler, such manufacturing rights will automatically be deemed covered under this Agreement for all purposes and Exhibit A will be deemed
automatically amended to add any manufacturing facilities acquired in such acquisition to the list of Regional Manufacturing Facilities identified in Exhibit A, and any separate agreement that may exist concerning such manufacturing
rights will be deemed amended, restated and superseded by this Agreement. 

  
 -6- 

	8.2.	 The parties agree to cooperate in taking such other actions as may reasonably be required to further document any
amendments and modifications resulting from the application of Section 8.1 to Bottler’s acquisition of manufacturing rights from another U.S. Coca-Cola Bottler. 

 

	9.	 EFFECT OF NEW OR AMENDED MANUFACTURING AGREEMENTS WITH OTHER REGIONAL PRODUCING BOTTLERS

  

	9.1.	 If Company or a Company Affiliate on or after [Note to Draft: insert effective date of initial Regional
Manufacturing Agreement] (a) enters into a new authorization agreement to manufacture all or substantially all Authorized Covered Beverages in territories in the United States of America with another Regional Producing Bottler (other than a
Company Owned Distributor) that is more favorable to such other Regional Producing Bottler than the terms and conditions of this Agreement in any material respect, or (b) agrees to an amendment of the terms of a regional manufacturing agreement
or other similar agreement authorizing manufacture of all or substantially all Authorized Covered Beverages in territories in the United States with another Regional Producing Bottler (other than a Company Owned Distributor) that is more favorable
to such other Regional Producing Bottler than the terms and conditions of this Agreement in any material respect, then Company will offer such other new agreement or amended agreement, as the case may be (a “New Agreement”), in its
entirety, to Bottler. If the New Agreement relates to less than all of the Authorized Covered Beverages, then the New Agreement offered to Bottler under this Section 9.1 will cover only those Authorized Covered Beverages covered
by the New Agreement. 

  

	9.2.	 The foregoing obligation will not apply to any consent, waiver or approval provided under this Agreement or under
any agreement held by another Regional Producing Bottler; provided, however, that Company will not waive or otherwise enter into any agreement with any other Regional Producing Bottler that limits (a) the requirement set forth in
Section 14.1 or any equivalent requirement under any Regional Manufacturing Agreement held by another Regional Producing Bottler or (b) the requirement set forth in Section 14.3.1 or any equivalent
requirement under any Regional Manufacturing Agreement held by another Regional Producing Bottler. 

  

	9.3.	 Nothing in this Section 9 will affect (a) Company’s obligation under
Section 15.2 or (b) Company’s agreement that the list of Covered Beverages identified on Exhibit B will be the same for all Regional Producing Bottlers. 

 

	9.4.	 The parties agree to cooperate in taking such other actions as may reasonably be required to further document any
amendments and modifications resulting from the provisions of this Section 9. 

  

	10.	 OBLIGATIONS OF BOTTLER AS TO MANUFACTURE OF OTHER BEVERAGE PRODUCTS 

 

	10.1.	 Bottler covenants and agrees (subject to any requirements imposed upon Bottler under applicable law) not to
manufacture any Beverage, Beverage Component, or other beverage product except for: 

  

	 	10.1.1.	 Authorized Covered Beverages, subject to the terms and conditions of this Agreement and any Related Agreement;

  
 -7- 

	 	10.1.2.	 Beverages (including Incubation Beverages), Beverage Components and other beverage products, if and to the extent
(a) authorized under any separate written agreement with Company or any of Company’s Affiliates, or (b) otherwise requested by Company or any of its Affiliates; 

 

	 	10.1.3.	 Permitted Beverage Products distributed by Bottler or its Affiliates for their own account, subject to the terms and
conditions of Bottler’s or Bottler Affiliate’s CBA; 

  

	 	10.1.4.	 Beverages, Beverage Components and other beverage products manufactured by Bottler under license from a third party
brand owner and supplied by Bottler to a Recipient Bottler, subject to the terms and conditions of the Recipient Bottler’s CBA or other bottling and distribution agreements between Company and Recipient Bottler; provided that Bottler
will not supply any such Beverage, Beverage Component or other beverage product to any Recipient Bottler if Company provides Bottler with Notice that such Beverage, Beverage Component or other beverage product is not a Permitted Beverage Product
under such Recipient Bottler’s CBA (or that is prohibited by other bottling and distribution agreements between Company and Recipient Bottler); provided, further, that Bottler’s supply of any Beverage, Beverage Component or
other beverage product to a Recipient Bottler that is not a Permitted Beverage Product under such Recipient Bottler’s CBA (or that is prohibited by other bottling and distribution agreements between Company and Recipient Bottler) will not be a
breach of this Section 10.1.4 unless Company provides Bottler with such Notice and Bottler continues to supply such Beverage to such Recipient Bottler thereafter in violation of such Notice; 

 

	 	10.1.5.	 Beverages, Beverage Components and other beverage products manufactured by Bottler under license from a third party
brand owner and supplied by Bottler to another U.S. Coca-Cola Bottler as of the Effective Date, as specified on Schedule 10.1.5; and [Note to Draft: Bottler to provide Company with list of such Beverages
produced for each recipient U.S. Coca-Cola Bottler; Company to confirm that any such U.S. Coca-Cola Bottler is permitted to distribute any such Beverage to under such bottler’s agreements with Company.] 

 

	 	10.1.6.	 Beverages, Beverage Components and other beverage products, not otherwise permitted under Sections 10.1.3,
10.1.4, or 10.1.5, manufactured by Bottler under license from a third party brand owner with Company’s prior written consent, which consent will not be unreasonably withheld and will be specified on Schedule
10.1.5. [Note to Draft: Bottler to provide Company with list of such Beverages produced for each recipient for Company’s consideration in developing initial Schedule 10.1.5.] 

 

	10.2.	 Notwithstanding anything in Section 10.1 to the contrary, if the NPSG reasonably determines
during product supply system sourcing plan development routines that Bottler should supply any Beverage manufactured by Bottler under license from a third party brand owner to certain Recipient Bottlers and/or certain other Regional Producing
Bottlers in order to optimize the location for production of such Beverages, then Bottler may do so on a temporary basis as reasonably determined by the NPSG (but in any event not to exceed one hundred eighty (180) days). 

  
 -8- 

	11.	 WARRANTIES OF COMPANY RELATING TO MANUFACTURE AND QUALITY OF THE CONCENTRATE 

Company agrees and warrants that the Concentrates supplied to Bottler, as well as Company’s package designs and design
specifications of packages and labels authorized by Company for use on Authorized Covered Beverages, shall comply with all food, labeling, health, packaging and all other applicable laws, including the Federal Food, Drug and Cosmetic Act, as amended
(the “Act”), and regulations, and when supplied to Bottler will not be adulterated, contaminated, or misbranded within the meaning of the Act or any other federal, state or local law, rule or regulation applicable thereto. 

 

	12.	 OBLIGATIONS AND WARRANTIES OF BOTTLER RELATING TO MANUFACTURE AND QUALITY OF THE AUTHORIZED COVERED BEVERAGES

  

	12.1.	 Bottler agrees and warrants that Bottler’s handling and storage of the Concentrates and Bottler’s
manufacture, handling, storage, transportation and delivery of the Authorized Covered Beverages, including any Authorized Covered Beverages supplied to Company or any Recipient Bottler, will at all times and in all events: 

 

	 	12.1.1.	 be accomplished in accordance with the product, package and equipment quality; food safety; workplace safety; and
environmental sustainability standards, requirements and instructions reasonably established and routinely communicated in writing, including through electronic systems and media, by Company to Bottler from time to time (collectively
“Technical Requirements”); and 

  

	 	12.1.2.	 comply with all food, labeling, health, packaging, environmental, safety, sanitation and all other applicable laws,
rules, orders, regulations and requirements of any federal, state, city, county or other local government, including any law, statute, ordinance, rule regulation, order, determination, restrictive covenant or deed restriction that regulates the use,
generation, disposal, release, storage or presence at the Regional Manufacturing Facilities of substances based upon corrosiveness, toxicity, carcinogenic properties, radioactivity, environmentally hazardous or similar characteristics.

  

	12.2.	 The Technical Requirements as of the Effective Date are identified on Schedule 12.2, which schedule
will be updated by Company from time to time following discussion with the NPSG and Notice to each Regional Producing Bottler (including any Company Owned Manufacturers). 

 

	 	12.2.1.	 Company agrees that all Regional Producing Bottlers will be required to comply with same Technical Requirements;
provided, however, that (i) Company may make limited exceptions in application or enforcement where necessary to prevent undue hardship for a Regional Producing Bottler, which exceptions shall not in any way be deemed to modify
the Technical Requirements and (ii) this Section 12.2.1 shall not in any way effect, limit, or modify any of Bottler’s or Company’s respective rights and obligations under this Agreement, including Bottler’s
obligations under Section 12.1. 

  
 -9- 

	12.3.	 Bottler represents, warrants and covenants that Bottler possesses, or will possess, prior to the manufacture of
the Authorized Covered Beverages, and will maintain during the Term, such plant or plants, machinery and equipment, qualified technical personnel and trained staff as are capable of manufacturing the Authorized Covered Beverages in Authorized
Containers in accordance with this Agreement and in sufficient quantities to meet fully the demand for the Authorized Covered Beverages in Authorized Containers by Bottler in the Territory in accordance with sourcing plans developed by the NPSG from
time to time. 

  

	12.4.	 Bottler agrees to use commercially reasonable efforts to meet fully the demand for the Authorized Covered
Beverages in Authorized Containers from Recipient Bottlers in accordance with sourcing plans developed by the NPSG from time to time. 

  

	12.5.	 Bottler recognizes that increases in the demand for the Authorized Covered Beverages, as well as changes in the
list of Authorized Containers, may, from time to time, require adaptation of its existing manufacturing or packaging equipment or the purchase of additional manufacturing or packaging equipment. Bottler agrees to use commercially reasonable efforts
to make such modifications and adaptations as necessary and to purchase and install such equipment, in time to permit the introduction and manufacture of sufficient quantities of the Authorized Covered Beverages in Authorized Containers, to
satisfy fully the demand for the Authorized Covered Beverages in Authorized Containers in the Territory and to fulfill Bottler’s supply obligations, if any, to Recipient Bottlers, in each case in accordance with sourcing plans developed by the
NPSG from time to time. 

  

	12.6.	 As of the date the Authorized Covered Beverages in Authorized Containers are shipped by Bottler, the Authorized
Covered Beverages manufactured by Bottler will meet the Technical Requirements and will comply with all applicable laws; provided, however, that Bottler will not be responsible for any failure to comply with the Technical Requirements
or applicable laws to the extent such failure results from the content or design of labels authorized by Company for use on Authorized Covered Beverages. 

 

	12.7.	 Bottler, in accordance with such instructions as may be given from time to time by Company, will submit to
Company, at Bottler’s expense, samples of the Authorized Covered Beverages and the raw materials used in the manufacture of the Authorized Covered Beverages. Bottler will permit representatives of Company to have access to the premises of
Bottler during ordinary business hours to inspect the plant, equipment, and methods used by Bottler in order to ascertain whether Bottler is complying with the terms of this Section 12, including whether Bottler is complying
strictly with the Technical Requirements with respect to the manufacturing, handling and storage of the Authorized Covered Beverages. Bottler will also provide Company with all the information regarding Bottler’s compliance with the terms of
this Section 12, as Company may reasonably request from time to time. 

  

	12.8.	 Bottler is authorized to use only Authorized Containers in the manufacture of the Authorized Covered Beverages,
and will use only such Authorized Containers, closures, cases, cartons and other packages and labels as will be authorized from time to time by Company for Bottler and will purchase such items only from manufacturers approved by Company, which
approval will not be unreasonably withheld. 

  
 -10- 

	 	12.8.1.	 Company will approve three (3) or more manufacturers of such items, if in the reasonable opinion of Company, there
are three (3) or more manufacturers who are capable of producing such items to be fully suitable for the purpose intended and in accordance with the high quality standards and image of excellence of the Trademarks and the Authorized Covered
Beverages. 

  

	 	12.8.2.	 Such approval by Company does not relieve Bottler of Bottler’s independent responsibility to assure that the
Authorized Containers, closures, cases, cartons and other packages and labels purchased by Bottler are suitable for the purpose intended, and in accordance with the good reputation and image of excellence of the Trademarks and Covered Beverages (it
being understood and agreed, however, that Bottler will not be responsible for the review or inspection of the content or design of labels authorized by Company for use on Authorized Covered Beverages). 

 

	12.9.	 Company reserves the right to withdraw from time to time its approval of any of the Authorized Containers upon
six (6) months’ prior Notice to Bottler, and, in such event, the repurchase provisions of Section 24.1.2 will apply to such containers so disapproved that are owned by Bottler. Company will exercise its right to approve,
and to withdraw its approval of, specific Authorized Containers in good faith and after consultation with Bottler so as to permit Bottler to continue to satisfy the demand in Bottler’s Territory as a whole for Authorized Covered Beverages.

  

	12.10.	 Bottler will use commercially reasonable efforts to maintain at all times a stock of, or have entered into other
alternate supply arrangements to obtain, Authorized Containers, closures, labels, cases, cartons, and other essential related materials bearing the Trademarks, sufficient to satisfy fully the demand for Authorized Covered Beverages in Authorized
Containers in Bottler’s Territory and to fulfill Bottler’s supply obligations, if any, to Recipient Bottlers, in each case in accordance with sourcing plans developed by the NPSG from time to time, and Bottler will not use or authorize any
other Person to use Authorized Containers, or such closures, labels, cases, cartons and other materials, if they bear the Trademarks or contain any Beverages, for any purpose other than the packaging of the Authorized Covered Beverages.

  

	12.11.	 Bottler agrees not to refill or otherwise reuse nonreturnable containers. 

 

	12.12.	 The parties acknowledge that Bottler makes the representations, warranties and agreements set forth in this
Section 12 in reliance on Company’s warranty in Section 11. 

  

	13.	 OBLIGATIONS OF COMPANY AND BOTTLER RELATING TO RECALL OF AUTHORIZED COVERED BEVERAGES

  

	13.1.	 If Company determines or becomes aware of the existence of any quality or technical problems relating to any
Authorized Covered Beverages, or any package used for such Authorized Covered Beverage, in Bottler’s Territory, Company will immediately notify Bottler by telephone, facsimile, e-mail or any other form of immediate communication. This
notification will include, to the extent available to Company, (a) the identity and quantities of Authorized Covered Beverages involved, including the specific packages, (b) coding data, and (c) all other relevant data that will
assist in tracing such Authorized Covered Beverages. 

  
 -11- 

	 	13.1.1.	 Company may require Bottler to take all necessary action to recall all of such Authorized Covered Beverages, or any
package used for such Authorized Covered, or withdraw immediately such Authorized Covered Beverages from the market or the trade, as the case may be. 

  

	 	13.1.2.	 Company will notify Bottler by telephone, facsimile, e-mail or any other form of immediate communication of the decision
by Company to require Bottler to recall Authorized Covered Beverages or withdraw such Authorized Covered Beverages from the market or trade. 

  

	13.2.	 If Bottler determines or becomes aware of the existence of quality or technical problems relating to Authorized
Covered Beverages, then Bottler must immediately notify Company by telephone, e-mail or any other form of immediate communication. This notification must include: (a) the identity and quantities of Authorized Covered Beverages involved,
including the specific packages, (b) coding data, and (c) all other relevant data that will assist in tracing such Authorized Covered Beverages. 

  

	13.3.	 In the event of a withdrawal or recall of any Authorized Covered Beverage or any package used for such Authorized
Covered Beverage, that was produced by Bottler and sold to a Recipient Bottler, Bottler will use its commercially reasonable efforts to respond promptly and fairly if a claim is made by a Recipient Bottler as a result of any such withdrawal or
recall. 

  

	13.4.	 If any withdrawal or recall of any Authorized Covered Beverage or any of the packages used therefor is caused by
(i) quality or technical defects in the Concentrates, or other materials prepared by Company from which the product involved was prepared by Bottler, or (ii) quality or technical defects in Company’s designs and design specifications
of packages and labels authorized by Company for use on Authorized Covered Beverages (and specifically excluding designs and specifications of other parties and the failure of other parties to manufacture packages in strict conformity with the
designs and specifications of Company), Company will reimburse Bottler for Bottler’s total reasonable expenses incident to such withdrawal or recall, including any payment made by Bottler to a Recipient Bottler in connection with the specific
withdrawal or recall. 

  

	13.5.	 Conversely, if any withdrawal or recall is caused by Bottler’s failure to comply with the Technical
Requirements or any applicable laws, rules and regulations (it being understood and agreed that Bottler will not be responsible for any failure to comply with the Technical Requirements or applicable laws to the extent such failure results from the
content or design of labels authorized by Company for use on Authorized Covered Beverages), Bottler will bear its total expenses of such withdrawal or recall and reimburse Company for Company’s total reasonable expenses incident to such
withdrawal or recall. 

  

	14.	 OBLIGATIONS OF BOTTLER RELATING TO MANUFACTURE OF AUTHORIZED COVERED BEVERAGES, SYSTEM GOVERNANCE, INVESTMENT,
MANAGEMENT, REPORTING AND PLANNING ACTIVITIES 

  

	14.1.	 Bottler will participate fully in, and comply fully with, the requirements and programs established from time to
time by the NPSG Board; provided, however, that Bottler will not be required to engage in conduct that would result in breach of this Agreement, Bottler’s CBA, or any other agreements between Company and Bottler.

  
 -12- 

	14.2.	 Bottler will provide competent and well-trained management and recruit, train, maintain and direct all personnel
as required to perform all of Bottler’s obligations under this Agreement, and, in accordance with any requirements imposed upon Bottler under applicable laws, consult with Company, as applicable, before hiring a new Chief Executive Officer,
senior operating officer, senior financial officer, senior product supply or manufacturing officer, or senior commercial officer of Bottler; provided however, that Company’s consent will not be required with respect to such hiring
decisions made by Bottler. 

  

	14.3.	 Company and Bottler hereby agree that: 

 

	 	14.3.1.	 Notwithstanding any provision of Bottler’s CBA to the contrary regarding minimum capital expenditures,
Bottler shall make capital expenditures (as defined under generally accepted accounting principles in force in the United States of America or in any successor set of accounting principles that may then be in effect), in Bottler’s business of
marketing, promoting, distributing, selling and manufacturing Covered Beverages in Bottler’s Territory, in sufficient amounts such that, when taken together with the capital expenditures required under Section 14.5 of Bottler’s
CBA, Bottler’s aggregate capital expenditures with respect to such business shall equal the greater of (a) two and one/half percent (2.5%) of Bottler’s Annual Net Revenue related to the manufacture, distribution and sale of
Covered Beverages over each rolling five-calendar year period during the Term, or (b) such other amount as reasonably required for Bottler to comply with its obligations under Bottler’s CBA and this Agreement. Such capital expenditures
will be for the organization, installation, operation, maintenance and replacement within Bottler’s Territory of such manufacturing, warehousing, distribution, delivery, transportation, vending equipment, merchandising equipment, and other
facilities, infrastructure, assets, and equipment. For the avoidance of doubt, any capital expenditures related to Strategic Infrastructure Planning projects approved by the NPSG Board are separate from, and in addition to, the capital expenditures
described in this paragraph. 

  

	 	14.3.2.	 For this purpose, capital expenditures will be calculated on a cash (rather than accrual) basis (i.e., it will be
assumed that all such capitalized expenditures are expensed in the year made rather than capitalized and amortized). 

  

	14.4.	 Bottler will maintain the consolidated financial capacity reasonably necessary to assure that Bottler and all
Bottler Affiliates will be financially able to perform their respective duties and obligations under this Agreement. 

  

	14.5.	 Upon Company’s request, Bottler will provide to Company each year and review with Company an annual and long
range operating plan and budget for Bottler’s business of manufacturing Authorized Covered Beverages, including financials and capital investment budgets, and, if requested by Company, discuss changes in general management and senior management
of Bottler’s manufacturing business, except to the extent otherwise prohibited by applicable law. 

  

	14.6.	 Bottler will: 

  

	 	14.6.1.	 Maintain accurate books, accounts and records relating to the purchasing of Concentrate and the manufacture of
Authorized Covered Beverages under this Agreement; and 

  
 -13- 

	 	14.6.2.	 Upon Company’s request, provide to Company such operational, financial, accounting, forecasting, planning and other
information, including audited and unaudited detail of cost of goods sold and sales volume for Authorized Covered Beverages to the extent, in the form and manner, as permitted by applicable law and at such times as reasonably required (a) by
Company to determine whether Bottler is performing its obligations under this Agreement; (b) by Company to calculate finished goods pricing under the NPSG Finished Goods Supply Agreement or Regional Finished Goods Supply Agreement and
(c) by the NPSG Board for the purpose of implementing, administering, and operating the NPSG, subject to appropriate regulatory firewalls ((a), (b), and (c) collectively, the “Financial Information”); provided,
however, that Bottler will not be required to provide Company with duplicate copies of any compilation of Financial Information provided to the NPSG that expressly directs the NPSG to provide such compilation to Company.

  

	14.7.	 The parties recognize that the Financial Information is critical to the ability of Company and the NPSG to
maintain, promote, and safeguard the overall performance, efficiency, integrity, and competitiveness of the product supply system for Authorized Covered Beverages. 

 

	14.8.	 Company will hold the Financial Information provided by Bottler in accordance with the confidentiality provisions
of Section 39 and will not use such information for any purpose other than determining compliance with this Agreement, to calculate finished goods pricing under the NPSG Finished Goods Supply Agreement or Regional Finished Goods Supply
Agreement or as necessary to provide to the NPSG, subject to appropriate regulatory firewalls, for the purpose of facilitating the NPSG’s execution of operational responsibilities such as infrastructure optimization, national sourcing and
strategic initiative decisions. 

  

	15.	 PRICING AND OTHER CONDITIONS OF PURCHASE AND SALE OF CONCENTRATES 

 

	15.1.	 Subject to Section 15.2, Company reserves the right to establish and to revise at any time, in its sole
discretion, the price of any of the Concentrates, the terms of payment, and the other terms and conditions of supply, any such revision to be effective immediately upon Notice to Bottler. Bottler acknowledges that information related to pricing of
Company’s Concentrates is confidential and will be maintained as such in accordance with Section 39. 

  

	15.2.	 If Company exercises its discretion under Section 15.1, the “price” charged by Company or its
Affiliate for any of the Concentrates will be the same as the “price” charged by Company or its Affiliate for such Concentrate, the terms of payment and other terms and conditions of supply will be the same as those applied by Company for
such Concentrates, to each other Regional Producing Bottler (other than a Company Owned Manufacturer) in the United States. 

  

	15.3.	 Bottler will purchase from Company only such quantities of the Concentrates as will be necessary and sufficient
to carry out Bottler’s obligations under this Agreement. Bottler will use the Concentrates exclusively for its manufacture of the Authorized Covered Beverages. Bottler will not sell or otherwise transfer any Concentrates or permit the same to
get into the hands of third parties. 

  
 -14- 

	16.	 OWNERSHIP AND CONTROL OF BOTTLER 

 

	16.1.	 Bottler hereby acknowledges the personal nature of Bottler’s obligations under this Agreement, including
with respect to the performance standards applicable to Bottler, the dependence of the Trademarks on proper quality control, and the confidentiality required for protection of Company’s trade secrets and confidential information.

  

	16.2.	 Bottler represents and warrants to Company that, prior to execution of this Agreement, Bottler has made available
to Company a complete and accurate list of Persons that own more than five percent (5%) of the outstanding securities of Bottler, and/or of any third parties having a right to, or effective power of, control or management of Bottler (whether
through contract or otherwise). 

  

	16.3.	 Except as otherwise permitted under Bottler’s CBA, Bottler covenants and agrees: 

 

	 	16.3.1.	 To inform Company without delay of any changes in the record ownership (or, if known to Bottler, any change in the
Beneficial Ownership) of more than ten percent (10%) of the shares of Bottler’s outstanding equity interests in a transaction or series of related transactions, provided, that if Bottler is subject to the disclosure and reporting
requirements of the Securities Exchange Act of 1934, as amended, this Section 16.3.1 shall not apply; 

  

	 	16.3.2.	 To inform Company without delay if a Change of Control occurs with respect to Bottler; and 

 

	 	16.3.3.	 Not to change its legal form of organization without first obtaining the written consent of Company, which consent will
not be unreasonably withheld, conditioned or delayed. It is understood and agreed that Company will not withhold its consent unless the change in legal form could reasonably be expected to affect Bottler’s obligations under this Agreement. For
this purpose, (a) the making of an election to be taxed as a Subchapter S corporation for federal income tax purposes, or termination of such an election, and/or (b) reincorporation in another state within the United States of America,
will not be considered a change in Bottler’s legal form of organization and will not require Company’s consent. 

  

	16.4.	 Bottler acknowledges that Company has a vested and legitimate interest in maintaining, promoting and safeguarding
the overall performance, efficiency and integrity of Company’s bottling, distribution and sales system. Bottler therefore covenants and agrees: 

  

	 	16.4.1.	 Except as otherwise permitted by Bottler’s CBA, not to assign, transfer or pledge this Agreement or any interest
herein, in whole or in part, whether voluntarily, involuntarily, or by operation of law (including by merger or liquidation), or sublicense its rights under this Agreement, in whole or in part, to any third party or parties, without the prior
written consent of Company; and 

  

	 	16.4.2.	 Not to delegate any material element of Bottler’s performance under this Agreement, in whole or in part, to any
third party or parties without the prior written consent of Company. 

  
 -15- 

	16.5.	 Notwithstanding Section 16.4, the following shall be expressly permitted hereunder:

  

	 	16.5.1.	 Bottler may, after Notice to Company, assign, transfer or pledge this Agreement or any interest herein, in whole
or in part, or delegate any material element of Bottler’s performance of this Agreement, in whole or in part, to any wholly-owned Affiliate of Bottler; provided that (a) any such Affiliate must agree in writing to be bound by and
comply with the terms and conditions of this Agreement, and (b) any such assignment, transfer, pledge or delegation will not relieve Bottler of any of its obligations under this Agreement; and 

 

	 	16.5.2.	 Bottler may engage third party contractors and service providers for the purpose of receiving services relating
to non-core functions (e.g., back-office administrative services, human resources, payroll, information technology services and similar services); provided that (a) Bottler will retain full responsibility to Company for all of
Bottler’s obligations under this Agreement; and (b) Bottler may not subcontract core functions (i.e., manufacturing, market and customer-facing functions) without the prior written consent of Company. 

 

	16.6.	 Any attempt to take any actions prohibited by Sections 16.4 and 16.5 without
Company’s prior written consent shall be void and shall be deemed to be a material breach of this Agreement, unless such actions are otherwise permitted under Bottler’s CBA. 

 

	16.7.	 Bottler may not describe Company or Bottler’s relationship with Company in any prospectus, offering
materials, or marketing materials used by or on behalf of Bottler in connection with the issue, offer, sale, transfer, or exchange of any ownership interest in Bottler or any bonds, debentures or other evidence of indebtedness of Bottler, unless
Bottler provides Company with such description at least five (5) Business Days prior to filing or use. Company must provide any comments within three (3) Business Days following receipt of the materials from Bottler. Except as otherwise
provided by this Agreement in connection with a Change of Control or sale of the Business, Company shall not require Bottler to disclose the identity of prospective investors, bondholders or lenders or the terms, rates or conditions of the
underlying agreements with such Persons. Bottler will not be required to provide to Company any description that has been previously reviewed by Company. 

  

	17.	 TERM OF AGREEMENT 

This Agreement will commence on the Effective Date and continue so long as Bottler’s CBA is in effect (the
“Term”). 
  

	18.	 COMMERCIAL IMPRACTICABILITY AND FORCE MAJEURE 

 

	18.1.	 With respect to any one or more Concentrates (the “Affected Products”), as applicable:

  

	 	18.1.1.	 The obligation of Company (including any of its Affiliates) to supply Affected Products to Bottler, and Bottler’s
obligation to purchase Affected Products from Company and to manufacture any Authorized Covered Beverages manufactured from such Affected Products, shall be suspended during any period when there occurs a change in applicable laws, regulations or
administrative measures (including any government permission or authorization regarding customs, health or manufacturing, and further including the withdrawal of any government authorization required by any of the parties to carry out the terms of
this Agreement), or issuance of any judicial decree or order 

  
 -16- 

	 	 
binding on any of the parties hereto, in each case in such a manner as to render unlawful or commercially impracticable: 

 

	 	18.1.1.1.	 The importation or exportation of any essential ingredients of the Affected Products that cannot be produced in
quantities sufficient to satisfy the demand therefor by existing Company (including any of its Affiliates) facilities in the United States; 

  

	 	18.1.1.2.	 The manufacture and distribution of Affected Products to Bottler; or 

 

	 	18.1.1.3.	 Bottler’s manufacture of Authorized Covered Beverages using such Affected Products. 

 

	18.2.	 “Force Majeure Event” means any strike, blacklisting, boycott or sanctions imposed by a
sovereign nation or supra-national organization of sovereign nations, however incurred, or any act of God, act of foreign enemies, embargo, quarantine, riot, insurrection, a declared or undeclared war, state of war or belligerency or hazard or
danger incident thereto. 

  

	18.3.	 Neither Company (including any of its Affiliates) nor Bottler shall be liable for or be subject to any claim for
breach or termination as the result of a failure to perform their respective obligations to purchase or supply Concentrate under this Agreement or to manufacture Authorized Covered Beverages made from such Concentrate in quantities to satisfy demand
of Company and Recipient Bottlers, as applicable, if and to the extent that such failure is caused by or results from a Force Majeure Event; provided, however: 

 

	 	18.3.1.	 The party claiming the excuse afforded by this Section 18.3 must use commercially reasonable efforts
to comply with any excused obligations under this Agreement that are impaired by such Force Majeure Event; and 

  

	 	18.3.2.	 If Bottler is the party claiming the excuse afforded by this Section 18.3: 

 

	 	18.3.2.1.	 To the extent that Bottler is unable to remediate the effect on its ability to perform caused by such Force Majeure
Event within three (3) months from the date of the occurrence of the Force Majeure Event, then, 

  

	 	18.3.2.1.1.	 Company shall have the right (but not the obligation) upon not less than one (1) month prior Notice to suspend this
Agreement and Related Agreements during the period of time that such Force Majeure Event results in Bottler being unable to perform its obligations under this Agreement. 

 

	 	18.3.2.2.	 To the extent that Bottler is unable to remediate the effect on its ability to perform caused by such Force Majeure
Event within two (2) years from the date of occurrence of the Force Majeure Event, Company shall have the right to terminate this Agreement. 

  
 -17- 

	19.	 TERMINATION FOR DEFINED EVENTS 

 

	19.1.	 Company may, at Company’s option, terminate this Agreement, subject to the requirements of
Section 23, if any of the following events occur: 

  

	 	19.1.1.	 An order for relief is entered with respect to Bottler under any Chapter of Title 11 of the United States Code, as
amended; 

  

	 	19.1.2.	 Bottler voluntarily commences any bankruptcy, insolvency, receivership, or assignment for the benefit of creditors
proceeding, case, or suit or consents to such a proceeding, case or suit under the laws of any state, commonwealth or territory of the United States or any country, kingdom or commonwealth or sub-division thereof not governed by the United States;

  

	 	19.1.3.	 A petition, proceeding, case, complaint or suit for bankruptcy, insolvency, receivership, or assignment for the benefit
of creditors, under the laws of any state, territory or commonwealth of the United States or any country, commonwealth or sub-division thereof or kingdom not governed by the United States, is filed against Bottler, and such a petition, proceeding,
suit, complaint or case is not dismissed within sixty (60) days after the commencement or filing of such a petition, proceeding, complaint, case or suit or the order of dismissal is appealed and stayed; 

 

	 	19.1.4.	 Bottler makes an assignment for the benefit of creditors, deed of trust for the benefit of creditors or makes an
arrangement or composition with creditors; a receiver or trustee for Bottler or for any interest in Bottler’s business is appointed and such order or decree appointing the receiver or trustee is not vacated, dismissed or discharged within sixty
(60) days after such appointment or such order or decree is appealed and stayed; 

  

	 	19.1.5.	 Any of Bottler’s equipment or facilities is subject to attachment, levy or other final process for more than twenty
(20) days or any of its equipment or facilities is noticed for judicial or non-judicial foreclosure sale and such attachment, levy, process or sale would materially and adversely affect Bottler’s ability to fulfill its obligations under
this Agreement; or 

  

	 	19.1.6.	 Bottler becomes insolvent or ceases to conduct its operations relating to the Business in the normal course of business.

  

	20.	 DEFICIENCY TERMINATION 

 

	20.1.	 Company may also, at Company’s option, terminate this Agreement, subject to the requirements of
Section 21 and Section 23, if any of the following events of default occur: 

  

	 	20.1.1.	 Bottler fails to make timely payment for Concentrate, or of any other material debt owing to Company;

  

	 	20.1.2.	 The condition of the facilities or equipment used by Bottler in manufacturing the Authorized Covered Beverages, as
reflected in any data collected by Company or generated by Bottler, or in any audit or inspection conducted by or on behalf of Company, fails to meet the Technical Requirements reasonably established by Company, and Bottler fails to complete
corrective measures approved by Company within the timeframe therefor reasonably established by Company and specified in the applicable Technical Corrective Action Plan; 

  
 -18- 

	 	20.1.3.	 Bottler fails to handle the Concentrates or manufacture or handle the Authorized Covered Beverages in strict conformity
with the Technical Requirements and applicable laws, rules and regulations and Bottler fails to complete corrective measures approved by Company within the timeframe therefor reasonably established by Company; 

 

	 	20.1.4.	 Bottler or any Affiliate of Bottler engages in any of the activities prohibited under Section 10;

  

	 	20.1.5.	 A Change of Control occurs with respect to Bottler, except as permitted under Bottler’s CBA; 

 

	 	20.1.6.	 Any Disposition of any voting securities representing more than fifty percent (50%) of the voting power of any
Bottler Subsidiary (other than to a wholly-owned Affiliate in connection with an internal corporate reorganization) is made by Bottler or by any Bottler Subsidiary, except as permitted under Bottler’s CBA. “Bottler Subsidiary”
means any Person that is Controlled, directly or indirectly, by Bottler, and that is a party, or Controls directly or indirectly a party, to an agreement with Company or any of its Affiliates regarding the manufacturing of Authorized Covered
Beverages; 

  

	 	20.1.7.	 Bottler breaches in any material respect any of Bottler’s other material obligations under this Agreement;

  

	 	20.1.8.	 Bottler breaches in any material respect any of Bottler’s material obligations under the NPSG Governance Agreement
and such breach is not timely cured; or 

  

	 	20.1.9.	 Any event of default occurs under Section 22 of Bottler’s CBA that is not timely cured in the
manner provided in Bottler’s CBA. 

  

	20.2.	 In any such event of default, Company may either exercise its right to terminate under this
Section 20 (subject to Section 21 and Section 23), or pursue any rights and remedies (other than termination) against Bottler with respect to any such event of default; provided, that
Company will not take any action pursuant to this Section 20.2 or Section 21.4 that would limit Bottler’s right to cure under Section 21 of this Agreement or Section 23 of
Bottler’s CBA. 

  

	21.	 BOTTLER RIGHT TO CURE 

 

	21.1.	 Upon the occurrence of any of the events of default enumerated in Section 20, Company will
give Bottler Notice of default. 

  

	21.2.	 In the case of an event of default due to a material breach by Bottler of its obligations under
Section 12 (other than Sections 12.2 or 12.4) or Section 13: 

  

	 	21.2.1.	 Bottler shall have a period of sixty (60) days from receipt of the Notice of default within which to cure such
default, by: 

  
 -19- 

	 	21.2.1.1.	 at the instruction of Company and at Bottler’s expense, promptly withdrawing from the market and destroying any
Authorized Covered Beverage that fails to meet the Technical Requirements; 

  

	 	21.2.1.2.	 compliance with the “Corrective Action” provision of the Technical Requirements; and 

 

	 	21.2.1.3.	 implementing a corrective action plan (the “Technical Corrective Action Plan”), to be negotiated in
good faith and agreed to by Company and Bottler, that reasonably meets the applicable requirements of the “Corrective Action” provision of the Technical Requirements (which Technical Corrective Action Plan may, by mutual agreement of the
parties, provide for actions to be taken after expiration of the cure periods specified herein). 

  

	 	21.2.2.	 If such default has not been cured within such initial sixty (60) day period (or such extended period, if any,
provided for under a Technical Corrective Action Plan), then Bottler must cure such default within a second period of sixty (60) days (or such extended period, if any, provided for under a Technical Corrective Action Plan) during which period
Company may, by giving Bottler further Notice to such effect, suspend sales to Bottler of Concentrates and require Bottler to cease manufacture of Authorized Covered Beverages and the supply and sale of Authorized Covered Beverages by Bottler to
Recipient Bottlers; provided, however, that if Bottler has throughout the first and second cure periods strictly complied with Section 13 (Recall) and Section 30 (Incident Management), then such
suspension of Concentrate sales and cessation of manufacture and supply shall be limited to the manufacturing facilities in which the default occurred. 

  

	 	21.2.3.	 If such default has not been cured during such second period of sixty (60) days (or such extended period, if any,
provided for under a Technical Corrective Action Plan), then Company may terminate this Agreement, by giving Bottler Notice to such effect, effective immediately; provided, however, that if Bottler has throughout the first and second
cure periods strictly complied with Section 13 (Recall) and Section 30 (Incident Management), then Bottler will have a third period of sixty (60) days (or such extended period, if any, provided for under a
Technical Corrective Action Plan) within which to cure the default. 

  

	 	21.2.4.	 If such default has not been cured during any such third period of sixty (60) days (or such extended period, if
any, provided for under a Technical Corrective Action Plan), then Company may terminate this Agreement, by giving Bottler notice to such effect, effective immediately. 

 

	21.3.	 In the case of an event of default other than those specified in Section 21.2:

  

	 	21.3.1.	 Within sixty (60) days of receipt of such Notice, Bottler will provide Company with a corrective action plan (the
“Non-Technical Corrective Action Plan”). The Non-Technical Corrective Action Plan must provide for correction of all issues identified in the Notice of default within one (1) year or less from the date on which the
Non-Technical Corrective Action Plan is provided to Company. 

  
 -20- 

	 	21.3.2.	 Company will negotiate in good faith with Bottler the terms of the Non-Technical Corrective Action Plan.

  

	 	21.3.3.	 If Company and Bottler fail to agree on a Non-Technical Corrective Action Plan within sixty (60) days of
Bottler’s tender of such plan, Bottler must cure the default described in the Notice of default within one (1) year of Bottler’s receipt of the Notice of default. If Bottler fails to cure the default described in the Notice of default
within one (1) year of Bottler’s receipt of the Notice, the default will be deemed not to have been cured. 

  

	 	21.3.4.	 If Company and Bottler timely agree on a Non-Technical Corrective Action Plan, but Bottler fails to implement the agreed
Non-Technical Corrective Action Plan to Company’s reasonable satisfaction within the time period specified by the Non-Technical Corrective Action Plan, the default will be deemed not to have been cured. 

 

	 	21.3.5.	 In the event of an uncured default under this Section 21.3, Company may, by giving Bottler further
Notice of termination, terminate this Agreement under Section 20 and require Bottler to cease manufacturing Authorized Covered Beverages. 

  

	21.4.	 The provisions of this Section 21 (including any cure) will not limit Company’s right to
pursue remedies under this Agreement on account of Bottler’s default, other than (a) termination of this Agreement under Section 20, (b) cessation of Company’s performance of its obligations under this
Agreement, or (c) rescission. 

  

	21.5.	 In the case of a breach by Bottler or one of its Affiliates of its obligations under this Agreement (other than
an event of default specified by Section 21.2), such breach will be deemed to be cured for purposes of this Section 21 if Bottler (or its Affiliate) has terminated the acts or omissions described in such Notice
of breach, and has taken reasonable steps under the circumstances to prevent the recurrence of such breach. 

  

	22.	 BOTTLER’S RIGHTS AND OBLIGATIONS WITH RESPECT TO SALE OF ITS BUSINESS 

For purposes of clarity, the parties hereby agree that any purchase or sale of the “Business”, as that term is used in
Bottler’s CBA, will include Bottler’s aggregate business directly and primarily related to the manufacture of Authorized Covered Beverages and other beverage products. [Note to Draft: Bottler’s CBA Schedule
24.1 will include Bottler’s manufacturing business as an “Included Business”.] 
  

	23.	 EFFECT OF THIS AGREEMENT ON BOTTLER’S CBA IN CERTAIN EVENTS 

 

	23.1.	 Unless otherwise agreed in writing by the parties, if Company terminates this Agreement in accordance with
Section 19 or Section 20 hereof, Company will concurrently terminate Bottler’s CBA in accordance with Section 21.1.7 thereof, and the compensation provisions set forth in Section 25 of
Bottler’s CBA will govern. 

  

	23.2.	 Upon any termination of Bottler’s CBA by Company, Company will concurrently terminate this Agreement unless
otherwise agreed in writing by the parties. 

  
 -21- 

	23.3.	 If Bottler’s CBA is amended in accordance with Section 24.4.3 thereof, then this Agreement will
be deemed automatically amended to revise the text in Section 10.1.3 by deleting it in its entirety and replacing it with the following: “Permitted Beverage Products distributed by Bottler or its Affiliates, subject to the
terms and conditions of Bottler’s or Bottler Affiliate’s CBA;”. Except as set forth in the preceding sentence, the amendment of Bottler’s CBA in accordance with Section 24.4.3 thereof will not affect any of the other
rights or obligations of the parties under this Agreement. 

  

	24.	 POST-EXPIRATION AND POST-TERMINATION OBLIGATIONS 

 

	24.1.	 Upon the termination of this Agreement, except to the extent provided in any other agreement between Bottler and
Company (or one of Company’s Affiliates): 

  

	 	24.1.1.	 Bottler shall not thereafter continue to manufacture any of the Authorized Covered Beverages in Authorized Containers or
to make any use of the Trademarks or Authorized Containers, or any closures, cases or labels bearing the Trademarks; and 

  

	 	24.1.2.	 Bottler shall forthwith deliver all materials used by Bottler exclusively for the manufacturing of the Authorized
Covered Beverages in Authorized Containers, including Concentrates, usable returnable or any nonreturnable containers, cases, closures, and labels bearing the Trademarks, still in Bottler’s possession or under Bottler’s control, to Company
or Company’s nominee, as instructed, and, upon receipt, Company shall pay to Bottler a sum equal to the reasonable market value of such supplies or materials; provided, however, that no such payment shall be made in connection
with a purchase by Company of Bottler’s Business or production assets in accordance with Section 22. Company will accept and pay for only such articles as are, in the opinion of Company, in first-class and usable condition,
and all other such articles shall be destroyed at Bottler’s expense. Containers, closures and all other items bearing the name of Bottler, in addition to the Trademarks, that have not been purchased by Company shall be destroyed without cost to
Company, or otherwise disposed of in accordance with instructions given by Company, unless Bottler can remove or obliterate the Trademarks therefrom to the satisfaction of Company. The provisions for repurchase contained this
Section 24.1.2 shall apply with regard to any Authorized Container approval of which has been withdrawn by Company under Section 12.10, except under circumstances under which this Agreement is terminated by
Company in accordance with Section 20. 

  

	25.	 COMPANY’S RIGHT OF ASSIGNMENT 

Company may assign any of its rights and delegate all or any of its duties or obligations under this Agreement to one or more of its
Affiliates; provided, however, that any such assignment or delegation will not relieve Company from any of its contractual obligations under this Agreement. 
  

	26.	 LITIGATION 

  

	26.1.	 Company reserves and has the sole and exclusive right and responsibility to institute any civil, administrative
or criminal proceedings or actions, and generally to take or seek any available legal remedy it deems desirable, for the protection of its reputation, the Trademarks, and other intellectual property rights, as well as for the Concentrates, and to
defend any action affecting these matters. 

  
 -22- 

	26.2.	 At the request of Company, Bottler will render reasonable assistance in any such action, including, if requested
to do so in the sole discretion of Company, allowing Bottler to be named as a party to such action. However, no financial burden will be imposed on Bottler for rendering such assistance. 

 

	26.3.	 Bottler shall not have any claim against Company or its Affiliates as a result of such proceedings or action or
for any failure to institute or defend such proceedings or action. 

  

	26.4.	 Bottler must promptly notify Company of any litigation or proceedings instituted or threatened against Bottler
affecting these matters. 

  

	26.5.	 Bottler must not institute any legal or administrative proceedings against any third party that may affect the
interests of Company in the Trademarks without the prior written consent of Company, which consent Company may grant or withhold in its sole discretion. 

  

	26.6.	 Bottler will consult with Company on all product liability claims, proceedings or actions brought against Bottler
in connection with the Authorized Covered Beverages and will take such action with respect to the defense of any such claim or lawsuit as Company may reasonably request in order to protect the interests of Company in the Authorized Covered Beverages
or the goodwill associated with the Trademarks. 

  

	27.	 INDEMNIFICATION 

 

	27.1.	 Company will indemnify, protect, defend and hold harmless each of Bottler and its Affiliates, and their
respective directors, officers, employees, shareholders, owners and agents, from and against all claims, liabilities, losses, damages, injuries, demands, actions, causes of action, suits, proceedings, judgments and expenses, including reasonable
attorneys’ fees, court costs and other legal expenses (collectively, “Losses”), to the extent arising from, connected with or attributable to: (a) Company’s manufacture of the Concentrates (except to the extent
arising from matters for which Bottler is responsible under Section 13.5 or Section 27.2); (b) the breach by Company of any provision this Agreement; (c) Bottler’s use, in accordance with this
Agreement and Company guidelines respecting use of Company intellectual property, of the Trademarks or of package labels; or (d) the inaccuracy of any warranty or representation made by Company herein or in connection herewith. None of the
above indemnities shall require Company to indemnify, protect, defend or hold harmless any indemnitee with respect to any claim to the extent such claim arises from, is connected with or is attributable to the negligence or willful misconduct of
such indemnitee. 

  

	27.2.	 Bottler will indemnify, protect, defend and hold harmless each of Company and its Affiliates, and their
respective directors, officers, employees, shareholders, owners and agents, from and against all Losses to the extent arising from, connected with or attributable to: (a) Bottler’s manufacture of the Authorized Covered Beverages (except to
the extent arising from matters for which Company is responsible under Section 13.4 or Section 27.1); (b) the breach by Bottler of any provision of this Agreement; or (c) the inaccuracy of any warranty
or representation made by Bottler herein or in connection herewith. None of the above indemnities shall require Bottler to indemnify, protect, defend or hold harmless any indemnitee with respect to any claim to the extent such claim arises from, is
connected with or is attributable to the negligence or willful misconduct of such indemnitee. 

  
 -23- 

	27.3.	 Neither party will be obligated under this Section 27 to indemnify the other party for Losses
consisting of lost profits or revenues, loss of use, or similar economic loss, or for any indirect, special, incidental, consequential or similar damages (“Consequential Damages”) arising out of or in connection with the performance
or non-performance of this Agreement (except to the extent that an indemnified third party claim asserted against a party includes Consequential Damages). 

  

	28.	 BOTTLER’S INSURANCE 

Bottler will obtain and maintain a policy of insurance with insurance carriers in such amounts and against such risks as would be
maintained by a similarly situated company of a similar size and giving full and comprehensive coverage both as to amount and risks covered in respect of matters referred to in Section 27 (including Bottler’s indemnity of
Company contained therein) and will on request produce evidence satisfactory to Company of the existence of such insurance. Compliance with this Section 28 will not limit or relieve Bottler from its obligations under
Section 27. In addition, Bottler will satisfy the insurance requirements specified on Schedule 28. 
  

	29.	 LIMITATION ON BOTTLER REPRESENTATIONS OR DISCLOSURES REGARDING AUTHORIZED COVERED BEVERAGES

 Bottler covenants and agrees that, except as required by law, it will make no representations or disclosures
to the public or any Governmental Authority or to any third party concerning the attributes of the Authorized Covered Beverages (other than statements consistent with representations or disclosures previously made or authorized by Company), without
the prior written consent of Company. If Bottler is required to make any such representations or disclosures to a Governmental Authority, Bottler first will notify Company before making any such representation or disclosure and will cooperate with
Company in good faith to ensure the accuracy of all such information (except to the extent that such Notice and cooperation would otherwise be prohibited under applicable law). This Section 29 will not apply to financial
information disclosed in accordance with applicable securities laws. 
  

	30.	 INCIDENT MANAGEMENT 

 

	30.1.	 Company and Bottler recognize that incidents may arise that can threaten the reputation and business of Bottler
and/or negatively affect the good name, reputation and image of Company and the Trademarks. 

  

	30.2.	 In order to address such incidents, including any questions of quality of the Authorized Covered Beverages that
may occur, Bottler will designate and organize an incident management team and inform Company of the members of such team. 

  

	30.3.	 Bottler further agrees to cooperate fully with Company and such third parties as Company may designate and
coordinate all efforts to address and resolve any such incident consistent with procedures for crisis management that may be issued to Bottler by Company from time to time. 

  
 -24- 

	31.	 SEVERABILITY 

If any provision of this Agreement is or becomes legally ineffective or invalid, the validity or effect of the remaining provisions of
this Agreement shall not be affected; provided that the invalidity or ineffectiveness of such provision shall not prevent or unduly hamper performance hereunder or prejudice the ownership or validity of the Trademarks. 

 

	32.	 REPLACEMENT OF CERTAIN PRIOR CONTRACTS, MERGER, AND REQUIREMENTS FOR MODIFICATION 

 

	32.1.	 As to all matters and things herein mentioned, the parties agree: 

 

	 	32.1.1.	 Subject to Section 32.1.4, upon the execution and delivery of this Agreement and
Bottler’s CBA, the existing bottle contracts under which Company (or its Affiliate) has previously authorized Bottler (or one or more of its Affiliates) to manufacture in certain authorized containers, and/or market, promote, distribute and
sell, Coca-Cola and other beverages marketed under Company’s trademarks, including those contracts identified on Exhibit D of Bottler’s CBA (other those contracts set forth on Schedule 32.1.4), are
amended, restated and superseded in their entirety by this Agreement and Bottler’s CBA, and all rights, duties and obligations of Company and Bottler regarding the Trademarks and the manufacture of the Authorized Covered Beverages will be
determined under this Agreement and Bottler’s CBA, without regard to the terms of any prior agreement and without regard to any prior course of conduct between the parties (the parties acknowledge that any existing bottle contract authorizing
Bottler to produce Coca-Cola and other beverages marketed under Company’s trademarks between Company and Bottler that is not listed on Exhibit D of Bottler’s CBA is nevertheless amended, restated and superseded hereby,
except as otherwise provided in Section 32.1.4); 

  

	 	32.1.2.	 This Agreement, together with the National Product Supply System Governance Agreement and the documents
implementing and governing the NPSG and the NPSG Board set forth the entire agreement between Company and Bottler with respect to the subject matter hereof, and all prior understandings, commitments or agreements relating to such matters between the
parties or their predecessors-in-interest are of no force or effect and are cancelled hereby; provided, however, that any written representations made by either party upon which the other party relied in entering into this Agreement
will remain binding to the extent identified on Schedule 32.1.2; 

  

	 	32.1.3.	 Any waiver, amendment or modification of this Agreement or any of its provisions, and any consents given under
this Agreement will not be binding upon Bottler or Company unless made in writing, signed by an officer or other duly qualified and authorized representative of Company or by a duly qualified and authorized representative of Bottler; and

  

	 	32.1.4.	 Except as expressly provided in this Agreement, this Section 32.1 is not intended to affect in
any way the rights and obligations of Bottler (or any of its Affiliates) or Company (or any of its Affiliates) under Bottler’s CBA or the agreements listed in Schedule 32.1.4. 

  
 -25- 

	33.	 NO WAIVER 

  

	 	 Failure of Company or Bottler (including any of their respective Affiliates) to exercise promptly any right herein
granted, or to require strict performance of any obligation undertaken herein by the other party, will not be deemed to be a waiver of such right or of the right to demand subsequent performance of any and all obligations herein undertaken by
Bottler or by Company. 

  

	34.	 NATURE OF AGREEMENT AND RELATIONSHIP OF THE PARTIES 

 

	34.1.	 Bottler is an independent contractor and is not an agent of, or a partner or joint venturer with, Company.

  

	34.2.	 Each of Company and Bottler agree that it will neither represent, nor allow itself to be held out as an agent of,
or partner or joint venturer with the other (including any of its Affiliates). 

  

	34.3.	 Bottler and Company do not intend to create, and this Agreement will not be construed to create, a partnership,
joint venture, agency, or any form of fiduciary relationship. Each party covenants and agrees never to assert that a partnership, joint venture or fiduciary relationship exists or has been created under or in connection with this Agreement and the
Related Agreements. There is no partnership, joint venture, agency, or any form of fiduciary relationship existing between Bottler and Company, but if it there is determined or found to be a partnership, joint venture, or agency, then Bottler and
Company expressly disclaim all fiduciary duties that might otherwise exist under applicable law. 

  

	34.4.	 Nothing in this Agreement, express or implied, is intended or will be construed to give any Person, other than
the parties to this Agreement and their successors and permitted assigns, any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained in this Agreement. This Agreement does not, and is not intended
to, confer any rights or remedies upon any Person other than Bottler and Company. 

  

	35.	 HEADINGS AND OTHER MATTERS 

 

	35.1.	 The headings herein are solely for the convenience of the parties and will not affect the interpretation of this
Agreement. 

  

	35.2.	 As used in this Agreement, the phrase “including” means “including, without limitation” in
each instance. 

  

	35.3.	 References in this Agreement to Sections are to the respective Sections of this Agreement, and references to
Exhibits and Schedules are to the respective Exhibits and Schedules of this Agreement as they may be amended from time to time. 

  

	36.	 EXECUTION IN MULTIPLE COUNTERPARTS 

The parties may execute this Agreement in counterparts, each of which is deemed an original and all of which only constitute one
original. 
  

	37.	 NOTICE AND ACKNOWLEDGEMENT 

 

	37.1.	 Notices. 

  
 -26- 

	 	37.1.1.	 Requirement of a Writing and Permitted Methods of Delivery. Each party giving or making any notice, request,
demand or other communication (each, a “Notice”) pursuant to this Agreement must give the Notice in writing and use one of the following methods of delivery, each of which for purposes of this Agreement is a writing:

  

	 	37.1.1.1.	 personal delivery; 

 

	 	37.1.1.2.	 Registered or Certified Mail, in each case, return receipt requested and postage prepaid;

  

	 	37.1.1.3.	 nationally recognized overnight courier, with all fees prepaid; 

 

	 	37.1.1.4.	 facsimile; or 

  

	 	37.1.1.5.	 e-mail (followed by delivery of an original by another delivery method provided for in this Section).

  

	 	37.1.2.	 Addressees and Addresses. Each party giving a Notice must address the Notice to the appropriate person at the
receiving party (the “Addressee”) at the address listed below or to another Addressee or at another address designated by a party in a Notice pursuant to this Section. 

 

					
	 Company:
	  	  
	  	
			
		  	  
	  	
			
		  	  
	  	
			
		  	 Attention:
	  	
			
		  	 Facsimile:
	  	
			
		  	 E-mail:
	  	
			
	 With a copy to:
	  	  
	  	
			
		  	  
	  	
			
		  	  
	  	
			
		  	 Attention: General Counsel
	  	
			
		  	 Facsimile:
	  	
			
		  	 E-mail:
	  	

  
 -27- 

 
					
	 Bottler:
	  	  
	  	
			
		  	  
	  	
			
		  	  
	  	
			
		  	 Attention:
	  	
			
		  	 Facsimile:
	  	
			
		  	 E-mail:
	  	
			
	 With a copy to:
	  	  
	  	
			
		  	  
	  	
			
		  	  
	  	
			
		  	 Attention:
	  	
			
		  	 Facsimile:
	  	
			
		  	 E-mail:
	  	

  

	 	37.1.3.	 Effectiveness of a Notice. Except as specifically provided elsewhere in this Agreement, a Notice is effective
only if the party giving or making the Notice has complied with Sections 37.1.1 and 37.1.2 and if the Addressee has received the Notice. A Notice is deemed to have been received as follows: 

 

	 	37.1.3.1.	 If a Notice is delivered in person, when delivered to the Addressee. 

 

	 	37.1.3.2.	 If delivered by Registered or Certified Mail, upon receipt by Addressee, as indicated by the date on the signed
receipt. 

  

	 	37.1.3.3.	 If delivered by nationally recognized overnight courier service, one Business Day after deposit with such courier
service. 

  

	 	37.1.3.4.	 If sent by e-mail, when sent (if followed promptly by delivery of an original by another delivery method provided
for in this Section). 

  

	 	37.1.3.5.	 If the Addressee rejects or otherwise refuses to accept the Notice, or if the Notice cannot be delivered because
of a change in address for which no Notice was given, then upon the rejection, refusal or inability to deliver. 

  

	 	37.1.3.6.	 Despite the other clauses of this Section 37.1.3, if any Notice is received after 5:00 p.m. on
a Business Day where the Addressee is located, or on a day that is not a Business Day where the Addressee is located, then the Notice is deemed received at 9:00 a.m. on the next Business Day where the Addressee is located.

  

	37.2.	 If Bottler’s signature or acknowledgment is required or requested with respect to any document in connection
with this Agreement and any employee or representative authorized by Bottler “clicks” in the appropriate space on the website designated by Company or takes such other 

  
 -28- 

	 	 
action as may be indicated by Company, Bottler shall be deemed to have signed or acknowledged the document to the same extent and with the same effect as if Bottler had signed the document
manually; provided, however, that no such signature or acknowledgment shall amend or vary the terms and conditions of this Agreement. 

  

	37.3.	 Bottler acknowledges and agrees that Bottler has the ability and knowledge to print information delivered to
Bottler electronically, or otherwise knows how to store that information in a way that ensures that it remains accessible to Bottler in an unchanged form. 

  

	38.	 CHOICE OF LAW AND VENUE 

 

	38.1.	 This Agreement shall be interpreted, construed and governed by and in accordance with the laws of the State of
Georgia, United States of America, without giving effect to any applicable principles of choice or conflict of laws, as to contract formation, construction and interpretation issues, and the federal trademark laws of the United States of America as
to trademark matters. 

  

	38.2.	 The parties agree that any lawsuit commenced in connection with, or in relation to, this Agreement must be
brought in a United States District Court, if there is any basis for federal court jurisdiction. If the party bringing such action reasonably concludes that federal court jurisdiction does not exist, then the party may commence such action in any
court of competent jurisdiction. 

  

	39.	 CONFIDENTIALITY 

 

	39.1.	 In the performance of this Agreement, each party may disclose to the other party certain Proprietary Information.
The Proprietary Information of the Disclosing Party will remain the sole and exclusive property of the Disclosing Party or a third party providing such information to the Disclosing Party. The disclosure of the Proprietary Information to the
Receiving Party does not confer upon the Receiving Party any license, interest, or right of any kind in or to the Proprietary Information, except as expressly provided under this Agreement. 

 

	39.2.	 At all times and notwithstanding any termination or expiration of this Agreement or any amendment hereto, the
Receiving Party agrees that it will hold in strict confidence and not disclose to any third party the Proprietary Information of the Disclosing Party, except as approved in writing by the Disclosing Party. The Receiving Party will only permit access
to the Proprietary Information of the Disclosing Party to those of its or its Affiliates’ employees or authorized representatives having a need to know and who have signed confidentiality agreements or are otherwise bound by confidentiality
obligations at least as restrictive as those contained in this Agreement (including external auditors, attorneys and consultants). 

  

	39.3.	 The Receiving Party will be responsible to the Disclosing Party for any third party’s use and disclosure of
the Proprietary Information that the Receiving Party provides to such third party in accordance with this Agreement. The Receiving Party will use at least the same degree of care it would use to protect its own Proprietary Information of like
importance, but in any case with no less than a reasonable degree of care, including maintaining information security standards specific to such information as set forth in this Agreement. 

  
 -29- 

	39.4.	 If the Receiving Party is required by a Governmental Authority or applicable law to disclose any of the
Proprietary Information of the Disclosing Party, the Receiving Party will (a) first give Notice of such required disclosure to the Disclosing Party (to the extent permitted by applicable law), (b) if requested by the Disclosing Party, use
reasonable efforts to obtain a protective order requiring that the Proprietary Information to be disclosed be used only for the purposes for which disclosure is required, (c) if requested by the Disclosing Party, take reasonable steps to allow
the Disclosing Party to seek to protect the confidentiality of the Proprietary Information required to be disclosed, and (d) disclose only that part of the Proprietary Information that, after consultation with its legal counsel, it determines
that it is required to disclose. 

  

	39.5.	 Each party will immediately notify the other party in writing upon discovery of any loss or unauthorized use or
disclosure of the Proprietary Information of the other party. 

  

	39.6.	 The Receiving Party will not reproduce the Disclosing Party’s Proprietary Information in any form except as
required to accomplish the intent of this Agreement. Any reproduction of any Proprietary Information by the Receiving Party will remain the property of the Disclosing Party and must contain any and all confidential or proprietary Notices or legends
that appear on the original, unless otherwise authorized in writing by the Disclosing Party. 

  

	39.7.	 Neither party will communicate any information to the other party in violation of the proprietary rights of any
third party. 

  

	39.8.	 Upon the earlier of termination of this Agreement, written request of the Disclosing Party, or when no longer
needed by the Receiving Party for fulfillment of its obligations under this Agreement, the Receiving Party will, if requested by the Disclosing Party, either: (a) promptly return to the Disclosing Party all documents and other tangible
materials representing the Disclosing Party’s Proprietary Information, and all copies thereof in its possession or control, if any; or (b) destroy all tangible copies of the Disclosing Party’s Proprietary Information in its possession
or control, if any, in each case, except to the extent that such action would violate applicable regulatory or legal requirements. Each party’s counsel may retain one copy of documents and communications between the Parties as necessary for
archival purposes or regulatory purposes. 

  

	40.	 ACTIVE AND COMPLETE ARMS LENGTH NEGOTIATIONS 

The parties acknowledge and agree that the terms and conditions of this Agreement have been the subject of active and complete
negotiations, and that such terms and conditions must not be construed in favor of or against any party by reason of the extent to which a party or its professional advisors may have participated in the preparation of this Agreement. 

 

	41.	 RESERVATION OF RIGHTS 

Company reserves all rights not expressly granted to Bottler under this Agreement or Bottler’s CBA. 

 

	42.	 BOTTLER AFFILIATES 

Bottler hereby absolutely, unconditionally and irrevocably guarantees that any actions taken by any of Bottler’s Affiliates
pursuant to this Agreement will be taken in accordance with all applicable requirements set forth herein to the same extent as if such actions had been taken by Bottler. Bottler acknowledges and agrees that any breach of this Agreement by any
Affiliate of Bottler shall be considered a breach by Bottler for all purposes hereof. 
 [Signature page(s) follow] 

  
 -30- 

 IN WITNESS WHEREOF, COMPANY AT ATLANTA, GEORGIA, AND BOTTLER AT
                         HAVE CAUSED THESE PRESENTS TO BE EXECUTED IN TRIPLICATE BY THE DULY AUTHORIZED PERSON OR PERSONS
ON THEIR BEHALF ON THE DATES INDICATED BELOW. 
  

			
	 THE COCA-COLA COMPANY

			
		
	 By:
	 	 

			
	
	 Authorized Representative

			
		
	 Date:
	 	 

			
	
	 [BOTTLER]

			
		
	 By:
	 	 

			
	
	 Authorized Representative

			
		
	 Date:
	 	 

 EXHIBIT A 

Regional Manufacturing Facilities 

 EXHIBIT B 

Authorized Covered Beverages 

[Subject to further discussion. To be agreed by the parties prior to Closing] 

The following Beverages and all SKUs, packages, flavor, calorie and other variations (e.g., Sprite Cranberry, Sprite Zero Cranberry) of each such
Beverage offered by Company that are identified by the primary Trademark that also identifies such Beverage or any modification of such primary Trademark, such as, e.g., the primary Trademark used in conjunction with a prefix, a suffix or other
modifier: 
 Coca-Cola 
 Caffeine Free Coca-Cola 

Diet Coke 
 Diet Coke with Lime 

Diet Coke with Splenda® 

caffeine free Diet Coke 
 Coca-Cola Life 

Coca-Cola Zero 
 caffeine free Coca-Cola Zero 

Cherry Coke 
 Diet Cherry Coke 

Cherry Coke Zero 
 Vanilla Coke 

Diet Vanilla Coke 
 Vanilla Coke Zero 

Barq’s 
 Diet Barq’s 

DASANI 
 DASANI Plus 

DASANI Sparkling 
 Fanta 

Fanta Zero 
 Fresca 

Mello Yello 
 Mello Yello Zero 

PiBB Xtra 

 PiBB Zero 
 Seagram’s ginger ale

 Seagram’s mixers 
 Seagram’s seltzer water 

Sprite 
 Sprite Zero 

TaB 
 VAULT 

VAULT Zero 
 Delaware Punch 

FUZE 
 FUZE iced tea 

FUZE Juices 
 FUZE Refreshments 

FUZE slenderize 

 [EXHIBIT C] 

[Finished Goods Supply Agreements] 

 Schedule 2.17 

Related Agreements 
 [To be completed prior to
execution of this Agreement.] 

 Schedule 2.18 

[***] 
 [***] 

[***] 
 [***] 

[***] 
  

	
	  
 [***]

 
 [***]

 
 [***]

 

 [***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 

 [***] 

[***] 
 [***] 

 
 [***] – THIS CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 

 Schedule 10.1.5 

Third Party Beverages 
  

	A.	 As of the Effective Date: 

[To be completed prior to execution of this Agreement.] 
  

	B.	 Added After the Effective Date: 

 Schedule 12.2 

Technical Requirements 
 All of
Company’s product, package and equipment quality; food safety; workplace safety; and environmental sustainability specifications, standards, instructions and requirements published by Company in the Beverage Products and Environmental
Sustainability sections of the Coca-Cola Operating Requirements (KORE) website documents library, as updated by Company from time to time following discussion with the NPSG and Notice to each Regional Producing Bottler (including any Company Owned
Manufacturers). 

 Schedule 28 

Insurance Requirements 

 Schedule 32.1.2 

Agreements not affected by this Agreement 

 Schedule 10.1.5 

Third Party Beverages 
 A.    
As of the Effective Date: 
 None. 
 B.    
Added After the Effective Date: 

 Schedule 12.2 

Technical Requirements 
 All of
Company’s product, package and equipment quality; food safety; workplace safety; and environmental sustainability specifications, standards, instructions and requirements published by Company in the Beverage Products and Environmental
Sustainability sections of the Coca-Cola Operating Requirements (KORE) website documents library, as updated by Company from time to time following discussion with the NPSG and Notice to each Regional Producing Bottler (including any Company Owned
Manufacturers). 

 Schedule 28 

Insurance Requirements 
 Bottler
will, at its own cost and expense, acquire and maintain during the Term, with carriers having an AM Best Rating of A-VII or better, sufficient insurance to adequately protect the respective interests of the parties. Specifically, Bottler must
carry the following minimum types and amounts of insurance (the “Required Policies”) on an occurrence basis or in the case of coverage that cannot be obtained on an occurrence basis, then, coverage can be obtained on a claims-made
basis with a three (3) year tail following the termination or expiration of this Agreement:  
  

	 	a)	 Commercial General Liability including, but not limited to, premises-operations, broad form property damage,
products /completed operations, contractual liability, independent contractors, personal injury and advertising injury and liability assumed under an insured contract with limits of at least $25,000,000 per occurrence and $25,000,000
general aggregate and $25,000,000 Products / Completed Operations Aggregate; 

  

	 	b)	 Statutory Workers’ Compensation Insurance and Employer’s Liability Insurance in the minimum amount of
$1,000,000 each employee by accident, $1,000,000 each employee by disease and $1,000,000 aggregate by disease with benefits afforded under the laws of the state or country in which the services are to be performed. Policy
will include an alternate employer endorsement providing coverage in the event any employee of Bottler sustains a compensable accidental injury while on work assignment with Company. Insurer for Bottler will be responsible for the Workers’
Compensation benefits due such injured employee; 

  

	 	c)	 Commercial Automobile Liability for any owned, non-owned, hired, or borrowed automobile used in the performance
of Bottler’s obligations under this Agreement is required in the minimum amount of $25,000,000 combined single limit. If Bottler is driving a vehicle owned by Company in connection with the performance of its obligations under this
Agreement, then Bottler will be responsible for the cost of repairing any physical damage to the vehicle resulting from Bottler’s use of the vehicle. If the vehicle cannot be repaired, then Bottler will be responsible for replacing
Company’s vehicle; 

 Bottler will notify Company in writing within sixty (60) days of any cancellation,
non-renewal, termination, material change or reduction in coverage. 
 Bottler’s insurance as outlined above shall be primary and
non-contributory coverage. 
 The coverage territory for the stipulated insurance shall be The United States of America. 

Bottler will cause their insurance companies to waive their right of recovery against Company under the Required Policies. 

Bottler will be solely responsible for any deductible or self-insured retention. 

The above insurance limits may be achieved by a combination of primary and umbrella/excess policies.

 The Coca-Cola Company, its subsidiaries, affiliates, authorized bottlers, directors,
officers, employees, partners, customers and agents shall be included as an “Additional Insured” on Bottler’s Commercial General Liability and Commercial Auto Liability policies listed above and shall be evidenced on the
certificate of insurance. Prior to the execution of this Agreement and annually upon the anniversary date(s) of the insurance policy’s renewal date(s), Bottler will furnish Company with a properly executed Certificate of Insurance clearly
evidencing compliance with the insurance requirements set forth above. The certificate of insurance should be sent to: The Coca-Cola Company, attn.: General Counsel – Bottler Contracts, 1 Coca-Cola Plaza, Atlanta GA 30313. 

The stipulated limits of coverage above shall not be construed as a limitation of any potential liability to Company, and failure to request evidence of
this insurance shall not be construed as a waiver of Bottler’s obligation to provide the insurance coverage specified. 

 Schedule 32.1.2 

Agreements not affected by this Agreement 
 Exhibit
D of Bottler’s CBA is incorporated herein by reference.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}]]